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ABSTRACT (Englisch) 
The generation of platelets and megakaryocytes (MK) in vitro provides a potent strategy to 
overcome the shortage of today’s platelet transfusions to patients with acute needs. The 
amount of patients, depending on donations, and in need for transfusions are increasing 
while platelet donors are not more frequent. Furthermore, the risk of bacterial 
contamination in platelet products is high due to their storage at room temperature to 
prevent platelet activation. This also shortens the shelf life of platelet products. After 
repetitive transfusions, patients can develop refractoriness and immunity adding further 
complications to the use of platelet therapies. Therefore, alternative sources for platelets 
are sought for. Platelets can be produced in vitro from MK progenitors, hematopoietic 
stem cells or pluripotent stem cells. However, production is inefficient, particularly taking in 
consideration that the tremendous amount 4-5 x 1011 platelets have to be produced for 
filling one transfusion unit. 
In this study, we wanted to explore whether the expression of single supporting candidate 
factors in murine induced pluripotent stem cells (iPSC) could increase platelet production 
in vitro. We concentrated on the overexpression of major transcription factors of early-
phase megakaryopoiesis (Gata1, Pbx1, and Evi1) and late phase (Nfe2) to enhance MK 
production platelet release. Furthermore, to support platelet release from MK, we 
expressed hyperactive variants of the small GTPases RhoA and Cdc42. Gene 
modifications in iPSC, however, experience major drawbacks because of silencing of 
ectopic gene expression especially during differentiation. Furthermore, expression of the 
supportive factors has to be tightly controlled to avoid unwanted interference of the factors 
with pluripotency and differentiation since the transduction has to be performed in the 
pluripotent state. To overcome this, a tet-inducible expression system in iPSC was 
developed which was based on the generation of iPSC containing the reverse tetracycline 
(rt) transactivator TA-M2 in the Rosa26 safe harbor locus to prevent gene silencing of the 
(rt)TA-M2 and thereby guaranteeing its robust expression throughout the differentiation 
process. After verification of pluripotency and differentiation potential of the generated 
iPSC, the candidate factors were introduced with gammaretroviral vectors containing the 
respective transgene expressed from a Tet-responsive minimal promoter. In our 
experiments we found that overexpression of Gata1 elevated production of 
megakaryocyte progenitors, however, full maturation of the cells was impaired. In 
contrast, overexpression of Nfe2 elevated numbers of released platelets. In a second 
approach, we developed a doxycycline (dox)-induced overexpression system that should 
be transferable to human cells. We improved Tet-inducible all-in-one gammaretroviral 
vectors by introducing different ubiquitous chromatin opening elements derived from the 
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human HNRPA2B1/CBX3 locus (A2UCOE), previously proven to prevent silencing of 
constitutive-expressing retroviral vectors in hiPSC. Tet-all-in-one retroviral vectors rely on 
a persistent expression of the transactivator and good regulation of the tet-responsive 
promoter. The incorporation of an additional element (with promoter activity) can interfere 
with the regulation. We incorporated elements of different sizes in sense and antisense 
transcriptional orientation into Tet-all-in-one gammaretroviral vectors and tested these for 
the regulation and anti-silencing capacity in different cell lines including murine and 
human iPSC. The U670 was identified to be the most potent element in preventing 
silencing which also conferred the strongest expression from the vector in the induced 
state. Longer fragments also sustained the gene expression but vector titers and induction 
efficiencies were impaired. Gammaretroviral Tet-all-in-one vectors turned out to be 
superior to their lentiviral counterparts due to the capability to produce higher titers. 
Finally, the expression and tight regulation of the thrombopoietin receptor Mpl within Tet-
inducible gammaretroviral vectors after incorporation of the U670s element was confirmed 
by cytokine-dependent cell growth. In addition, the PGK promoter could be replaced by 
the 670bp elements and sustained transgene silencing without interfering with the tight 
regulation of the vectors. With this part of the study, we found potent gammaretroviral 
vector candidates which pave the way for future application of overexpression of GATA1 
and NFE2 in the human system to increase MK and platelet production in vitro. 
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ZUSAMMENFASSUNG 
 
Die Verabreichung von Thrombozyten zur Behandlung von Folgen verschiedener 
medizinischer Indikationen ist nicht immer komplikationslos. Zum einen steigt die Zahl der 
Patienten, die diese Therapien benötigen, bei gleichbleibender Zahl von Thrombozyten-
Spendern, was die Knappheit der Produkte in den nächsten Jahren zur Folge haben 
könnte. Außerdem erhöht die Aufbewahrung der Thrombozyten-Konzentrate bei 
Raumtemperatur das Risiko bakterieller Kontaminationen. Somit können die Blutprodukte 
nur wenige Tage gelagert werden und viele Einheiten müssen unverwendet entsorgt 
werden. Darüber hinaus reagieren einige Spender mit Immunreaktion auf die erhaltenen 
Präparate, was zur Refraktärität von Thrombozyten führt. Eine mögliche Lösung hierfür ist 
die Produktion von patienteneigenen und HLA-kompatiblen Thrombozyten in der Zellkultur 
aus induzierten pluripotenten Stammzellen (iPSC). Ein großes Hindernis ist dabei die 
große Menge an Zellen, die hergestellt werden muss (4-5 x 1011) und die mindere 
Funktionalität der in Kultur hergestellten Thrombozyten im Vergleich zu den gespendeten. 
In dieser Arbeit haben wir eine Strategie entwickelt, um Ausbeute und Funktionalität der 
im Labor hergestellten Thrombozyten zu steigern. Dies basiert auf einem induzierbaren 
gammaretroviralen Vektorsystem. Im ersten Teilprojekt sollen Ausbeute und Funktionalität 
von in vitro erzeugten Thrombozyten gesteigert werden, indem spezifische Faktoren zu 
einem bestimmten Zeitpunkt während der Differenzierung überexprimiert werden. Im 
Fokus standen hierbei die Transkriptionsfaktoren Gata1, Pbx1 und Evi1 die ein frühes 
Stadium der Megakaryopoese kontrollieren und Nfe2, der die Freisetzung von 
Thrombozyten steuert. Eine besondere Herausforderung ist die Stilllegung der 
eingebrachten Gene, insbesondere während der Differenzierung von iPSC. Der PGK 
Promotor, der in vielen Systemen die Expression des Transaktivators des Tet-
induzierbaren Systems steuert, ist davon ganz besonders betroffen durch seine vielen 
potenziellen Methylierungsstellen. Durch die Erzeugung von murinen iPSC, die den 
(rt)TA-M2 von einem internen Lokus exprimieren, konnte dessen kontinuierliche 
Expression gewährleistet werden. Nach Verifizierung der Pluripotenz und des 
Differenzierungsmusters der generierten iPSC und deren Transduktion mit den einzelnen 
unterstützenden Faktoren wurde gezeigt, dass die Überexpression von Gata1 zu einem 
prozentualen Anstieg der Vorläuferzellen führte, die jedoch Defizite in der finalen 
Ausreifung aufwiesen. Im Gegensatz dazu führte die Überexpression von Nfe2 zu einer 
gesteigerten Anzahl von freigesetzten Thrombozyten pro Megakaryozyt. Überexpression 
beider Faktoren in Kombination wäre daher eine vielversprechende Kombination für 
künftige Studien. Um dieses System auf die Differenzierung von humanen Thrombozyten 
ZUSAMMENFASSUNG 
 
8 
 
aus iPSC übertragen zu können, haben wir gammaretrovirale All-in-one-Vektoren 
optimiert. Hierbei wird die Stilllegung des PGK Promotors durch das Einfügen eines 
Chromatin-öffnenden-elements (A2UCOE) verhindert. Dieses stammt vom humanen 
HNRPA2B1/CBX3 Genlokus. Da die Elemente Promotoraktivität besitzen, könnte deren 
Einbringen die Regulierbarkeit der Vektoren beeinträchtigen. Wir haben Elemente 
verschiedener Größen und Lokalisationen in jeweils zwei verschiedenen transkriptionellen 
Orientierungen vor den PGK Promotor eingesetzt. Dabei stellte sich heraus, dass sich das 
Element U670s besonders eignet, da die Regulierung nicht beeinträchtigt war und die 
Stilllegung des Transgens in verschiedenen Zelllinien inklusive hiPSC verzögert bzw. 
verhindert werden konnte. Dabei waren gammaretrovirale Vektoren den lentiviralen 
überlegen, aufgrund der höheren Titer, die erreicht werden konnten. Die Funktionalität 
des Vektors wurde durch die regulierte Expression des Thrombopoietinrezeptors Mpl und 
das daraus relsultierende Cytokin-abhängige Wachstum von transduzierten Zellen 
bestätigt. Auch der Austausch des PGK Promotors durch das U670 Element konnte die 
Expression des Transgens weiterhin regulieren. Hiermit haben wir Vektoren hergestellt, 
um die Faktoren GATA1 und NFE2 auch im humanen System überexprimieren zu können 
und somit zur Steigerung der Ausbeute generierter Megakaryozyten und Thrombozyten in 
der Zellkultur auch im humanen System beitragen zu können. 
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1 INTRODUCTION 
1.1 Megakaryopoiesis and platelet biogenesis 
 
Adult platelet biogenesis in mammals is a multistep process that is initiated in 
hematopoietic stem cells (HSC) residing in the bone marrow (BM) (Figure 1). In the 
classical megakaryopoiesis model, MK evolve from Megakaryocyte-Erythrocyte-
Progenitor cells (MEP) in a hierarchical order where high proliferative potential-colony-
forming unit-megakaryocytes (HPP-CFU-MK) stem from MEPs directly. HPP-CFU-MK 
give rise to burst-forming unit-megakaryocytes (BFU-MK) which then produce more 
differentiated progenitors, colony-forming unit-megakaryocytes (CFU-MK). CFU-MKs 
develop into immature MKs or megakaryoblasts (Debili et al., 1996; N Debili, L 
Coulombel, L Croisille, A Katz, J Guichard, J Breton-Gorius and W Vainchenker, 1996; 
Szalai et al., 2006; Sanada et al., 2016). The megakaryoblasts proliferate and increase in 
size up to 100 µm during further development. They also undergo endomitosis, a process 
in which the DNA content is increasing while cell division does not occur, and become 
multilobulated with nuclei up to 64 and 128N. The formation of the demarcation 
membrane system (DMS) during cytoplasmic maturation of MK was shown to divide the 
cells into small platelet areas. These are the source for the cell membranes for future 
platelets and serve as membrane reservoir for platelet release at the tips of the cellular 
protrusions (Eckly et al., 2014). Formation of cellular elongation of the MK is initiated by 
microtubules migrating to the cell cortex, a network of actin filaments at the edge of the 
cells which is responsible for their shape. Organelles and granules are transported to the 
tips of the protrusions by microtubules (Patel et al., 2005). During maturation, 
megakaryocytic progenitors migrate from the osteoblastic niche to the vascular niche 
within the BM (Behrens and Alexander, 2018). Once homed to the vascular niche, MK 
extend their protrusions through gaps of the endothelial cells, lining of the vascular 
sinusoids into the blood stream. Subsequently, pro-platelets are formed which then 
rupture into platelets once exposed to the shear forces of the blood stream in the lumen of 
BM sinusoids (Italiano et al., 2007; Brown et al., 2018). 
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Figure 1 Mammalian megakaryopoiesis and platelet biogenesis. HSC residing in the BM undergo different 
intermediate maturation steps which result in the generation of a committed progenitor called MEP which then 
gives rise to proliferating megakaryoblasts. After proliferation, they perform endomitosis and cytoplasmic 
maturation forming cellular protrusions which extend through gaps of the endothelial cells lining the vascular 
sinusoids. Once exposed to the shear forces of the bloodstream, pro-platelets are generated which release 
platelets into the circulation. Since the process involves multiple intermediate steps, it is also regulated at 
multiple steps during differentiation by early and later transcription factors (modified after Pang et al., 2005).  
1.1 Platelet morphology and functionality  
 
There are about 1.5-4 x 105 platelets per microliter of blood circulating in the human body 
and about 1 x 106 per microliter in murine blood. In the non-activated state in the blood, 
platelets are small discoid shaped cells of about 2 µm in diameter in humans and 0.5 µm 
in mice. They have a very specific cellular morphology, depicted in Figure 2 without a 
nucleus and with different types of granules. Alpha granules (α-granules) are the most 
abundant type of granules in platelets and contain coagulation factors (e.g. Factor V, 
Factor VIII and Factor VI) as well as adhesion molecules (e.g. P-selectin, Von-Willebrand-
Factor (VWF), fibrinogen and fibronectin), playing a role in adhesion and interaction 
between platelets with leukocytes and endothelial cells (Li et al., 2017). In addition, 
cytokines such as VEGF and angiogenin as well as platelet-factor 4 and antiangiogenic 
factors, involved in the regulation of growth and angiogenesis, are stored in α-granules 
(Whiteheart, 2011). They further contain chemokines (interleukin (IL)-8, RANTES) as well 
as immunomodulatory molecules and antibodies (Complement factors, IgG) (Burnouf et 
al., 2016). The cargo of dense granules (δ-granules), named as such because of their 
INTRODUCTION 
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high electron density in electron microscopy, are mainly small molecules like serotonin, 
histamine, ADP and polyphosphates (Ali et al., 2015; Li et al., 2017; Sharda and 
Flaumenhaft, 2018). The third type of granules are the lysosomes (λ-granules) which 
mainly store hydrolases, proteases and glycosidase for the lysis of phagocytic 
components. They may also have a role in degradation of extracellular matrix components 
(Ramadan A. Ali et al.; Ali et al., 2015; Heijnen and van der Sluijs, 2015). Another 
morphological structure unique to platelets is the presence of two different internal 
membrane structures, the open canalicular system (OCS) and the dense tubular system 
(DTS). The OCS is derived from the cytoplasma membrane of MK and is therefore 
connected to the surface (van Nispen tot Pannerden et al., 2010). Platelets can take up 
plasma proteins such as fibrinogen and tissue factor (TF) via the OCS (Harrison et al., 
1989; Escolar et al., 2008). α-granules and δ-granules can fuse with the OCS and release 
their contents during platelet activation. Furthermore, they are a reservoir for platelet 
surface receptors in the inactivated state and a reservoir for the membrane itself during 
formation of filopodia and final spreading after activation (Selvadurai and Hamilton, 2018). 
The DTS in contrast is not connected to the surface and is derived from the smooth 
endoplasmic reticulum of MK. It serves as a site of synthesis for prostaglandin and 
thromboxane, two major effector molecules of platelet activation, and as an internal 
calcium storage (Gerrard et al., 1978).  
 
Even though the major function of platelets is in thrombosis and hemostasis, platelets 
critically contribute to a variety of other vascular functions. In angiogenesis, platelets 
release pro- and antiangiogenic factors after activation and thereby impact angiogenesis-
dependent processes such as wound healing and vessel formation (Walsh et al., 2015). In 
immune responses, the translocation of the granules to the surface after activation leads 
to the release of inflammatory and bioactive molecules such as PF4 and RANTES 
responsible for the activation of monocytes and the differentiation of monocytes into 
macrophages (Ali et al., 2015). Platelets have been shown to interact as defense 
mechanism against bacterial invasion as they are able to directly or indirectly bind to 
bacteria via Low affinity immunoglobulin gamma Fc region receptor II-a (FcγRIIa), Toll-
like-receptors (TLRs), Glycoprotein (GP) IIb-IIIa, and GPIb and bundle fibrinogen-bound 
bacteria. With this, they contribute to the first line of host defense by reducing bacterial 
growth rate and producing reactive oxygen species (ROS) with direct antimicrobial activity 
(Yeaman, 2014; Gaertner et al., 2017). During thrombosis and hemostasis, activation of 
the normally quiescent platelets by vessel injury is initiated by interaction with the 
subendothelial matrix such as collagen and von VWF. First, platelets become partially 
activated and change their shape. Degranulation releases signaling molecules and 
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recruits additional platelets to the site of injury. At the same time, the tissue factor (TF) 
clotting cascade is initiated, resulting in the full activation of platelets. TF in the vessel 
lumen comes into contact with Factor VIIa and Factor IXa in the blood. Factor IXa 
interacts with Factor Va, leading to the cleavage of small amounts or the zymogen 
prothrombin into thrombin. Increased thrombin production is regulated by a feedback loop 
mediated by Factor Xa, followed by full activation of platelets. Thrombin initiates the 
cleavage of fibrinogen into fibrin which then is cross-linked to fibers forming a mash to 
stabilize the clot (Nieman and Schmaier, 2007; Ali et al., 2015). During platelet activation, 
the stimulation of rapid reorganization of the actin skeleton at the cortex of platelets 
results in the transformation of before discoid to fully spread shapes. Here, extension of 
filopodia and the generation of lamellipodia result in an increased surface area (Coughlin, 
2005; Aslan et al., 2012). Furthermore, thrombin is a potent agonist for platelet activation 
ex vivo and is responsible for shape change as well as release of effector molecules 
(Coughlin, 2005).   
 
On their surface, platelets are equipped with different receptors, shown in Figure 2. 
GPIIbIIIa (also termed integrin αIIbβIII; or CD41/ CD61) is the most abundant surface 
receptor (15% of the total surface proteins, 80,000 receptors per platelet) (Jennings and 
Phillips, 1982; Wagner et al., 1996; French and Seligsohn, 2000). It is involved in the 
adhesion to the endothelium as well as aggregation by crosslinking of adjacent platelets 
via fibronectin. In the resting state, the receptor moderately binds to VWF, but after 
activation, it undergoes a conformational change resulting in an increase of the binding 
affinity to adhesive fibrinogen and thereby participating in plug formation (Durrant et al., 
2017). GPIIbIIIa also can interact with fibrinogen and collagen (Andrews et al., 2014). The 
second surface receptor of the βIII family is the αvβ3 which is involved in platelet adhesion 
to extracellular matrix proteins mainly interacting with vitronectin (Bennett, 2005). The 
second most abundant surface molecule is the GPIb-IX-V multiprotein complex consisting 
of GPIbα (CD42b), GPIbβ (CD42c), GPIX (CD42a) and GPV (CD42d) which belongs to 
the family of the leucine-rich receptors. Its major ligand is the VWF and therefore 
responsible for rolling and adhesion to the subendothelium, however, it also interacts with 
other ligands such as thrombin and P-selectin (Li and Emsley, 2013). Under 
immobilization or increased shear forces, VWF undergoes morphological changes which 
in turn lead to the binding to the GPIbα. Subsequently, downstream signaling of GPIbα 
increase intracellular calcium release, expression of P-Selectin on the surface and 
filopodia formation resulting in platelet clearance (Deng et al., 2016). Platelets also 
express 3 members of the β1 family receptors (Bennett, 2005). GPVI (α2β1, 
CD49b/CD29) is the major receptor for collagen and is a member of the Ig receptor family 
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which exists in up to 10,000 copies on the platelet surface. It can exist as a dimer, 
whereas dimerization is enhanced by platelet activation and after ligand binding (Arthur et 
al., 2007; Andrews et al., 2014). The glycoprotein α6β1 is the major receptor of laminin 
which is highly abundant in the basement membrane. Laminin is an important extracellular 
matrix protein which is exposed after vascular damage. The interaction between laminin 
and its receptor α6β1 not only supports the adhesion of platelets to the site of vascular 
injury but also platelet spreading (Inoue et al., 2006). Another receptor involved in platelet 
adhesion is α5β1 which is interacting with fibronectin to initiate the interaction of resting 
platelets and promoting the interaction of other receptors to amplify the platelet response 
(Kasirer-Friede et al., 2007). At the edge of the cells, marginal bands can be detected in 
resting platelets. This is a peripheral network of microtubule bundles and actin filaments 
maintaining the discoid shape. During activation when platelets become spherical, the 
interaction between actin and tubulin leads to filopodia and lamellopodia formation as well 
as accumulation of the granules at the center of the cells and enhanced platelet 
degranulation (Sadoul, 2015).   
 
The major receptors for thrombin are protease activated receptor (PAR) 1 and PAR4 in 
humans. In mice, thrombin mainly interacts with PAR3 and PAR4 due to the lack of PAR1 
on platelets, which get cleaved by thrombin at their extracellular N-terminus and thereby 
initiating downstream signaling (Coughlin, 2000). The major receptors for the interaction of 
platelets with ADP are the P2 receptors P2Y1 and P2Y12. However, their abundance on 
the surface of a platelet is much lower (150 copies). They are required for full platelet 
activation in response to ADP. P2Y1 initiates weak responses to ADP and P2Y12 
completes the aggregation reaction (Hechler and Gachet, 2011). Another important 
stimulus of platelet activation is the agonist thromboxane A2 (TxA2) which is released 
after vessel injury. The interaction via the thromboxane receptor (TP) on the surface of 
platelets is involved in the initiation of platelet degranulation and shape change (Rucker 
and Dhamoon, 2019). Vascular endothelial cells produce prostaglandin I2 (PGI2) to 
prevent platelets from becoming activated in case of intact vascular integrity. The 
prostaglandin receptor (IP) on the platelet surface interacts with PGI2 and thereby 
counteracts platelet activation. Another receptor, highly expressed on the surface of 
platelets is the C-type lectin receptor (Clec-2) which interacts mostly with the 
transmembrane protein podoplanin highly expressed in various types of malignancies 
such as squamous cell carcinomas, mesotheliomas, glioblastomas and osteosarcomas. 
Therefore, interaction of Clec-2 and podoplanin is determined to be one of the 
mechanisms in which platelets are involved in tumor metastasis (Lowe et al., 2012). 
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Figure 2 Schematic overview of platelet structure and surface markers. Platelets show a unique 
ultrastructure when imaged with transmission electron microscopy. The absence of a nucleus is a major 
platelet feature. After activation of platelets, the granules fuse with the plasma membrane and the granule 
content is released to augment signaling. They contain two different internal networks, the OCN and DTN as 
well as lysosomes and mitochondria. On their surface, they are equipped with platelet-specific surface 
receptors which also mainly interact during platelet activation and are responsible for initiating downstream 
signaling after binding to their appropriate effector molecules. Human and murine platelets differ in terms of 
the PAR receptors (PAR1: human, PAR3:murine) (adapted from Zapata et al., 2014).  
 
1.2  Fetal platelet biogenesis 
 
During murine embryogenesis, hematopoiesis occurs in three phases of primitive and 
definitive hematopoiesis (Ciau-Uitz et al., 2014). In vertebrates, primitive hematopoiesis 
consisting of erythro-myeloid cells is initiated in blood islands within the yolk sac on day 7 
after gestation (Palis et al., 1999; Xu M et al., 2001; Ferkowicz et al., 2003). In 2001, Xu et 
al. showed evidence for primitive murine megakaryogenesis in the yolk sac (Xu M et al., 
2001). Until day 11, the hematopoietic progenitors increase in cell numbers in the yolk sac 
and in the para-aortic splanchnopleura/aorta-gonad-mesonephros region (PAS/AGM). 
Autonomous definitive hematopoietic stem cells (HSC) were first detected within the 
PAS/AGM on day 10.5 after gestation in the mouse. On day 11.5, HSCs can also be 
detected in the yolk sac (Jaffredo et al., 2005). This stadium defines the second wave of 
developmental hematopoiesis. Emerging HSC start decreasing in the PAS/AGM and yolk 
sac and migrate to the fetal liver. Proliferation of HSC in the fetal liver can be measured 
until day 15 or 16 and is followed by a decrease indicating the mobilization of HSC from 
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the fetal liver to the BM and spleen (Christensen et al., 2004). The generation of these 
HSC which emerge from their original compartment and seed different sites of 
hematopoiesis is considered to be the third phase of embryonic hematopoiesis (Ciau-Uitz 
et al., 2014). MEP appear during primitive hematopoiesis in the yolk sac at embryonic day 
7.5 and 9.5 (Xu M et al., 2001; Tober et al., 2007). More recent studies have discovered 
the presence of diploid platelet forming cells residing in the yolk sac at day 10.5 which 
express CD41 but lack the expression of CD45 (Potts et al., 2014). During the later stages 
of definitive hematopoiesis, MK are also localized in the fetal liver (FL) between embryonic 
day 9.5 and 10.5. Embryonic MK differ from adult ones in their response to thrombopoietin 
(Thpo) and in their size (Cortegano et al., 2018). However, FL-derived cells from day 10.5 
and 11.5 increase in size and ploidy during MK maturation (Matsumura and Sasaki, 
1988). 
 
1.3 Regulators of megakaryocyte and platelet differentiation 
 
During migration from the osteoblastic to the vascular niche in the BM, maturing cells are 
exposed to a gradient of cytokines and other environmental factors supporting maturation 
and platelet release. The factors are included in Figure 1. The major cytokine regulating 
MK differentiation and MK progenitor cell proliferation is Thpo (Kuter et al., 1994; Broudy 
and Kaushansky, 1995; Kato et al., 1995). The binding of Thpo to its specific cell surface 
receptor Mpl (homologue of the myeloproliferative leukemia virus oncogene) is followed 
by conformational changes of the receptor and subsequent phosphorylation, thus 
activating cellular downstream signaling via PI-3 kinase-Akt signaling (Pulikkan et al., 
2012) MAPK (Erk1/Erk2), p38 MAPK (Drachman et al., 1997) and Stat3/Stat5 pathways 
(Kirito et al., 2002). Thpo- and Mpl knockout mice have decreased numbers of MK and 
also decreased platelet counts of more than 80% (Gurney et al., 1994; Sauvage et al., 
1996). Thpo/Mpl-signaling also regulates the development of HSC by supporting their 
survival, proliferation and promotion of self-renewal and proliferation after BM 
transplantation (Kimura et al., 1998; Solar et al., 1998; Fox et al., 2002). In turn, Thpo/Mpl-
deficient mice have reduced granulocyte-macrophage, erythroid, and multilineage 
progenitors (Carver-Moore et al., 1996; Kuter, 2014). In vitro, the addition of Thpo 
stimulates polyploidization of primary immature MK (Broudy et al., 1995; Debili et al., 
1995).  
 
The fact that there are residual MK and platelets present in Thpo/Mpl knockout mice leads 
to the suggestion that also other cytokines are involved in MK and platelet production. For 
example, mice with a severe reduction in the levels of SCF (Stem cell factor) also develop 
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severe anemia and thrombocytopenia (Ebbe et al., 1978; Kaushansky, 2009). Cytokines 
affecting MK growth or maturation are IL-3, IL-6, IL-11. Crossing Mpl-deficient mice with 
other cytokine-receptor-deficient mice shows that cytokines of the IL-family alone are 
dispensable for normal or stimulation of hematopoiesis in vivo (Kaushansky, 2009).   
 
In vitro, cytokines of the IL-family alone also have little or no effect on the proliferation or 
maturation of MK but they are known to augment megakaryopoiesis in vitro (Behrens and 
Alexander, 2018). Supplementation with IL-3 leads to an increase in numbers of MK from 
MK cell lines (Avraham et al., 1992). IL-6, IL-11and LIF interact on the increased size and 
ploidy of MK in vitro (Ishibashi et al., 1989; Burstein et al., 1992; Teramura et al., 1992). In 
vivo, application of IL-6 and IL-11 increases platelet counts in mice in vivo or facilitates the 
recovery from thrombocytopenia after chemotherapy and transplantation, indicating their 
supportive role for megakaryopoiesis and platelet release.   
 
In addition to cytokines, transcription factors are essential for different maturation steps of 
megakaryopoiesis, pro-platelet formation and platelet release. Gata1, the most important 
transcription factor, is named after its DNA binding motif 5'-[AT]GATA[AG]-3´. It controls 
MK maturation until the state of establishment of mature MK. In mice, Gata1 knockout is 
embryonal lethal at day 11.5 due to severe anemia (Fujiwara et al., 1996). Lineage-
specific knockout of Gata1 in MK results in the accumulation of late-stage MK, lacking the 
capacity for pro-platelet formation and thereby causing thrombocytopenia and showing its 
role in earlier stages of megakaryopoiesis until mature MK are generated (Shivdasani et 
al., 1997). In vitro, knockout of Gata1 in fetal liver MK leads to the differentiation of smaller 
cells with lower ploidy. The cell cycle gene cycline D1 is a direct target of Gata1, showing 
its influence on endomitosis and demonstrating the role of Gata1 in MK maturation 
(Muntean et al., 2007). Furthermore, Gata1 is also involved in granule formation since a 
mutation in the human GATA1 gene is one of the mutations responsible for development 
of the Gray platelet syndrome, a bleeding disorder associated with markedly reduced 
number or absence α-granules, moderate bleeding and macrothrombocytopenia (Tubman 
et al., 2007). Gata1 cooperates with its co-factor friend of Gata1 (FOG1), a zinc finger 
protein that plays a critical role in the formation of a cell-specific transcriptional complex 
and bridges DNA-bound GATA-1 to distant sites along the chromatin (Tsang et al., 1997). 
Similar to Gata1, Runx1 (Runt-related transcription factor 1) is involved in cytoplasmic 
maturation and polyploidization processes (Tijssen and Ghevaert, 2013). Conditional 
knockout of Runx1 in mice shows a reduction of mature multilobulated nuclei in the BM 
with accumulation of premature MK with a similar morphology to micromegakaryocytes, 
observed in human myelodysplastic syndromes with defects in polyploidization and 
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formation of the demarcation membrane (Ichikawa et al., 2004; Tijssen and Ghevaert, 
2013). However, the conditional knockout has no impact on the HSC maintenance or 
survival, the mice show also other abnormalities like reduction of platelet counts, a block 
in lymphocyte development and development of myeloproliferative phenotype (Growney 
et al., 2005). In humans, chromosomal translocations and mutations of the RUNX1 gene 
are associated with different types of acute myeloid leukemias (AML) and acute 
lymphoblastic leukemia (ALL) (Asou, 2003). Pbx1 (Pre B-cell leukemia factor 1) is a co-
factor of the HOX transcription factors and is expressed during embryonic hematopoiesis. 
Furthermore, studies in Pbx1-/- mice show that the lack of the transcription factor is 
embryonically lethal at day 16 of embryonic development due to anemia (DiMartino et al., 
2001). Pbx1 overexpression in a Mpl knockout background mouse model of adult 
hematopoiesis (performed by our own group) results in an enrichment of MK in the BM, 
indicating its essential role from early until final stages of MK development and maturation 
(Kohlscheen et al., 2019). The transcription factor Scl1 (stem cell leukemia 1), also known 
as Tal1 (T-cell acute lymphocytic leukemia 1), was also first described in association with 
the occurrence of an acute lymphoblastic leukemia and was shown to regulate yolk sac 
hematopoiesis in Scl-/- in mice since the embryos were dying at embryonic day 9.5, thus 
indicating the role in regulation of embryonic hematopoiesis (Begley and Green, 1999). 
Furthermore, conditional Scl-null mice show an increased number of MK with higher 
ploidy but impaired platelet production, indicating a regulation also on the level of platelet 
release under thrombopoietic stress conditions (McCormack et al., 2006). Another 
transcription factor involved in platelet release is Nfe2 (Nuclear factor erythroid 2). Nfe2 is 
heterodimer of a hematopoietic restricted p45 subunit and Maf proteins (p18) such as 
MafK and MafG(Andrews, 1998). Knockout of the p45 subunit in mice results in increased 
prenatal death of animals due to hemorrhages and, in case of their survival, postnatal 
thrombocytopenia (Shivdasani et al., 1995). Nfe2-/- MK entirely lack the capability of pro-
platelet formation and show reduced granule formation along with reduced DMS 
establishment (Lecine et al., 1998). Evi1 (Ectopic viral integration site 1) is a transcription 
factor highly expressed in hematopoietic progenitor cells, MKs and platelets (Tozawa et 
al., 2014) and its overexpression is associated with the development of myeloid leukemia. 
However, conditional knockout in mice results in the establishment of thrombocytopenia 
without affecting the white blood cell counts (Goyama et al., 2008; Huang and Cantor, 
2009). Whereas it negatively regulates the development from HSC into granulocytes and 
erythrocytes, the overexpression in a megakaryocytic cell line in vitro increases their 
polyploidy, showing that Evi1 is a further key factor for MK maturation at later stages 17 
(Shimizu et al., 2002; Tozawa et al., 2014).   
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Despite the role of transcription factors on different levels of megakaryopoiesis, GTPases 
facilitate various cellular processes like cell division, exocytosis, and actin cytoskeletal 
dynamics (Etienne-Manneville and Hall, 2002; Aslan and McCarty, 2013). RhoA is a 
guanosine exchange factor which circulates between an inactive GDP-bound state and an 
active GTP-bound state. Conditional knockout in mice results in severe 
macrothrombocytopenia, indicating RhoA’s essential role in platelet release from mature 
MK. Platelets isolated from RhoA knockout mice perform less spreading and clot 
formation, which also shows interference of RhoA in platelet functionality (Pleines et al., 
2012). Another well studied GTPase, Cdc42, is also involved in generation of stress fibers 
as well as filopodia and lamellipodia formation (Nobes and Hall, 1995). Cdc42 knockout in 
mice also showed a phenotype similar to that of RhoA knockout mice. They also present 
with macrothrombocytopenia and reduced platelet numbers. However, here, Cdc42 
knockout also results in the increased granule secretion and slightly increased activation 
potential (Pleines et al., 2010). Cdc42 was shown to be a main regulator of DMS during 
megakaryopoiesis in vitro and in vivo (Antkowiak et al., 2016).   
 
1.4 Gene modification with viral vectors 
 
1.4.1 Self-inactivating retroviral vectors 
 
In our study, we aimed for stable and long-term gene modification. Therefore, a retroviral 
vector system, derived from the murine leukemia virus (MLV) which belongs to the genus 
of gammaretroviruses, as well as lentiviral vectors, derived from human immunodeficiency 
virus (HIV), were employed. Viral particles of enveloped viral vector harbor capsid proteins 
enclosing two copies of single-stranded RNA, the viral genome. A fully functional retroviral 
genome carries genes for the formation of infectious particles from the infected host cells 
which encode gag and pol for the structural and enzymatic proteins like polymerase (pol: 
polymerase, reverse transcriptase, integrase) and group associated antigen (gag: matrix, 
capsid, nucleocapsid) which are shared by all retroviruses. The integrated provirus in 
return does not code for these structural proteins and therefore lacks the ability to form 
infectious particles. Detailed pictures of the viral genomes of gammaretroviruses and 
lentiviruses and the descending viral vectors are shown in Figure 3. The first retroviral 
vectors have already been developed more than 30 years ago from different viral origins 
including Moloney murine leukemia virus (MMTV) and MLV (Gilboa et al., 1982; Williams 
et al., 1984; Mulligan, 1993). Over the course of time, they have been engineered for a 
safer and more efficient transduction (Baum et al., 1995). The so-called split packaging 
design supplies these, together with the envelope (env) of choice on separate plasmids 
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during the generation of the viral vector particles (Miller, 1990). Deletion of the enhancer 
promoter from the LTR led to the so called self-inactivating (SIN) configuration (Yu et al., 
1986). Also, pseudotyping with envelope proteins derived from other viruses has 
broadened the host range of the vector particles (Emi N., 1991). In contrast to 
gammaretroviral vectors, lentiviral vectors have the ability to transduce also non-dividing 
cells, which allows higher transduction efficiencies (Naldini et al., 1996; Dull et al., 1998; 
Schambach et al., 2013).  
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Figure 3 Genome of gammaretroviruses and lentiviruses and the corresponding designed expression 
vectors with helper plasmids and the split packaging design. The genomes are flanked by long terminal 
repeats (LTR) which can be dissected to the unique region 3 (U3), repeat region (R), and the U5 region. 
Further structural elements are the primer binding site (PBS), the packaging signal ψ, the splice donor (SD) 
and acceptor sites (SA) and the retrovirus-specific polypurine tract (PPT) initiating the DNA synthesis of the 
reverse transcription. For generation of retroviral vectors, the retroviral genomes have been deleted for all viral 
genes. The gene of interest (GOI) and an additional woodchuck posttranscriptional regulatory element (wPre) 
are flanked by long terminal repeats (LTR). For the 3rd generation of gammaretroviral and lentiviral vectors, 
the enhancer (E) and promoter (P) were deleted, resulting in a SIN configuration where the transgene is 
expressed from an internal promoter of choice (IP). For the production of the viral vector particles, the 
expression vector has to be co-transfected with the helper plasmids expressing gag/pol, env and rev genes 
(the latter only in the lentiviral context) from the cytomegalovirus promoter (CMV) or rous sarcoma virus 
promoter (RSV). (A) Gammaretrovirus and the descending viral vector. The genome of a gammaretrovirus is 
segmented into three main sequences: gag (encoding for Matrix protein (MP), protein p12, the capsid (CA) 
and the nucleocapsid (NC); pol (encoding for the protease (PR), the reverse transcriptase (RT), the integrase 
(IN), and env (encoding for the surface (SU) and transmembrane (TM) domain of the envelope protein. (B) 
Lentivirus and the descending viral vector. In Addition to the genes shared with gammaretroviruses, the 
lentiviral genome encodes virulence genes vif, vpr, vpu and nef. The tat protein is important for promoter 
activation and the rev protein stabilizes unspliced viral mRNA and leads to its cytoplasmatic transport by 
binding to the rev responsive element (RRE). Lentiviruses contain a second central polypurine tract (cPPT) 
(modified after Maetzig et al., 2011; Schambach et al., 2013). 
 
 
Gammaretrovirus and descending viral vector 
Lentivirus and descending viral vector 
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Generation of viral vector particles is shown in Figure 4. MLV-derived retroviral vectors 
can be pseudotyped by various viral envelopes such as vesicular stomatitis viral 
glycoprotein (VSVg) (Burns et al., 1993). Viral particles enveloped by VSVg enter the host 
cell via receptor-mediated endocytosis and release the virus core, containing capsid, 
reverse transcriptase, integrase, nuclear capsid and RNA, into the host cell cytoplasm or 
they enter the cell by transition through the endosome, which results in the unpacking of 
the viral particles (Maetzig et al., 2011). Once entered and unpacked, reverse 
transcriptase (RT) converts the viral RNA into double-stranded DNA, followed by the entry 
into the nucleus. In the case of the gammaretroviral vectors, nuclear entry occurs during 
the breakdown of the nuclear membrane during mitosis, which then leads to permanent 
integrase-meditated integration into the host cell genome (Hindmarsh and Leis, 1999).  
 
 
 
Figure 4 Generation of retroviral vectors. During the retroviral life cycle, viral particles enter their target 
cells via receptor-mediated endocytosis in case of a VSVg envelope and release the virus core into the 
cytoplasm of the cells. Reverse transcriptase converts the viral RNA into double stranded DNA which then 
integrates into the host cell mediated by the enzyme integrase. Information for the formation of new viral 
particles is encoded on the viral RNA. The proteins assemble together with viral RNA and particles released 
by budding of the host cell membrane. For the generation of viral vectors, the genes encoding for envelope, 
polymerase and integrase are split on different expression plasmids which are transfected separately into the 
packaging cells. Due to the lack of the packaging signal of the so-called helper plasmids, only the genetic 
information of the transfer plasmid is packaged into the viral particles. Hereby, formation of viral particles after 
integration of the viral vector of the host cell genome is prevented (Adapted and modified after Maetzig et al., 
2011; Vannucci et al., 2013).  
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The self-inactivating (SIN) technology, developed by Gilboa and colleagues in 1986 and 
further modified to achieve high titers, contains a deletion of the 3’U3 region harboring the 
enhancer/promoter region allowing the non-viral regulation of the gene expression (Yu et 
al., 1986; Dull et al., 1998; Schambach et al., 2006). When the 3’UTR is copied into the 
5’UTR during reverse transcription, the enhancers/promoters are deleted and the gene 
expression of the vector can be initiated from an internal promoter of choice (Maetzig et 
al., 2011) (see Fig 5). 
 
Figure 5 Self-inactivating retroviral vectors. The deletion of the U3 region of the 3’LTR (ΔU3, orange) leads 
to the loss of the promoter activity of the LTR. Two different mRNAs are generated from the viral vector 
plasmid: One originates from the original promoter in the U3 of the 5’ LTR (red), the other one from the 
internal promoter (IP, blue). Only the full length RNA carries the packaging signal (Ψ) and is, therefore, 
included in the viral vector particle. During reverse transcription, the ΔU3 of the 3’LTR is copied to the 5’LTR 
result in in its loss of promoter activity. After integration, both LTR are devoid of enhancer/promoter sequences 
by the deletion in the U3 and the resulting mRNA after vector integration into the host genome is initiated from 
the IP (blue line) (Modified after Maetzig T. et al, 2011).  
 
1.4.2 Doxycycline inducible all-in-one retroviral vectors 
 
In 1992, Gossen and Bujard first published a system relying on regulatory elements of the 
tetracycline (Tet) -resistance operon in E.coli. Herein, transcription of Tet-resistant genes 
is negatively regulated by a repressor. This system turned out to have the ability of gene 
regulation in mammalian cells. Gossen and Bujard generated an artificial transcription 
factor consisting of a Tet repressor (TetR) and the C-terminal domain of VP16 protein 
from herpes simplex virus (HSV) which is essential for the activation of early viral genes. 
This hybrid transactivator (tTA) is prone to stimulate promoters fused to the Tet operon 
(TetO). Within the “Tet-Off” system, application of low doses of dox prevents the 
transactivator to bind to the TetO and thus, transcription does not take place (Gossen and 
Bujard, 1992).  
Random mutagenesis of the tTA led to the development of a reverse controlled 
transgenesis transactivator (rt)TA which interacts in an opposite way. Application of dox 
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leads to the inactivation of the repressor and therefore, the rtTA can bind to the TetO 
leading to transcriptional activation of downstream genes. This is known to be the “Tet-
On” system (Benabdellah et al., 2011). The rtTA used in this case is the rtTA2S-M2 
((rt)TA-M2) which is expressed under the control of a constitutively active 
phosphoglycerate kinase promoter (PGK). The Tet-operator fused to a minimal promoter 
(T11) and the cDNA of choice build the Tet-responsive unit. Conformational changes in 
M2 upon binding to dox lead to the interaction of M2 with the TetO. In turn, the T11 
minimal promoter initiates transcription of the transgene of choice which is located 
downstream of the Ptet-T11 (Heinz et al., 2011).  
Despite the all-in-one vectors, all the components of the system can also be delivered as 
a two-vector system for robust genetic modification (Vigna et al., 2002). In 2005, Konrad 
Hochedlinger and colleagues developed a knockin mouse containing the reverse 
transactivator (rt)TA-M2 in the Rosa26 safe harbor locus named B6.Cg-Gt(ROSA)26Sor 
tm1(rtTA*M2)Jae/J. Here, the transactivator is constitutively expressed from the Rosa26 locus 
(Hochedlinger et al., 2005). In animal experiments, residual components can be delivered 
via retroviral vectors expressing the Tet-responsive internal promoter and the transgene of 
choice (Magnusson et al., 2007; Kustikova et al., 2013). 
1.5 Induced pluripotent stem cells (iPSC) 
 
In 2006, Takahashi, Yamanaka and colleagues succeeded in the discovery of a paradigm 
shift, the generation of induced pluripotent stem cells that reverses somatic cells into an 
embryonic state (Takahashi and Yamanaka, 2006). The murine fibroblasts used in their 
first experiments were transduced with viral vectors overexpressing embryonic 
transcription factors Oct3/4 (Octamer-binding transcription factor-3/4), Klf 1(Kruppel Like 
Factor-4), Sox2 (Sex-determining region Y)-box 2, and cMyc (OSKM factors). Shortly after 
having succeeded in reprogramming mouse fibroblasts into iPSC, the same approach 
could also be applied to human cells (Takahashi and Yamanaka, 2006; Takahashi et al., 
2007; Yu et al., 2007). The first sign of successful reprogramming is the appearance of a 
cellular morphology resembling embryonic stem cells. Additionally, iPSC also show other 
embryonic stem cell features like self-renewing capacity and the ability of differentiation 
into ectoderm, endoderm and mesoderm. The discovery of the generation of iPSC is very 
valuable for new approaches in patient-specific cellular therapies and disease modeling 
as well as drug screening. Furthermore, it paves the way for wildlife and animal 
conservation efforts as well as reanimation of extinct species (Stanton et al., 2019). 
During the course of time, reprogramming methods changed from the original use of 
integrating viral vectors (e.g. lentiviral vectors) in which the reprogramming cassette was 
excisable at later stages. Non-integrating strategies were based on viral vectors derived 
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from sendai virus or adenoviruses (Stadtfeld et al., 2008; Chen et al., 2013). Also, non-
integrating non-viral based reprogramming such as the delivery of synthetic modified 
mRNA or proteins as well as episomal vectors can be used to deliver the reprogramming 
factors (Kim et al., 2009; Jia et al., 2010; Warren et al., 2010). 
1.6 Ubiquitous chromatin opening elements (UCOE) 
 
The development of retroviral vectors provides tools for a multitude of applications in gene 
therapy and regenerative medicine. The usage retroviral vectors for genetic modification 
of pluripotent stem cells can be applied in patient-specific therapies. However, one major 
obstacle is the variegated transgene expression depending on the integration site, called 
position effect variegation and silencing of the retroviral vectors (Jähner et al., 1982; 
Challita and Kohn, 1994). Pluripotent stem cells in particular are susceptible for silencing 
of retroviral vectors during differentiation into effector cells (Minoguchi and Iba, 2008). 
Also, after integration into the genome during generation of iPSC reprogramming, vectors 
get silenced by epigenetic mechanisms (Hotta and Ellis, 2008). Molecular mechanisms 
responsible for epigenetic silencing are DNA methylation and histone modifications.  
 
To prevent silencing, a couple of strategies have been developed such as addition of anti-
silencing sequences (McInerney et al., 2000). Insertion of insulator elements such as the 
chicken HS4 insulator and scaffold/matrix attachment regions (S/MAR) into retroviral 
vectors shield the vectors from the spread of heterochromatin into the euchromatic 
regions and associated gene silencing (Agarwal et al., 1998; Emery et al., 2000; Neville et 
al., 2017). Another strategy is the incorporation of UCOE. The best studied element is 
derived from an intergenic region between two ubiquitously expressed genes which are 
transcribed in opposite orientation (see Figure 6): the heterologous nuclear 
ribonucleoprotein A2B1 (HNRA2B1) and the chromobox homolog 3 (CBX3) first 
discovered by M. Antoniou et al. in 2003. It was discovered by integrating a 16kb region 
into centromeric heterochromatin (Antoniou et al., 2003). Further experiments revealed 
that the element can be dissected into smaller functional units, which allows their usage in 
retroviral vectors (Lindahl Allen et al., 2009). The intergenic region is highly enriched in 
unmethylated CpG, also termed CpG island (Gardiner-Garden and Frommer, 1987). 
Although the molecular mechanism of the functionality of the element remains still 
unknown, it is incorporated into retroviral vectors in a variety of applications such as the 
ex vivo bioengineering of iPSC-derived macrophages or in vivo chemoselection after 
transplantation of genetically modified cells (Pfaff et al., 2013; Phaltane et al., 2014; 
Ackermann et al., 2017). Further modification and thereby removal of a canonical splice 
donor and a cryptic splice site of the 670bp element spanning the transcriptional start site 
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of the CBX3 resulted in enhanced anti-silencing capacity after incorporation into 
constitutively expressed lentiviral vectors (Müller-Kuller et al., 2015). 
 
Figure 6 Ubiquitous chromatin opening elements and their location. The different A2UCOEs are derived 
from two housekeeping genes expressed in opposite orientation. Exons are indicated by horizontal black bars, 
arrows indicate transcriptional start sites of the corresponding genes. Annotation of exons based on 
NM_007276.4 (transcriptvariant1,CBX3), NM_016587.3 (transcriptvariant2,CBX3) and NM_002137.3 
(transcriptvariantA2). Mutations in cryptic splice site and canonical splice donor in the CBX3 element are 
indicated by vertical bars. (Modified after Cullmann et al., 2019).  
 
1.7 In vitro generation of platelets 
 
Platelet transfusion is the treatment of choice for patients suffering from thrombocytopenia 
caused by e.g. chemotherapy, radiation treatment, organ transplantation and inherited 
diseases. However, this is associated with several drawbacks such as the limited shelf life 
of the platelet products, the storage-related deterioration, the donor-dependency as well 
as patients developing allogenic antibodies against donor platelets after repetitive 
transfusions, a disease called platelet refractoriness. Due to this, several laboratories 
have made great efforts in the in vitro generation of platelets from different sources. 
Achieving the tremendous amount of 2-5 x 1011 platelets per transfusion unit from in vitro 
sources with platelet functionality comparable to freshly isolated cells still seems to be 
challenging. Platelets can be differentiated in vitro from two major sources. 1) 
Hematopoietic progenitors produce fully functional MK and platelets, however, they still 
show limited expansion potential and there is still a risk for alloreactivity of the patients 
(Choi et al., 1995; Di Buduo et al., 2015; Strassel et al., 2016) 2) Pluripotent stem cells 
including ESC and iPSC provide a renewable and unlimited source which also paves the 
way for personalized medicine. Two very promising technologies using iPSC resulted in 
the generation of expandable MK cell lines from either overexpression of major supportive 
factors (GATA1, SCL1, FLI1, c-MYC, BMI1) or anti-apoptotic factors BCL-XL) from which 
platelets can be produced showing comparable functionality to freshly isolated platelets 
(Nakamura et al., 2014; Moreau et al., 2016). Efforts made by Börger et al. showed that 
INTRODUCTION 
 
26 
 
also HLA-universal MK and platelets can be differentiated in vitro by silencing HLA I, 
which is a step towards universal platelet transfusions (Börger et al., 2016). With regards 
to the increase in output of in vitro generated platelets, several types of bioreactors have 
been developed. Two systems were designed to increase the platelet release by the 
application of shear forces under flow conditions: static MK attach to an appropriate matrix 
and extend their protrusions under shear, for example through small gaps, mimicking 
those of the endothelial cells lining the vascular sinusoids of the BM (Thon et al., 2014). A 
bioreactor is based on VWF-coated micro pillars to which the MK can attach, elongate and 
rupture under microfluidic conditions (Blin et al., 2016). The latest approach combines 
usage of immortalized MK, their proliferation up to 5x1010 followed by exposure to 
turbulence in a liquid bioreactor. Shedded platelets show similar functions to freshly 
isolated ones whilst achieving cell counts in the range of 1011. However, the underlying 
MK still produce only around 80 platelets per MK, which is still far less than the predicted 
1000 a MK can produce in vivo (Ito et al., 2018). 
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2 AIM OF THE STUDY 
Since the medical demand for blood products is increasing but blood donations will stay 
constant, a blood crisis in the upcoming years is very likely. Platelet products for 
transfusion are especially affected due to their short shelf life and special storage 
conditions to prevent activation and bacterial contamination. In vitro generated platelets 
and MK progenitors from iPSC are one of the earliest and most promising bioengineered 
blood products coming to application in human patients in the future. Furthermore, MK 
and platelets generated from iPSC could be utilized for disease modeling. However, there 
are still some hurdles to take since the production of platelets and MK from pluripotent 
stem cells is inefficient and also the functionality of culture-derived MK progenitors and 
platelets is impaired. iPSC can be modified with retroviral vectors in the pluripotent state. 
Overexpression of supporting factors such as major transcription factors can be beneficial 
for the manufacturing process and the quality of generated cells. However, their 
overexpression at very early stages of pluripotency might also be disadvantageous for the 
differentiation process. In this project, we were aiming for the overexpression of single 
supportive factors via a dox-inducible gammaretroviral vector to increase numbers and 
functionality of generated platelets and their progenitors in vitro. We therefore chose to 
overexpress the major transcription factors involved in early and late stages of 
megakaryopoiesis and platelet release, Gata1 and Pbx1. We also thought that 
overexpression of Evi1 would lead to directed proliferation of progenitors. Another very 
important candidate is Nfe2, a transcription factor that regulates mostly platelet release. 
To also enhance platelet release and functionality, we chose to overexpress hyperactive 
variants of the two very important GTPases RhoA and Cdc42 (RhoAhc and Cdc42hc, 
respectively) with Tet-inducible retroviral vectors.   
Retroviral vectors are often susceptible to epigenetic silencing via methylation of cytosine 
residues of the DNA. In our system, we utilized a human phosphoglycerate kinase (PGK) 
promoter for ubiquitous expression of the transactivator ((rt)TA-M2) in Tet-all-in-one 
retroviral vector configurations. The PGK promotor is highly enriched in CpG islands and 
therefore the most vulnerable component of the vector concerning epigenetic silencing. To 
prevent silencing during pluripotency and differentiation, we were following these two 
different strategies.   
 
1) Generation of murine iPSC expressing the (rt)TA-M2 from the Rosa26 locus (B6.Cg-
Gt(ROSA)26Sortm1(rtTA*M2)Jae/J should allow a continuous expression of (rt)TA-M2 and 
prevent transgene silencing during differentiation. Transduction of the respective single 
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supportive factors should be controlled by a Tet-responsive T11 minimal promoter. Based 
on the transduction of the iPSC in the pluripotent state, the cells should express the 
transgene (Gata1, Nfe2, Pbx1, Evi1, RhoAhc, Cdc42hc) after the induction with dox 
during the differentiation of the iPSC into MK and platelets. Generation of MK will further 
be supported by co-cultivation on OP9 feeder cells and supplementation with Thpo and 
Scf. The supportive effect of each single factor was evaluated by MK/platelet-specific 
surface maker expression, MK/platelet yield and morphology.  
 
2) Dox-inducible gammaretroviral vectors should also be applicable for usage in a human 
system of MK and platelet bioengineering from iPSC in the future. Epigenetic silencing 
especially during differentiation is comparable. We were, therefore, aiming to generate 
dox-inducible gammaretroviral all-in-one vectors that are less susceptible to epigenetic 
silencing. UCOE can be inserted upstream the PGK promoter; however, it is not clear 
whether they would influence the Tet-inducible system and maintain anti-silencing 
potential. We inserted UCOE of different sizes and locations in different orientations into 
the all-in-one vectors and tested their performance in terms of anti-silencing potential and 
regulation in various cell types including iPSC. 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Technical devices 
 
Table 1 Technical equipment 
Device Label Manufacturer, Headquarter 
0.5-1000µl pipets Pipetman Gilson; Limburg Offheim (GER) 
Balance Kern ABJ 320-4NM Kern & Sohn GmbH; Balingen (GER) 
Centrifuges 
Fresco 17 
Thermo Fischer Scientific; Waltham (MA 
USA) 
Multifuge X3R 
Cytospin 4 
Clean bench MSC-Advantage 
Thermo Fischer Scientific; Waltham (MA 
USA) 
CO2/O2 Incubator Series C Binder; Tuttlingen (GER) 
Counting chamber Neubauer Marienfeld, Lauda Königshofen (GER) 
Electrophorese power 
supply 
EV245 neoLab; Heidelberg (GER) 
Electrophorese 
chamber 
  neoLab; Heidelberg (GER) 
Suction System Aspir8 4.4 CS CellMedia; Gutenborn (GER)  
Flow cytometers 
Accuri C6 
BD Biosciences; Heidelberg (GER) LSR II SORP 
AriaIII 
CytoFLEX S Beckmann Coulter; Krefeld (GER) 
Fridge-Freezing  
combination 
  Liebherr; Biberach and der Riss (GER) 
Gel documentation    Intas; Göttingen (GER) 
Heating block Thermomixer basic CellMedia; Gutenborn (GER) 
Incubation shaker MaxQ 6000 
Thermo Fischer Scientific; Waltham (MA 
USA) 
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Device Label Manufacturer, Headquarter 
Incubator 
Microbiology 
4360 
Thermo Fischer Scientific; Waltham (MA 
USA) 
Microscope 
Primo Vert Carl Zeiss; Oberkochen (GER) 
Eclipse Ti-S  Nikon GmbH; Düsseldorf (GER) 
Fluoreszenzmikros
kop 
Observer Z1 
Carl Zeiss; Oberkochen (GER) 
Microwave KMW225 Koenic; Ingolstadt (GER) 
Multipipette Multipette M4 Eppendorf; Hamburg (GER) 
NanoPhotometer  P 300 Implen; München (GER) 
Orbital shaker Fisherbrand Digital 
Thermo Fisher Scientific; Waltham (MA 
USA) 
PCR devices  
Tpersonal 
Biometra; Göttingen (GER) Thermocycler 
Tprofessional 
Pipet  accu-jet pro Brand; Wertheim (GER) 
Real-time PCR system StepOnePlus 
Applied Biosystems; Thermo Fisher 
Scientific 
Waltham (MA, USA) 
Vortex VV3 VWR; Westchester (PA USA) 
Water bath Isotemp 
Thermo Fischer Scientific; Waltham (MA 
USA) 
3.1.2 Expendable items  
 
Table 2 Expendable items 
Material Manufacturer  
Cell culture dish Sarstedt; Nümbrecht (GER) 
Reaction tubes 15ml, 50ml Greiner Bio-One; Frickenhausen (GER) 
Cell strainer (70µm, nylon) BD Biosciences; Heidelberg (GER) 
Multiwell plates (6, 12, 24 well) Sarstedt; Nümbrecht (GER) 
PCR-Reaction tubes  Nerbe plus; Winsen/Luhe (GER) 
Petri dishes (Molecular Biology) Greiner Bio-One; Frickenhausen (GER) 
MATERIALS AND METHODS 
 
31 
 
Material Manufacturer  
Reaction tubes 1,5ml Sarstedt; Nümbrecht (GER) 
Serological pipettes Greiner Bio-One; Frickenhausen (GER) 
Syringes B.Braun; Melsungen (GER) 
Syringe driven filter unit, Milltex, 0.2µm Merck Millipore; Cork (IRL) 
3.1.3 Chemicals and reagents  
 
Unless otherwise stated, chemicals and reagents were obtained from the in-house facility 
at the Paul-Ehrlich-Institute. 
Table 3 Chemicals and Reagents 
Label Manufacturer 
1-Thioglycerol Gibco; Carlsbad (CA, USA) 
2-Mercaptoethanol Gibco; Carlsbad (CA, USA) 
Agarose 
Thermo Fisher Scientific; 
Waltham, MA USA 
Apyrase Sigma Aldrich; Seelze (GER) 
Ampicillin sodium salt Sigma Aldrich; Seelze (GER) 
Bovine serum albumin Sigma Aldrich; Seelze (GER) 
Calcium chloride (CaCl2) Sigma Aldrich; Seelze (GER) 
Chloroquine Sigma Aldrich; Seelze (GER) 
C reactive peptide (CRP) Sigma Aldrich; Seelze (GER) 
Collagenase IV Sigma Aldrich; Seelze (GER) 
4′,6-Diamidin-2-phenylindol (DAPI) Sigma-Aldrich; Seelze (GER) 
Doxycycline hyclate Sigma Aldrich; Seelze (GER) 
Ethylenediaminetetraacetic acid (EDTA) 
Promega BioSciences, San 
Luis Obispo, (CA, USA) 
Ethanol 
Ethanol (per analysis) 
Berkel AHK, Ludwigshafen 
(GER) 
Ethanol denatured   
Fetal calf sera for cultivation of ESC Gibco; Carlsbad (CA, USA) 
Fetal calf sera, pharma grade Biochrom; Berlin (GER) 
Fibrinogen Sigma Aldrich; Seelze (GER) 
Glutamine Biochrom; Berlin (GER) 
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Label Manufacturer 
Giemsa modified solution Sigma Aldrich; Seelze (GER) 
Glutamine Biochrom; Berlin (GER) 
Heparin Sigma Aldrich; Seelze (GER) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Carl Roth; Karlsruhe (GER) 
Isofluran CP CP Pharma, Burgdorf (GER) 
Isopropyl alcohol 
Berkel AHK, Ludwigshafen 
(GER) 
Magnesium chloride (MgCl2) Ambion; Austin (TX, USA) 
Matrigel  Corning; Amsterdam (NL) 
May-Grünwald solution Sigma-Aldrich; Seelze (GER) 
Minimum essential medium non-essential amino acids Gibco; Carlsbad (CA, USA) 
Penicillin Calbiochem; Darmstadt (GER) 
Potassium acetate   
Potassium dihydrogen orthophosphate(KH2PO4)   
Potassiumchloride (KCl)   
Prostacyclin (PGI2) Sigma Aldirch; Seelze (GER) 
Protamine sulfate Sigma Aldirch; Seelze (GER) 
Retronectin Takara Bio; Shiga (JPN) 
SDS   
Sodium azide (NaN3)   
Sodium chloride (NaCl) 
Promega BioSciences, San 
Luis Obispo, (CA, USA) 
Sodium hydrogen phosphate (Na2HPO4)   
Sodium hydroxide (NaOH)   
Streptomycin sulphate Calbiochem; Darmstadt (GER) 
TrisHCl pH 7,5 ultra-pure Gibco; Carlsbad (CA, USA) 
Vectashield® Mounting Medium 
Vector Laboratories, 
Burlingame (CA,USA) 
X-Gal CarlRoth; Karlsruhe (GER) 
Prestoblue® cell viability reagent  
Thermo Fischer Scientific; 
Waltham (MA, USA) 
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3.1.4 Buffers and solutions  
 
Unless otherwise stated, buffers and solutions were manufactured in the Paul-Ehrlich-
Institute in house facility. Buffers for platelet activation were obtained from the group of Dr. 
Markus Bender, Würzburg University. 
Table 4 Buffers and solutions 
Label Composition/Concentration 
2 x HeBS 280mM NaCl, 50mM HEPES, 1,5mM Na2HPO4, pH 7,05 
20 x Tyrode’s 
buffer (Maus) 
2.73M NaCl, 53.6mM KCl, 238mM NaHCO3, 8mM Na2HPO4, 0.5M 
HEPES  
20x TAE buffer 0.2mM EDTA, 0.8M TRIS, 22.84ml/l glacial acetic acid,  
Ampicillin 100mg/ml dissolved in ddH2O 
Blocking buffer for 
Retronectin 
PBS + 2% BSA 
BSA 10% 
Dulbecco’s PBS 
136.89mM NaCl, 2.86mM KCl, 1.46mM KH2PO4, 8.1mM Na2HPO4, 
pH 7.1, CaCl2 2 H2O 0.9mM, MgCl2 6H2O 0.5mM 
FACS-buffer 
164mM NaCl, 16.55mM Na2HPO4, 2.7mM KCl,  
1.2mM EDTA, 1.9mM KH2PO4, 0.1% NaN3 
Fixation buffer 
platelet activation 
PHEM buffer, 4% PFA, 0.033% NP40 
Gelatin 0.125%  
Glucose 10% 
LB-Agar LB-Medium, 1.5% Agar 
MACS-buffer  
137mM NaCL, ,1mM Na2HPO4, 2.7mM KCl, 2mM EDTA, 1.5mM  
KH2OP4, 0.07mM BSA (fraction V), pH 7.2  
P2 0.2M NaOH, 1% SDS 
P3 3M KaAC, pH 5.5 
PBS 
136.89mM NaCl, 2.86mM KCl, 1.46mM KH2PO4, 8.1mM Na2HPO4, 
pH 7.1 
Penicillin/Streptom
ycin 
17mM Streptomycin sulphate, 40.8mM Penicillin G potassium 
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Label Composition/Concentration 
PHEM buffer 100nM PIPES, 5.25nM HEPES, 10mM EGTA, 20mM MgCl2, pH6.8 
X-Gal 20ng/µl 
Trypsin-EDTA 0.5g/l Trypsin, 0.2g/l EDTA dissolved in PBS 
Washing buffer for 
Retronectin 
PBS + 2.5% HEPES 
3.1.5 Cytokines 
 
Table 5 List of Cytokines 
Cytokine  Manufacturer 
mIL-3  PeproTech; Rocky Hill (NJ, USA) 
mLIF PeproTech; Rocky Hill (NJ, USA) 
mScf PeproTech; Rocky Hill (NJ, USA) 
mThpo PeproTech; Rocky Hill (NJ, USA) 
3.1.6 Antibodies 
 
All antibodies used for flow cytometry were monoclonal and of an IgG isotype except for 
the αCD15 which was IgM.  
 
Flow cytometry 
 
Table 6 Antibodies for flow cytometry 
Antibody  Antigen Manufacturer  Catalog No.  
rat α-mouse 
CD41-PerCpCy5.5 
GPIIb Biolegend; San Diego (USA) 133918 
rat α-mouse  
CD41-APC 
GPIIb eBioscience; San Diego (USA) 133914 
hamster α-mouse 
CD42d-APC 
GPV eBioscience; San Diego (USA) 148506 
mouse α-mouse  
CD15-PE 
SSEA-1 
(pluripotent 
stem cells) 
Biolegend; San Diego (USA) 125606 
mouse α-mouse 
CD62P-PE 
P-selectin eBioscience; San Diego (USA) 148306 
mouse α-HA-biotin 
Influenza 
hemaglutinin 
Roche Diagnostics, Mannheim 
(GER) 
11583816001 
 
Visualization of the HA-Tag of the Mpl occurred via PE-conjugated streptavidin SAv-PE 
(BioLegend).  
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Immunostainings    
 
Table 7 Antibodies for pluripotency marker immunostaining 
Antibody Antigen  Manufacturer  Catalog No.  
sc-5279 
mouse α-human 
hOCT3/4 
Santa Cruz Biotechnology 
Dallas (USA) 
sc-5279 
sc17320 
mouse α-human 
hSOX2 
Santa Cruz Biotechnology 
Dallas (USA) 
sc-17320 
ab80892 
rabbit α-mouse 
mNanog Abcam, Cambridge (UK) ab80892 
Alexa Fluor® 488 
AffiniPure 
goat α-mouse 
IgG 
anti-mouse IgG 
IgG-Alexa 488 
(secondary) 
Jackson ImmunoResearch 
Cambridgeshire (UK) 
A-11001 
Cy™3 AffiniPure  
donkey  anti-Rabbit 
IgG 
(secondary) 
Jackson ImmunoResearch 
Cambridgeshire (UK) 
AB_2338000 
 
 
Table 8 Antibodies for platelet spreading assays 
Antibody Antigen  Manufacturer  Catalog No.  
14A3_Alexa488 CD41/CD61  
B.Nieswandt 
(Würzburg University)   
GTX107175 
rabbit α-mouse 
β1-tubulin (primary) 
GeneTex 
Irvine (USA) 
GTX107175 
56F8-Alexa487 GPVI 
 B.Nieswandt 
(Würzburg University)   
Cy™3 AffiniPure  
donkey  anti-Rabbit 
IgG 
(secondary) 
Jackson ImmunoResearch 
Cambridgeshire (UK) 
AB_2338000 
3.1.7 Enzymes 
 
Restriction enzymes were purchased from Thermo Scientific (Waltham, MA, USA) unless 
otherwise stated. The concentration of the restriction enzymes was 10U/µl. For restriction 
digest, about 1µg of plasmid DNA was used.  
 
All enzymes were used according to the instruction of the manufacturer  
Taq polymerase; Thermo Scientific, 5U/µl (Waltham, MA, USA)   
Pfu polymerase; Thermo Scientific 2.5U/µl (Waltham, MA, USA)  
T4-DNA Ligase; Thermo Scientific 5U/µl (Waltham, MA, USA)  
Alkaline phosphatase; Thermo Scientific 1U/µl (Waltham, MA, USA)   
RevertAid H Minus Reverse Transcriptase Thermo Scientific 200U/µl (Waltham, MA, 
USA)  
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3.1.8 Kits 
 
All kits were used according to the manufacturer’s instructions.  
 
 
Table 9 Kits 
Name  Manufacturer 
Nucleo Spin Tissue MACHEREY-NAGEL; Düren (GER) 
NucleoBond Xtra Maxi MACHEREY-NAGEL; Düren (GER) 
NucleoSpin Plasmid MACHEREY-NAGEL; Düren (GER) 
Nucleo Spin Gel and PCR clean up  MACHEREY-NAGEL; Düren (GER) 
Direct-Zol RNA Kit Zymo Research Europe; Freiburg (GER)  
EZ DNA Methylation Kit Zymo Research Europe; Freiburg (GER)  
pGEM®TEasyVector Kit  Promega; Mannheim (GER) 
Lineage cell depletion Kit 
Miltenyi Biotech; Bergisch Gladbach 
(GER) 
STEMdiff™ Trilineage Differentiation Kit 
 
StemCell Technologies, Vancouver (CAN) 
ReLeSRTM StemCell Technologies, Vancouver (CAN) 
Stemgent™ Alkaline Phosphatase Staining 
Kit 
ReproCell, Glasgow (UK) 
 
3.1.9 Plasmids 
 
pBlueScript II SK (+) (Addgene)  
All gammaretroviral (GV) and lentiviral (LV) vector backbones used in these studies were 
kindly provided by Prof. Dr. Axel Schambach (Institute of Experimental Hematology, 
MHH).  
Plasmids to generate gammaretroviral vectors  
SERS11.T11-iGFP.pre 
SERS11.T11-Gata1-iGFP.pre 
SERS11.T11-Nfe2-iGFP.pre 
SERS11.T11-Evi1-iGFP.pre 
SERS11.T11-Pbx1-iGFP.pre 
SERS11.T11-RhoAhc-iGFP.pre 
SERS11.T11-Cdc42hc-iGFP.pre 
SERS11.T11-eGFP-PGK-M2.pre 
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SERS11.T11-eGFP-U630s-PGK-M2.pre 
SERS11.T11-eGFP-U630as-PGK-M2.pre 
SERS11.T11-eGFP-U670s-PGK-M2.pre 
SERS11.T11-eGFP-U670as-PGK-M2.pre 
SERS11.T11-eGFP-U1.0s-PGK-M2.pre 
SERS11.T11-eGFP-U1.0as-PGK-M2.pre 
SERS11.T11-eGFP-U1.5s-PGK-M2.pre 
SERS11.T11-eGFP-U1.5as-PGK-M2.pre 
SERS11.T11-eGFP-CBX3-PGK-M2.pre 
SERS11.T11-eGFP-EFS-M2.pre 
Plasmids for the generation of lentiviral vectors:  
SIN.Lv.SFFV.OKSM.dTom 
RRL.PPT.T11-eGFP-PGK-M2.pre 
RRL.PPT.T11-eGFP-U670s-PGK-M2.pre 
 
Helper plasmids 
Table 10 Helper plasmids 
Plasmid Application 
pcDNA3.MLVsyng/p Gammaretroviral vector, gag/pol 
pCDNA3.GP.CCCC Lentiviral vector, gag/pol 
pMD2.G Envelope, vsvg 
pRSV_Rev Rev 
3.1.10 Oligonucleotides 
 
Table 11 Primers 
Primer Sequence Dye 
GFP forward GTAAACGGCCACAAGTTCAGC   
GFP reverse  TGGTGCAGATGAACTTCAGGG   
probe GFP CTTGCCGTAGGTGGC FAM 
wPre forward GAGGAGTTGTGGCCCGTTGT   
wPre reverse TGACAGGTGGTGGCAATGC   
probe wPre CTGTGTTTGCTGACGCAAC FAM 
PTBP2 forward TCTCCATTCCCTATGTTCATGC   
PTBP2 reverse GTTCCCGCAGAATGGTGAGGTG   
probe PTBP2 ATGTTCCTCGGACCAACTTG JOE 
Methylation PCR 
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Primer Sequence Dye 
U670 fw 
TAACCGGTCGTTCACCATGGGGGAGGTGGTCCCTGCA
GTTACGCC 
 
  
U670 rv TAGCGGCCGCGGCCCTCCGCGCCTACAGCTC 
  
  
qRT PCR 
TaqMan Assay 
Sox2 
Mm00488369_s1 (Thermo Fischer Scientific; Waltham 
USA) 
FAM 
TaqmMan Assay 
Oct4 
Mm00658129_gH (Thermo Fischer Scientific; Waltham 
USA) 
FAM 
TaqMan Assay 
Nanog 
Mm02384862_g1 (Thermo Fischer Scientific; Waltham 
USA) 
FAM 
TaqMan Assay 
Actin β 
Mm00607939_s1 (Thermo Fischer Scientific; Waltham 
USA) 
VIC 
   
Plasmid generation 
U670 fw 
TAACCGGTCGTTCACCATGGGGGAGGTGGTCCCTGCA
GTTACGCC 
 
 
U670 rv 
TAGCGGCCGCGGCCCTCCGCGCCTACAGCTC 
 
 
Mpl fw 
TAACCGGTATGCCCTCTTGGGCCCTCTTCAT 
 
 
Mpl rv 
TACCATGGTCAGGGCTGCTGCCAATAGCTTAG 
T 
 
EFS fw 
TAGCGGCCGCTGGCTCCGGTGCCCGTCAGTG 
 
 
EFS rv 
TATCTAGACATGGTACCGGTGATGATCCCCCGCGTCA
CGACACCTGTGTTCTGG 
 
 
3.1.11 Bacterial strains, cells and cell lines   
 
The bacterial E.coli strain XL1 gold was used for amplification of plasmid DNA during 
cloning procedures. Cell lines and primary cells are listed below . 
 
Table 12 Cells and cell lines 
Cell line 
Origin and 
cell type 
Organism  Reference 
HEK 293T 
Embryonic 
kidney  
carcinoma 
cells  
Homo 
sapiens 
Xie et al., 1996 
MEF (C3H) 
Murine 
embryonic 
fibroblasts 
isolated from 
Mus 
musculus 
Amit et al., 2003 
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Cell line 
Origin and 
cell type 
Organism  Reference 
C3H/HeNRj 
mice 
OP9 
BM stromal 
cells  
(mesenchyme) 
(C57BL/6 x 
C3H)F2 -op/op 
Mus 
musculus 
Nakano et al., 
1994 
SC1 
Murine 
fibroblasts 
Mus 
musculus 
Hartley and 
Rowe, 1975 
32D 
 
myeloid 
leukemia cells  
Mus 
musculus 
Greenberger et 
al., 1983 
P19 
Murine 
embryonic 
carcinoma 
cells  
Mus 
musculus 
McBurney et al., 
1982 
primary hematopoietic stem and 
progenitor cells (HSPC) 
B6Cg-
Gr(ROSA)26 
Sortm1(rtTA*M2)Jae
/J 
Mus 
musculus 
Hochedlinger et 
al., 2005 
3.1.12 Culture media  
 
Table 13 Culture media  
Strain/Cell line Medium Manufacturer (Medium) 
XL1 gold 
LB-Medium, ampicillin 
(1:1000) 
Paul-Ehrlich-Institute;  
Langen (GER) 
HEK 293T  
DMEM (10% FCS, 
1% L-glutamine) 
Biowest; Nuaillé (FR) 
SC1 
DMEM (10% FCS, 
1% L-glutamine) 
Biowest; Nuaillé (FR) 
primary bone  
marrow cells 
StemSpan SFEM (1%  
L-glutamine, 1% 
Pen/Strep,  
20ng/ml hIGF-2, 
20ng/ml mThpo, 10 
ng/ml mFGF-1,  
10ng/ml mSCF 
STEMCEll technologies; 
 Grenoble (FR) 
Murine embryonic 
fibroblasts (MEF) 
DMEM (10% FCS, 1% 
L-glutamine, 1% 
Pen/Strep,  
1% NEAA, 30 mM β-
mercaptoethanol) 
Biowest; Nuaillé (FR) 
R26M2 iPSC 
DMEM (15% ES cell 
qualified FBS, 1% L-
glutamine, 1% 
Pen/Strep, 1% NEAA, 
30 mM β-
mercaptoethanol, 1000 
U/ml 
Gibco;  
Thermo Fisher Scientific; 
 Waltham (MA USA) 
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Strain/Cell line Medium Manufacturer (Medium) 
OP9 
alpha Medium (20% 
FCS, 1% L-glutamine) 
Biochrom; Berlin (GER) 
Differentiation;  
embryoid bodies  
SF-IMDM (15% FCS, 
1% Pen/Strep, 
1% L-glutamine; 
Ascorbic Acid, MTG)  
Paul-Ehrlich-Institute;  
Langen (GER) 
Differentiation;  
MK 
α-Medium (20% FCS, 
1%  
L-glutamine,  
1% Pen/Strep, 25 
ng/mL SCF, 50 ng/mL 
TPO, ±dox (1µg/ml))  
Biochrom; Berlin (GER) 
32D 
RPMI (10% FCS, 1% 
L-glutamine,  
1% sodium pyruvate, 5 
ng/ml IL-3) 
Biowest SAS; Nuaillé (FR) 
P19 
αMEM (10% FCS, 2mM  
L-glutamine 1% 
Pen/Strep) 
Biochrom; Berlin (GER) 
mTeSRTM1   
Stem Cell Technologies; 
Vancouver (CAN) 
Medium for Transfection 
Medium for HEK293T 
10% HEPES 
25µM Protaminsulfat  
 
3.2 Methods 
3.2.1 Molecular biology tools 
3.2.1.1 Plasmids for viral vector generation 
 
Plasmids for generation of gammaretroviral vectors for transduction of murine iPSC 
The plasmids for the generation of gammaretroviral vectors overexpressing the supportive 
candidate factors are listed in the following. Restriction digest and ligation was performed 
according to the instruction of the manufacturer.  
SERS11.T11-iGFP.pre 
SERS11.T11-Gata1-iGFP.pre 
SERS11.T11-Nfe2-iGFP.pre 
SERS11.T11-Evi1-iGFP.pre 
SERS11.T11-Pbx1-iGFP.pre 
SERS11.T11-RhoAhc-iGFP.pre 
SERS11.T11-Cdc42hc-iGFP.pre 
SERS11.T11-eGFP-PGK-M2.pre 
 
For generation of the plasmids, the T11-Nfe2-iGFP and T11-Gata1-iGFP cassettes were 
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liberated from the pSERS.T11-Nfe2-iGFP-PGK-M2.pre plasmid using the restriction 
enzymes XhoI and NotI and inserted into pSERS11.T11-eGFP.pre plasmid using the 
same restriction enzymes. For generation of the pSERS11.T11.iGFP, the Nfe2 cDNA was 
digested from the plasmid using the AgeI restriction enzyme and the remaining backbone 
was re-ligated. The plasmids SERS11.T11-RhoAhc-iGFP.pre and SERS11.T11-Cdc42hc-
iGFP.pre were generated by isolation of the respective factor (RhoAhc, Cdc42hc) with 
AgeI from the pRRL.PPT.mPf4-RhoAhc-i-GFP.pre and pRRL.PPT.mPf4-Cdc42hc-i-
GFP.pre backbone and replacement of the Nfe2 of the pSERS.T11-Nfe2-iGFP-PGK-
M2.pre which could also be removed by AgeI. Furthermore, generation of the vectors 
SERS11.T11-Evi1-iGFP.pre was performed by isolation of the Evi1 gene from the 
pSERS11.SF-Evi1-i-GFP.pre template using the restriction enzyme BamHI. After 
digesting the SERS11.T11-Nfe2-iGFP.pre backbone, the Evi1 was inserted and replaced 
the Nfe2. The plasmid SERS11.T11-Pbx1-iGFP.pre was generated using the same 
strategy, and also the BamHI restriction enzyme. The template for isolation of the Pbx1 
was the plasmid pRRL.PPT.SFFV.Pbx1.iGFP.pre. The orientation of the respective genes 
was verified using by an appropriate restriction digest.  
  
Gammaretroviral vectors SERS11.T11-iGFP-RhoAhc-iGFP.pre and SERS11.T11-iGFP-
Cdc42hc-iGFP.pre were generated by F. Schenk, SERS11.T11-iGFP-Pbx1-iGFP.pre was 
generated by S. Lorke.   
 
Construction of plasmids to generate retroviral Tet-all-in-one vectors containing different 
A2UCOE 
 
Multiple restriction digests of the 4kb original DNA sequence (kindly provided by Prof. Dr. 
A. Thrasher and Dr. M. Antoniou, King’s College, London) were performed to obtain the 
different sized A2UCOE. The resulting A2UCOE were in the sizes of 437bp, 637bp, 
672bp, 1073bp and 1551 bp. The CBX2-A2UCOE contains mutations in the canonical 
donor splice site and potential crytic splice acceptor site at the first exon-intron boundary 
and the following intron. All A2UCOE were blunt-end ligated upstream of the human PGK 
promoter into the gammaretroviral Tet-inducible, all-in-one vector pSERS11.T11-eGFP-
PGK-M2.pre. The orientation of the A2UCOE was verified by restriction digests and 
sequencing. To generate the promoter-replaced variants, the gammaretroviral vector 
pSERS11.T11-eGFP-M2.pre was generated by liberation of the PGK.M2 from the 
pSERS11.T11-eGFP-PGK-M2 followed by PCR amplification of a donor M2 into the 
pBluescript II SK(+) (Stratagene, Amsterdam). Then, the PCR amplified M2 was digested 
by restriction enzymes BamHi and BspEI and subsequent ligation. Next, the A2UCOE 
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U670s and CBX3 were generated as described above and blunt-end ligaged into the 
gammaretroviral vector pSERS11.T11-eGFP-M2.pre resulting in pSERS11.T11-eGFP-
U670s-M2.pre and pSERS11.T11-eGFP-CBX3-M2.pre. The plasmid for the 
gammaretroviral vector pSERS11.T11-eGFP-EFS-M2.pre was generated by PCR 
amplification of the EFS promoter with the restriction sites for XbaI and NotI and inserted 
into the vector backbone using the respective enzymes. The lentiviral vector containing 
the U670s as promoter pRRL.PPT.T11-eGFP-U670s-M2 was generated by restriction 
enzyme digest of the T11-eGFP-U670s-M2 cassette from the corresponding 
gammaretroviral construct pSERS11.T11-eGFP-U670s-M2.pre using XhoI and BstZ17 
and inserting into the lentiviral backbone using the same enzymes. The plasmid for the 
generation of the gammaretroviral vector expressing the HA-Mpl receptor was generated 
by PCR amplification of the U670s. Restriction sites for NcoI and AgeI were added 
upstream the U670s element to the forward primer. Downstream of the U670s element, a 
restriction site for NotI was added to the reverse primer. After PCR amplification, the 
U670s element was inserted into the PSERS11.T11-eGFP-PGK-M2.pre backbone by 
replacing the eGFP via insertion with NcoI and NotI resulting in pSERS11.T11-U670s-
PGK-M2.pre.2. HA-Mpl was PCR-amplified and AgeI sites added to the appropriate 
primers. After restriction of the pSERS11.T11-U670s-PGK-M2.pre.2 with AgeI, amplified 
HA-Mpl was inserted with the corresponding restriction site resulting in pSERS11.T11-HA-
Mpl-U670s-PGK-M2.pre. The resulting vectors are listed in the following.   
 
N. Heinz and K. Blokland generated the gammaretroviral Tet-all-in-one vectors containing 
the different A2UCOE elements. F. Schenk generated the SERS11.T11-HA-Mpl-U670s-
PGK-M2.pre vector.  
 
Gammaretroviral vectors:  
SERS11.T11-eGFP-U630s-PGK-M2.pre 
SERS11.T11-eGFP-U630as-PGK-M2.pre 
SERS11.T11-eGFP-U670s-PGK-M2.pre 
SERS11.T11-eGFP-U670as-PGK-M2.pre 
SERS11.T11-eGFP-U1.0s-PGK-M2.pre 
SERS11.T11-eGFP-U1.0as-PGK-M2.pre 
SERS11.T11-eGFP-U1.5s-PGK-M2.pre 
SERS11.T11-eGFP-U1.5as-PGK-M2.pre 
SERS11.T11-eGFP-CBX3-PGK-M2.pre 
SERS11.T11-eGFP-EFS-M2.pre  
SERS11.T11-HA-Mpl-U670s-PGK-M2.pre 
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Lentiviral vectors:   
RRL.PPT.T11-eGFP-PGK-M2.pre 
RRL.PPT.T11-eGFP-U670s-PGK-M2.pre 
 
3.2.1.2 Bacteria transformation and cultivation 
 
100µl of chemically competent E. coli XL 10 Gold were thawed on ice and mixed with 
either 1µl of plasmid DNA or 10µl of ligation sample. Transformation was performed by 
heat shock at 42°C for 2min followed by incubation in 1ml LB medium for 30min (37°C). 
Bacteria were either inoculated onto LB-agar plates (100mg/ml ampicillin) for selection or 
inoculated into liquid LB medium (100mg/ml ampicillin, 200rpm).  
3.2.1.3 Blue-white screen 
 
Bisulfite-converted PCR products (see Chapter 3.2.1.6) for the determination of the 
methylation state of the PGK promoter were inserted into pGEM®TM plasmid. Positive 
colonies were selected via blue-white -screening. Therefore, IPTG and X-Gal were 
additionally applied on ampicillin LB-agar plates before the transformed bacteria were 
plated. Due to the inactivation of the β-galactosidase in the plasmid after insertion of the 
PCR product, the positive colonies were identified by their white color. 
3.2.1.4 Isolation of plasmid DNA from bacteria 
 
Plasmid DNA from bacteria was isolated by the NucleoSpin® Plasmid Kit, NucleoBond 
Xtra® Midi/Maxi Kit (MACHERY-NAGEL) according to the manufacturer’s instruction. For 
low amounts of plasmid DNA (1-3µg), transformed bacteria were grown in 5ml of 
ampicillin (100mg/l) containing LB medium at 37°C overnight. For higher amounts 
(>400µg), transformed bacteria were inoculated in 150-250ml LB medium (100mg/l) 
overnight (37°C, in a shaker 200rpm). After isolation, plasmid concentration was 
determined using the Nano Photometer (IMPLEN). 
3.2.1.5 Real-time PCRs 
 
All TaqMan™ real-time PCR experiments were performed with the TaqMan™ Fast 
Advanced Master Mix (Thermo Fischer Scientific, Waltham, MA, USA) according to the 
manufacturer’s instructions. Genomic DNA was isolated using the NucleoSpin® Tissue kit 
(MACHERY-NAGEL, Düren, Germany).   
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Vector copy number detection  
Specific primers and TaqMan probes were complementary to the PTBP2 (housekeeping 
gene) and the wPre element or the GFP. The average VCN was calculated by 
normalization to the housekeeping gene PTBP2 and the vector elements wPre or GFP 
and correlated to a plasmid standard as reference. The plasmid standard was kindly 
provided by Dr. Tobias Mätzig (Experimental Hematology, MHH). PCRs were run on the 
StepONEPlus Real-Time PCR System (Applied Biosystems; Thermo Scientific; Waltham; 
MA, USA).  
 
Table 14: Program VCN 
Step Temperature [°C} time [min] 
1 95 05:00 
2 94 00:15  
3 60 00:30 
4 68 01:00 
Step 1-4  34 cycles  
5 68 10:00 
6 4  ∞ 
 
 
Gene expression analysis by real-time PCR  
 
For determination of the pluripotency status of generated iPSC, the cells were depleted 
from the feeder cells and RNA was isolated with the Direct-Zol RNA Kit (Zymo Research). 
After reverse transcription of the RNA into cDNA using Random Hexamer Primers and 
RevertAid H Minus Reverse Transcriptase (Thermo Fischer Scientific, Waltham, MA, 
USA) according to the manufacturer’s instructions, gene expression of Oct4, Nanog and 
Sox2 was determined and compared to expression in MEF and OG2 embryonic stem 
cells. Gene expression analysis was calculated by the delta-delta CT method and the β-
actin expression was used as for normalization of the gene expression.   
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Table 15: PCR program gene expression analysis 
Step Temperature [°C} time [min] 
1 50 02:00 
2 95 02:00  
3 95 00:01 
4 60 00:20 
Step 3-4  40 cycles  
 
3.2.1.6 Promoter methylation analysis 
 
For determination of changes in the methylation status of the PGK promoter during 
differentiation, genomic DNA (gDNA) from undifferentiated KOLF2 hiPSC (kindly provided 
from Dr. Bill Skarnes (Sanger Institute’s Human Induced Pluripotent Stem Cells Initiative 
(Hip-Sci) project) as well as differentiated KOLF2 cells transduced with the U670s element 
and differentiated into the mesodermal germ layer was isolated. To test for methylated vs. 
non-methylated CpG residues within the promoter, a bisulfite conversion was performed. 
The gDNA of the transduced and differentiated/un-differentiated KOLF2 cells was 
isolated. The treatment of the DNA with sodium bisulfite converts non-methylated cytosine 
residues into uracil by a chemical reaction. Methylated cytosine residues remain 
unaffected. After bisulfite conversion of 600ng gDNA with the EZ DNA Methylation-Gold 
TM Kit (Zymo Research, Irvine CA, USA) according to the manufacturer’s instructions, the 
PGK promoter was amplified using the appropriate primers. Design of the primers was 
done by Dr. Mania Ackermann (Experimental Hematology, MHH) using the MethPrimer 
program (https://www.urogene.org/methprimer/). Sequences of the primers are included in 
Table 11. After PCR amplification, the PGK promoter fragment was subcloned into the 
pGEM®TM plasmid (Promega, Mannheim, GER). Positive colonies were identified by 
blue-white screening, isolated and subjected to sequencing with the supreme run 
sequencing technology (GATC biotech (Eurofins), Ebersberg, GER) according to the 
manufacturer’s instructions. Data were analyzed using the BiQ Analyzer software. 
3.2.2 Cell culture 
 
All cell lines, primary cells and differentiation cell cultures, were grown in the appropriate 
culture medium (Table 10) and incubated at 37°C and 5% CO2 and 90% humidity. 
HEK293T, SC1, MEF and OP9 and R26M2 iPSC were split every 2-3 days to 80% 
confluency. Prior to splitting, the cells were detached with Trypsin-EDTA (0.5 g/l Trypsin, 
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0.2g/l EDTA dissolved in PBS). 32D cells were grown in suspension to 80% confluency 
and split every 2-3 days. 
3.2.2.1 Production of viral particles and determination of the infectious 
particle titer 
 
Infectious viral vectors were produced in human HEK 293T packaging cells by transient 
transduction of the respective plasmids for the split packaging by calcium-phosphate 
transduction. All vectors were pseudotyped with VSVg glycoprotein (Naldini et al., 1996). 
Concentrations of the respective plasmids and chemicals for the production of 
gammaretro- and lentiviral vectors are listed in Table 16. One day prior to transfection, 
HEK 293T cells were plated at a density of 106 cells per 10cm culture dish. For 
transfection, culture medium was aspirated and 8ml of transfection medium containing 
chloroquine (25µM) was added (Table 13).  
 
 
Table 16: Concentration transfection gammaretroviral and lentiviral vectors 
 
Gammaretroviral vector  Lentiviral vector 
Transfer vector 
plasmid 
10µg 
 Transfer vector 
plasmid 
10µg 
Syngagpol plasmid 10µg  Gag/pol plasmid 10µg 
Envelope plasmid 1.5µg  Envelope plasmid 1.5µg 
CaCl2 (5M) 25µl   Rev plasmid 5µg 
H2O add to 500µl   CaCl2 (5M) 25µl  
   H2O add to 500µl  
 
After mixing the plasmids with CaCl2, the mixture was dropped to 500µl HEPES buffered 
saline (HeBS) using the “bubbling technique”. Hereby, DNA mixture was added to the 
HeBS buffer under constant mixing by air bubbling to improve precipitation. After 10min, 
incubation solution was added dropwise to the cell culture plate with transfection medium. 
Transfection medium was changed after 12h of incubation into DMEM containing HEPES 
(20mM) and 1% Penicillin/Streptomycin. The first supernatant was harvested 36h after 
transfection and filtrated though 22µm syringe filters. Supernatants were stored at 4°C 
until the second harvest after 48h. After pooling first and second harvest, supernatants 
were concentrated by centrifugation at 50.000x g for 1.5h, re-suspended in Stem Span 
and stored at -80°C.   
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The amount of infectious particles of the viral vector was determined with the help of SC1 
fibroblast cells. 6 x 104 to 1 x 105 SC1 cells were seeded per well of a 12-well plate. The 
plates were incubated until attachment of the SC1 cells to the cell culture dish was 
completed. Before transfection of SC1 cells with viral supernatants, the medium was 
changed to culture medium containing protamine sulfate (Sigma Aldrich) (4µg/ml). 
Medium containing dox (1µg/ml) was used to induce gene expression when testing the 
Tet-all-in-one vector system. Viral supernatants were applied to the cells in different 
volumes to a volume of 1ml per well. After culture overnight, the medium was changed to 
medium without protamine sulfate. After 72 h of culture, cells were detached using PBS 
without Ca2+ containing EDTA (1 M) and gentle pipetting. The number and percentage of 
transduced cells was then determined by flow cytometry. Viral titers can be calculated by 
using the following formula: 
𝑇𝑖𝑡𝑒𝑟 =
%𝑝𝑜𝑠 𝑐𝑒𝑙𝑙𝑠 𝑥 𝑛𝑜. 𝑐𝑒𝑙𝑙 𝑠𝑒𝑒𝑑𝑒𝑑
𝑣𝑜𝑙 𝑜𝑓 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑡𝑛𝑡 [𝑚𝑙]
  [
𝐼𝑃
𝑚𝑙
] 
3.2.2.2 Transduction of cell lines 
 
All cell lines were transduced in appropriate medium containing 4µg/ml of protamine 
sulfate (Sigma Aldrich). Prior to transduction, a defined cell number was seeded to allow 
the application of a defined MOI. Murine iPSC, 32D and P19 cells were transduced in 
suspension. 
3.2.2.3 Reprogramming of murine primary HSPC into induced 
pluripotent stem cells 
 
After isolation of lineage-negative (Lin-) cells from B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae/J 
mice cells were cultured in StemSpan-STIF medium for 24h prior transduction. Cells were 
grown on multi-well suspension plates and transduced with an appropriate volume of viral 
supernatant (SIN.Lv.OSKM.dTom) to achieve an MOI of 10 and a VCN of 1. The wells 
were pre-coated with RetroNectin (3.6µg/mm2) (Takara BIO Inc.; Otsu, Japan). Viral 
particles were loaded to the RetroNectin by centrifugation at 2000xg for 30min at 4°C 
before the respective cell number was added. One week after transduction, transduced 
cells were transferred onto mitomycin C (20µg/ml) treated MEF feeder cells. The first 
iPSC colonies were isolated approximately 4 weeks after transferring the cells onto the 
MEF. Colonies were harvested by scratching with a 27G needle and aspirated with a 
pipette before transferring into Trypsin-EDTA (0.5g/l Trypsin, 0.2g/l EDTA dissolved in 
PBS) to generate single cells. Single cells were transferred into one well of mitomycin C 
treated MEF feeder cells (24-well cell culture plate) and expanded. Early passages were 
frozen in FCS (10% DMSO) and stored in liquid nitrogen (-180°C). 
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3.2.2.4 Culture of murine iPSC 
 
Murine iPSC were cultivated on mitomycin C (20µg/ml) treated MEF feeder cells. MEF 
cells were seeded (40.000/well of a 6-well cell culture dish) onto gelatin-coated (0.125%) 
cell culture dishes and incubated for 2 days. MEF were incubated with mitomycin C for 
45min before washing 3 times with PBS. MEF were plated and cultured up to 4 days 
before iPSC were seeded. For splitting the iPSC, they were incubated with Trypsin-EDTA 
(0.5g/l Trypsin, 0.2g/l EDTA dissolved in PBS). Single cells were re-suspended in KO 
DMEM with 10% FCS. For transduction, single cell suspension of iPSC were transferred 
onto gelatin-coated cell culture dishes for 40min to deplete the MEF feeder cells. After 
harvesting the supernatant containing iPSC and washing with 10ml PBS (300x g), cells 
were re-suspended, counted and seeded in the appropriate medium (see Table 13) 
containing protamine sulfate (4mg/ml) before addition of the viral supernatant. 2-3 days 
after transduction, iPSC were transferred onto mitomycin C (20µg/ml) treated feeder cells. 
3.2.2.5 Culture and differentiation of human iPSC 
 
Human KOLF2 iPSC were cultivated under feeder-free conditions on Matrigel (Cornig, 
Amsterdam, NL)-coated cell-culture dishes in mTesRTM1 medium (Stem Cell 
Technologies, Vancouver, CAN) according to the instruction of the manufacturer. The 
cells were grown to 80% confluency and passaged in aggregates using ReLeSRTM (Stem 
Cell Technologies, Vancouver, CAN). Prior to transduction, cells were grown to 60% 
confluency. Transduction occurred once with an MOI of 5 under supplementation with 
protamine sulfate (4μg/ml). Differentiation was initiated 2 days after transduction. To 
generate embryoid bodies (EB), AggreWell plates and AggreWell EB Formation Medium 
(Stem Cell Technologies, Vancouver, CAN) were used according to the instructions of the 
manufacturer. Following 2h of incubation in the AggreWell plates to allow forming of the 
EB, these were then plated onto to poly-HEMA (Poly(2-hydroxyethyl methacrylate), 
Sigma-Aldrich) coated plates in the presence of dox for three days. Fluorescence 
microscopy was carried out using a Nikon Eclipse Ti-S microscope (Nikon GmbH, 
Düsseldorf, Germany). To induce differentiation into three germ layers, the STEMdiffTM 
Trilineage Differentiation Kit (Stem Cell Technologies) was used according to the 
instructions of the manufacturer. Briefly, cells were seeded onto Matrigel (Corning)-coated 
plates and incubated for the indicated times in differentiation media with or without dox. 
Cells were then harvested and analyzed by flow cytometry. 
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3.2.2.6 Differentiation of murine iPSC into megakaryocytes and 
platelets 
 
R26M2 iPSC were differentiated into EB. Therefore, cells were depleted from their feeder 
cells for 45min on 6-well gelatin-coated cell culture dishes and cultivated without feeders 
for 2 days on 6-well gelatin-coated cell culture dishes in differentiation medium (see Table 
13). For the EB formation, 45.000 cells/ml were seeded into 6-well suspension cell culture 
dishes in differentiation medium (see Table 13) and subjected to orbital shaking (0.2x g) 
for 7 days in total. At day 5 of differentiation, the medium was supplemented with 30ng/mL 
murine stem cell factor (SCF), 10ng/mL murine IL-3 to support hematopoietic 
differentiation. At day 7 of differentiation, EB were dissociated with collagenase IV 
(250U/ml) and CD41+ early hematopoietic progenitors were enriched either by 
fluorescence-activated cell sorting (FACS) or magnetic activated cell sorting (MACS). For 
MACS, the cells were incubated with the biotinylated anti-CD41 antibody (1:100) 
(eBioscience; San Diego, USA) (30min, 4°C). Enrichment of the CD41-expressing 
hematopoietic progenitors occurred using the Anti-BiotinMircro Beads (Miltenyi Biotec, 
Bergisch Gladbach) according to the manufacturer’s instruction. For FACS, cells were 
incubated with an APC-conjugated antibody against CD41 (Table 5). Further MK 
differentiation was performed by co-cultivation of CD41+ hematopoietic precursors on OP-
9 feeder cells. OP-9 cells were seeded (1 x 105/well) onto 6-well gelatin-coated cell culture 
dishes one day prior to EB dissociation and incubated overnight. To inactivate their 
proliferation, OP-9 were treated with mitomycin C (10µg/ml, 90min) and washed as 
described for MEF. After inactivation of the OP-9 and dissociation of the EB, 1 x 105 
CD41+ progenitors were seeded onto the feeder cells in MK differentiation medium (see 
Table 13). MK progenitor cells were harvested and analyzed earliest after 2 weeks of co-
cultivation (d21 of differentiation). Cell culture supernatant was harvested into cell culture 
reaction tubes. Residual cells were detached from the cell culture plates using Trypsin-
EDTA. OP-9 feeders were depleted by incubation on gelatin coated cell culture-dishes for 
40min and residual cells were pooled to the first harvest. The cells were washed (250x g, 
7min, RT) and re-suspended, counted and either re-seeded or analyzed according to their 
morphology or cell surface receptor expression. For further cultivation and differentiation 
1 x 105 total cells were seeded either on mitomycin C treated feeder cells as already 
described or on 6-well suspension cell culture plates. In vitro differentiated platelets were 
harvested from the supernatant of the pooled harvest of the MK. After centrifugation of the 
differentiated MK (250x g, 7min, RT), the supernatant was transferred into a fresh reaction 
tube and the platelets were pelleted at 900xg, 10min, RT and subjected to further 
analysis. 
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3.2.3 Cytospin and cytomorphological staining 
 
For the morphological analysis of the cells and the differentiation of the cell types, 
cytological analysis was performed by staining of the cytoplasm and the nuclei. 105 cells 
were spun on microscope slides by centrifugation (300xg, 5min, RT) and air dried. For 
staining, the slides were incubated in May-Grünwald staining solution for 5min and 
subsequently washed with ddH2O. Giemsa staining solution was applied for 20min, 
followed by another washing step, and finally air dried overnight. Slides were analyzed 
with the Leica DMRBE microscope (Leitz). 
3.2.4 Electron Microscopy 
 
Culture-derived platelets were harvested as described above. Cells were pelleted (900xg, 
10min, RT, without break) and re-suspended in PBS, before 2.5% glutaraldehyde was 
added and incubated for 20min at room temperature, followed by 40min incubation at 4°C. 
Cells were washed twice with PBS (900xg, 10min, RT) and stored at 4°C until further 
processing which was performed by the Division of Immunology at the Paul-Ehrlich-
Institute. 
3.2.5 Flow cytometry 
 
Characterization of the surface receptor expression of in vitro differentiated MK and 
platelets was analyzed by flow cytometry, using the BD Accuri C6 cytometer and the 
CytoFLEX (Beckman Coulter Krefeld, GER). Antibodies for characterization of the surface 
receptors for differentiated MK (CD41, CD42d) are listed in Table 6. The cells were 
incubated with the antibodies for 30min in the dark (4°C) in a 1:100 dilution. Differentiated 
MK were washed with PBS to remove unbound antibodies (300xg, 5min, RT) and re-
suspended in appropriate amount of FACS buffer for analysis. For the analysis of in vitro 
generated platelets, respective amounts of antibodies were incubated with the platelets in 
a similar manner, but platelets were pelleted with 900xg, 5min at RT during the washing 
steps. For determination of the GFP expression in murine iPSC, the cells were depleted 
from the feeder cells as described above. The anti HA-antibody used for the detection of 
the Mpl transgene in 32D cells after transduction with the UCOE-Tet vectors was 
incubated as described above. The respective PE-conjugated secondary antibody was 
incubated for 10min in the dark. 
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3.2.6 Platelet activation 
 
Platelet spreading and immunostainings were performed by M. Bender and M. Spindler 
(Würzburg University). Antibodies were kindly provided by B. Nieswand (Würzburg 
University)  
 
Platelet sample preparation  
 
For determination of the platelet activation, platelet spreading assays were performed. In 
vitro differentiated platelets were isolated as described in 3.2.2.5 and resuspended in 
Tyrode’s buffer. As positive control washed platelets were isolated from murine whole 
blood. About 1ml of blood was withdrawn from one mouse by bleeding from the retro 
orbital plexus into reaction tubes containing 300µl of heparin (20U/ml). The mouse was 
subsequently euthanized. Platelet rich plasma (PRP) was obtained by centrifugation (300x 
g, 6min, RT, without break) and transferred together with some red blood cells into a fresh 
reaction tube containing 200µl of heparin (20U/ml) and spinning was repeated (300x g, 
6min, RT, without break). PRP was transferred into a fresh reaction tube. To prevent 
activation of platelets, prostaglandin (PGI2, final concentration 50nM) and apyrase (final 
concentration 0.02U/ml) were added. Platelets were pelleted at 800xg and resuspended in 
Tyrode’s containing apyrase (final concentration 0.02U/ml) until spreading assay was 
performed (incubate at 37°C, at least 30min).  
 
Spreading assay  
 
For performance of the spreading assay, 24x60 mm cover slips were prepared in a humid 
chamber one day prior to the experiment. The covered area was labelled from the back. 
Cover slips were coated with 100µl fibrinogen (100µg/ml in sterile PBS, pH 7.14) or 
collagen recombinant peptide (CRP) (10µg/ml in sterile PBS, pH 7.14) and incubated 
overnight. The cover slips were blocked with 300µl BSA/PBS (1%, pH 7.14, 1h, RT). 
Before starting, the platelet spreading assays the cover slips were washed with 300µl PBS 
for several times to remove the remaining BSA. Reaction tubes were prepared for platelet 
spreading by adding 75µl of Tyrode’s buffer before 30µl of washed platelets or in vitro 
differentiated platelets were added. For platelet activation, 10µl Thrombin (0.01U/ml for 
fibrinogen coating) and ADP (10µM) and U46 (3µM) (for CRP coating) were added. 
Platelet suspension was immediately transferred onto the cover slips and incubated in the 
humid chamber (1h, 37°C). Spreading reaction was stopped by the addition of 300µl 
PFA/PHEM-buffer (4%) (20min, 4°C).   
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Fixation and immunostaining  
 
The microscope slides were washed 3 times with 300µl PBS and blocked with BSA (2% in 
PBS, 2h, 37°C or overnight, 4°C). BSA was removed by washing 3 times with 300ml PBS. 
Primary antibodies were incubated for 2-3h at 37°C or overnight at 4°C. Antibodies that 
did not bind were removed by washing of the slides 3 times with PBS. The secondary 
antibody was incubated for 45min at RT and the non-bound antibodies were again 
washed 3 times with PBS before the slides were mounted with Vectashield® Mounting 
Medium (Vector Laboratories, Burlingame, USA). Cover slips were dried overnight and 
stored at 4° until analysis. 
3.2.7 Immunocytochemistry for detection of pluripotency 
 
Murine iPSC were plated onto mitomycin C treated feeder cells into a 12-well cell culture 
plate as described above. For immunostainings, the medium was removed and the wells 
were washed twice with Dulbecco’s PBS and fixed in Dulbecco’s containing PFA (4%, 
15min, RT). Fixation reaction was stopped by washing twice with Dulbecco’s PBS. 
Permeabilization of the cells occurred with TritonX100 (0.2%, 15min, RT) followed by 
washing 3 times with Dulbecco’s PBS and subsequent blocking (Dulbecco’s PBS, 20% 
FCS, 20min, RT). Primary antibodies were incubated overnight (4°C). Antibodies that 
were not bound were removed by washing 3 times with Dulbecco’s PBS containing 1% 
FCS. Secondary antibodies were diluted in Dulbecco’s PBS (containing 1% FCS) and 
incubated for 1h (RT). Cells were washed 2 times with Dulbecco’s PBS (1% FCS), 
covered with Dulbecco’s PBS and stored until analysis (4°C, dark).  
 
 
 
Table 17: Antibody concentrations for pluripotency markers  
Antibody  Concentration 
Oct3/4 (Santa Cruz) 0.8µg/µl 
Sox2 (Santa Cruz) 0.3µg/µl 
Nanog (Abcam) 2µg/µl 
donkey anti-mouse IgG-Alexa 488 
(Jackson) 
1:400 dilution 
rabbit anti-mouse IgG-Alexa 546 (Jackson) 1:400 dilution 
goat anti-rabbit IgG-Alexa 488 (Jackson) 1:400 dilution 
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3.2.8 PrestoBlue® cell viability assay  
 
The functionality of the Tet-all-in one vector Tet-U670s.Mpl was investigated in 32D cells 
which were transduced with the Tet.U670s.Mpl using two different MOIs (MOI 10, 20). As 
control, 32D cells were transduced with the U670s.GFP vector (MOI: 5, 10). 32D cells 
were serum starved with RPMI medium supplemented with 0.5% FCS for 16h prior 
starting the stimulation with Thpo. For detection of cell viability, 2×104 cells/well were 
seeded in a 96-well plate. Cells were supplemented with dox (1μg/ml) or left non-induced 
and stimulated with 5ng/ml of murine Thpo or 2ng/ml murine IL-3. After cultivation for 24h, 
PrestoBlue® reagent was added according to the manufacturer’s instructions. OD570 and 
OD600 were detected after incubation of additional 16h (total 40h) (37°C and 5%CO2). 
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4 RESULTS 
4.1 Supporting factors for increased megakaryocyte differentiation 
and platelet release from murine iPSC 
 
The aim of the first part of my thesis was to optimize in vitro production of platelets and MK 
from pluripotent stem cells. Since this process is still inefficient in vitro, overexpression of 
single factors influencing megakaryopoiesis and platelet release at different stages 
throughout the differentiation process could enhance the output of generated MK and 
platelets and could also lead to better functionality of the differentiated cells. We chose to 
overexpress Gata1, Nfe2, Pbx1, Evi1 and two hyperactive variants of the GTPases RhoAhc, 
and Cdc42hc (Ebbe et al., 1978; Dütting et al., 2017). The GTPases cycle between inactive 
(GDP-bound) and active (GTP-bound) state. In order to achieve a constitutive activation via 
achieving a GTP-bound state, point mutations in RhoA (F30L) and Cdc42 (F28L) were 
introduced (Lin et al., 1999). In our study, overexpression of single supporting factors, 
delivered by gammaretroviral vectors, was studied. To avoid off-target effects during 
pluripotency and differentiation, overexpression should be restricted to specific time points 
during the differentiation. This was achieved by using a Tet-inducible gammaretroviral vector 
system transducing the iPSC in the pluripotent state. Induction of gene expression occurred 
at later stages during differentiation. For this purpose, Tet-all-in-one vectors can be used. In 
the Tet-inducible vector used in the study, a PGK promoter initiates expression of the reverse 
transactivator (rt)TA-M2. This transactivator undergoes conformational changes after 
addition of dox, which allows its binding to the operator sequence fused to a minimal 
promotor (T11), thus initiating the expression of the transgene of choice. One major 
drawback of this system is silencing of the gammaretroviral all-in-one vectors, especially 
when used in iPSC and their differentiated progenies. Silencing of the PGK promoter, 
needed for the expression of sufficient amounts of the (rt)TA-M2 and thereby for tight 
regulation of the system, is one possible explanation. The PGK is highly enriched in CpG 
sites which are the sites prone to be methylated. In the first part of the project, we were 
following the strategy to become independent from the PGK promoter by generation of 
miPSC containing the (rt)TA-M2 in the Rosa26 safe harbor locus. Therefore, miPSC were 
reprogrammed from B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae/J mice which are genetically 
engineered to carry and express the (rt)TA-M2 in the Rosa26 safe harbor locus. After 
successful generation and characterization of the miPSC, they were transduced with the 
Gata1, Nfe2, Pbx1, Evi1, RhoAhc, and Cdc42hc factors in the pluripotent states using 
gammaretroviral vectors (details of the gammaretroviral vectors see below). Afterwards, 
supporting effects during MK differentiation of the murine iPSC cells of each single candidate 
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factor was evaluated by cell surface receptor expression, morphology and quantification of 
the differentiated MK. 
4.1.1 Generation of R26M2 iPSC by lentiviral reprogramming and screening for 
hematopoietic differentiating clones 
 
For reprogramming, as depicted in Figure 7A, lineage marker-negative cells from BM of 
B6.Cg-Gt(ROSA)26Sor tm1(rtTA*M2)Jae/J mice were isolated and transduced on retronectin-
coated cell culture plates with a lentiviral vector expressing the Yamanaka factors OCT4, 
KLF4, SOX2, and MYC (SIN.Lv.SFFV.OKSM.dTom). After transduction, the cells were 
transferred onto mitomycin C-treated MEF feeder cells. Formation of typical miPSC colonies 
with morphological feature of embryonic stem cells (ESC) occurred 3-4 weeks after 
transduction, a first sign of reprogramming into the pluripotent state. The colonies were 
isolated and expanded. Out of the 56 isolated colonies, 31 were screened for hematopoietic 
differentiation potential. For this purpose, the iPSC cells were seeded as single cells into 
suspension cultures and subjected to orbital rotation, leading to the formation of 3-
dimentional aggregates named EB. EB cultures were kept for 7 days in total. Hematopoietic 
differentiation was further supported by the addition of mSCF and mIL-3 at day 5 of 
differentiation. On day 7 of differentiation, when the EB were dissociated, the cells should 
express CD41 on the surface, in this case a marker for early hematopoietic progenitors 
which can be detected by flow cytometry (Mitjavila-Garcia et al., 2002). Only 6 of the 31 
clones showed CD41 expression after 7 days of EB formation. Two of the 6 clones were 
further analyzed. Around 40% of the cells differentiated from R26rtTAM2_K2 (R26M2K2) and 
clone R26rtTAM2_K3 (R26M2K3) expressed the CD41 hematopoietic marker (Figure 7C). 
Since this expression was in the range of OG2 murine ESC, clones R26M2K2 and R26M2K3 
were further characterized for pluripotency and utilized for the differentiation studies of 
miPSC. 
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Figure 7 Generation of R26M2 iPSC. (A) Schematic overview over the generation of iPSC from of B6Cg-
Gr(ROSA)36Sortm1(rtTA*M2)Jae/J mice. Lin- BM cells were isolated and transduced with the lentiviral vector 
expressing the reprogramming cassette (OCT4, KLF4, SOX2 and MYC). After cultivation of the transduced cells 
and transfer onto MEF feeder cells, iPSC colonies were isolated 4-5 weeks after transduction. (B) Table of 
isolated iPSC colonies and their differentiation potential. After isolation, the clones were screened for their 
potential to express CD41 after hematopoietic differentiation. Two of the clones were selected for further 
experiments (protocol see Chapter 3.2.2.3). (C) Representative flow cytometry plots of CD41 expression at day 7 
of EB differentiation and subsequent dissociation. CD41+ gate was set based on an unstained negative control. 
The percentage of CD41 expression is indicated by the numbers in the plots, respectively. 
4.1.2 Characterization of pluripotency marker expression of R26M2K2 and 
R26M2K3 iPSC clones 
 
Characterization of pluripotency of miPSC clones R26M2K2 and R26M2K3 was performed 
on the basis of the classical pluripotency features as follows: Undifferentiated murine 
pluripotent stem cells including iPSC express the surface marker stage specific embryonic 
antigen-1 (SSEA-1) (Buecker et al., 2010). As shown in Figure 8A, flow cytometry 
experiments of feeder-depleted R26M2K2 and R26M2K3 showed similar SSEA-1 expression 
as the undifferentiated murine embryonic stem cell line OG2 and murine CD45.1 iPSC 
generated by A. Mucci and collegues (Mucci et al., 2018). Alkaline phosphatase (AP) is an 
enzyme that is highly active in the inner cell mass of preimplantation embryos in mice. It is 
therefore often used as a marker for assessment of the pluripotency in newly generated 
iPSC (Štefková et al., 2015). Active AP in cells will lead to the development of a red/purple 
end product (Nitroblue Tetrazolium (NBT)) when incubated with BICP (5-Bromo-4-Chloro-3-
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Indolyl Phosphate) (Stemgent™ Alkaline Phosphatase Staining Kit, ReproCell, UK). 
R26M2K2 and R26M2K3 both show the typical color for highly active AP showing the 
pluripotent state, whereas the mouse embryonic fibroblast feeders remain colorless (Figure 
8B). In addition, key transcription factors associated with pluripotency are sex determining 
region Y-box 2 (Sox2), octamer-binding transcription factor 4 (Oct4) and Nanog. In our 
pluripotency analysis, we determined the mRNA levels of Sox2, Oct4 and Nanog in the 
R26M2K2 and R26M2K3 iPSC clones by qRT-PCR and compared them to the expression in 
OG2 ESC control cells. mRNA expression of R26M2K2 and R26M2K3 was in a similar range 
and even slightly higher compared to the OG2 ESC control (Figure 8C). To verify these data, 
also on the protein level, immunofluorescent staining of SOX2, NANOG and OCT4 was 
performed on single colonies of R26M2K2 and R26M2K3. The results are shown in Figure 
8D. SOX2, NANOG and OCT4 proteins were detected in the nuclei of single colonies of 
R26M2K2 and R26M2K3 as detected by the overlay with DAPI staining. 
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Figure 8 Characterization of pluripotency of R26M2K2 and R26M2K3. (A) Representative flow cytometry plot 
of the expression of SSEA1 (green histogram) of R26M2K2 and R26M2K3 in comparison to the OG2 ESC and 
well characterized CD45.1 murine iPSC control in the pluripotent state. As a control, MEF feeder cells were 
stained with the SSEA1 marker (black line). SSEA-1 expression is detected by a PE labelled anti SSEA-1 
antibody. (B) Alkaline phosphatase staining of the R26M2K2 and R26M2K3 iPSC pluripotent stem cells, the scale 
bar indicates 100µm. (C) Expression of murine pluripotency markers Oct4, Nanog, Sox2 by qRT PCR (n=3, 
(performed in triplicates, each)), mean +/-SD, 1-way ANOVA, ns: not significant). (D) Immunofluorescence 
staining of R26M2K2 and R26M2K3 pluripotency markers SOX2, NANOG and OCT4.  
 
Additionally, the integration of the reprogramming vectors was detected by vector copy 
number (VCN) using qPCR. The results showed that R26M2K2 had a VCN of 1 and 
R26M2K3 of 3. Ideally, the reprogramming cassette consisting of the transcription factors 
OCT4, KLF4, SOX2 and cMyc can be excised from the integration by FRT sites flanking the 
cassette. For the reason that the reprogramming vectors get silenced by epigenetic 
remodeling during transition to pluripotency (Ho et al., 2011), it is not absolutely necessary to 
excise the cassette, although in some cases silencing may be incomplete. The vector copy 
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number (VCN) detection revealed 1 integration of the reprogramming vector in R26M2K2, 
whereas in the R26M2K3, 3 integrations were detected. Further experiments were performed 
with the R26M2K2 because of the lower VCN. 
4.1.3 Tet-inducible gammaretroviral vectors overexpressing supporting 
factors for megakaryocyte and platelet differentiation in vitro 
 
To express the candidate factors to support megakaryopoiesis, the residual components 
necessary for the expression of the transgene of choice were delivered by retroviral vectors 
(Figure 9B). Therefore, gammaretroviral vectors were generated, containing the dox-
inducible minimal promoter T11 which was fused to the operator sequence TetO7 followed 
by the coding sequence of Gata1, Nfe2, Pbx1, Evi1, RhoAhc and Cdc42hc, respectively, as 
functional transgenes to improve MK and platelet generation from the R26M2K2 iPSC in 
vitro. To track transgene expression during pluripotent state and differentiation, the 
transgenes were coupled to an eGFP (GFP) reporter via an internal ribosomal entry site 
(IRES). As a control, a vector encoding only for GFP was generated. The respective vectors 
are named as indicated in Table 18.   
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Figure 9 Rosa26 locus expressing (rt)TA-M2 and the design of the SIN gammaretroviral vector expressing 
the supporting factors to support megakaryopoiesis and platelet generation. (A) Schematic representation 
of the Rosa26 locus of the B6Cg-Gr(ROSA)36Sortm1(rtTA*M2)Jae/J mouse and descendent iPSC. The (rt)TA-M2gene 
was targeted into the Rosa26 locus and is ubiquitously expressed from the ROSA promoter. Conformational 
changes after exposure of the (rt)TA-M2 (depicted as triangles) to dox allow the interaction with the operator 
sequence fused to the minimal promoter of the gammaretroviral vectors. (B) Shown is the plasmid. The SIN 
deletion (ΔU3) is introduced in the 3’LTR. The LTR can be further dissected into the unique region 3 (U3), repeat 
region (R) and U5 region. The R region contains the polyA signal for the mRNA. The U3 region originally contains 
the enhancer and promoter activity which is deleted in the 3’LTR. The gene expression is initiated by an internal 
Tet-responsive minimal promoter (T11) which is fused to a TetO7 operator sequence. Each of the respective 
transgenes was incorporated downstream of the T11 separately and coupled to GFP by an internal ribosomal 
entry site (IRES) to visualize transgene expression in the transduced cells. 
 
Table 18 List of gammaretroviral vectors used for transduction of miPSC R26M2K2   
 
Transgene Name of the vector 
Gata1 Gata1.iGFP 
Nfe2 Nfe2.iGFP 
Evi1 Evi1.iGFP 
Pbx1 Pbx1.iGFP 
RhoAhc RhoAhc.iGFP 
Cdc42hc Cdc42hc.iGFP 
GFP control iGFP.control 
 
After production of retroviral particles of the respective vectors, supernatants were harvested 
and concentrated by highspeed centrifugation. The transducing units of the viral vectors were 
titered by transduction of a murine SC1 fibroblasts cell line. Transducing units were 
determined as described in Chapter 3.2.2.1. All vectors reached titers similar to that of the 
+ dox 
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GFP control vector (3 x 108 IP/ml) except for the Evi1.iGFP vector which only produced 
5 x 104 IP/ml using the same conditions as for the other vector productions (Figure 10). 
  
Figure 10 Titration of the Tet-inducible gammaretroviral vectors expressing the MK supporting genes.  
After production, the amount of infectious particles was evaluated by transducing the murine fibroblast cell line 
SC1. After transducing the cells with different volumes of the respective supernatants, GFP expression was 
determined by flow cytometry 4 days after transduciton. IP/ml was determined as shown in Chapter 3.2.2.1 (n=3-
6, Evi1:n=2, mean +/- SD1, way ANOVA with Dunnett’s multiple comparison, ns= not significant). 
 
4.1.4 Transduction of R26M2K2 iPSC with vectors supporting megakaryocyte 
differentiation 
 
Pluripotent R26M2K2 iPSC were transduced with the viral vectors in the pluripotent state of 
the cells. For this purpose, they were depleted from their feeders and seeded onto gelatin-
coated cell culture plates. After transduction of 105 cells with an MOI of 10 each in 
suspension and re-plating on the MEF feeder cells, iPSC were split in 2 fractions 
respectively. One fraction was induced with dox to evaluate transduction efficiency, whereas 
the other fraction remained non-induced for differentiation experiments. After 3-4 days, GFP 
expression was evaluated by flow cytometry. As shown in Figure 11, iPSC were transduced 
with levels of GFP expression between 49% (Pbx1.iGFP) and 71% (Gata1.iGFP). 
Transduction with Evi1.iGFP vectors resulted in very low transduction efficiency and was, 
therefore, not followed up in further differentiation experiments. 
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Figure 11 Transduction of R26 rtTAM2 iPSC with candidate vectors and induction of transgene 
expression in the pluripotent state. The iPSC were feeder-depleted and seeded onto gelatin-coated 6-well cell 
culture dishes. Cells were transduced in suspension with a MOI between 10 and 20. 3-4 days after transduction, 
iPSC were transferred onto fresh feeder cells to recover from the transduction. Expression of GFP was evaluated 
by flow cytometry 7 days after transduction (n=3, Evi1:n=1, mean +/- SD, 1-way ANOVA with Dunnett’s multiple 
comparison, ns=not significant). 
 
4.1.5 Differentiation of R26M2K2 into megakaryocyte progenitors and platelets 
 
The transduced but non-induced iPSC were differentiated as shown in Figure 12. The 
experimental procedure was divided into 3 steps: in the pre-differentiation culture, the cells 
were depleted from their feeder cells for 2 to 3 days on a gelatin-coated matrix; next, the 
cells were processed into a single cell suspension culture and EB generation was initiated by 
rotation on an orbital shaker. Five days after the differentiation was initiated, hematopoietic 
differentiation was induced by supplementation with mSCF and mIL-3. Seven days after the 
start of the EB formation, they were dissociated with collagenase IV and the cells which 
express the early hematopoietic marker CD41 in the experimental procedures were enriched 
either by FACS or magnetic activated cell sorting (MACS). CD41+ cells were then co-
cultivated on mitomycin C treated OP-9 feeder cells to further support MK differentiation. For 
this purpose, the culture medium was also supplemented with 25ng/ml mScf and 50ng/ml 
mThpo. MK, progenitors as well as platelets were analyzed first between d21 and d28 of 
differentiation. In case the differentiation produced a sufficient amount of cells, they were re-
plated onto gelatin-coated cell culture dishes for further differentiation and analysis. 
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Figure 12 Differentiation scheme and workflow for transduction of R26M2K2 iPSC and differentiation into 
MK and platelets. After transduction of the R26M2 iPSC with the different candidate gene vectors, transduced 
cells were differentiated into EB by rotation on an orbital shaker for 7 days. Hematopoietic differentiation was 
supported by addition of mScf and mIL-3 for 2 days starting at day 5. After EB dissociation at day 7, R26M2K2 
iPSC were seeded onto mitomycin C treated OP9 feeder cells. Gene expression was induced by the addition of 
dox. Supplementation with Thpo further supported MK differentiation. After 2-3 weeks (d21-d28 of differentiation) 
first MK could be detected by microscopy in the supernatant or attaching to the feeder cells which were analyzed 
according to their surface receptor expression pattern and morphology. Since also enlarged cells with long 
cellular protrusions were detected in the cultures at that time points, platelets were harvested by different 
centrifugation speeds (see Chapter 3.2.2.6) and analyzed also according to their surface receptor expression 
pattern and morphology. MK and platelets were quantified. For some experiments, MK were seeded again on 
mitomycin C treated OP9 cells or gelatin-coated cell culture plates for further differentiation and analysis. 
 
4.1.5.1 Characterization of MK differentiation of R26M2K2 iPSC 
 
Between d21 and d28 of differentiation, MK were detected by microscopy as suspension 
cells of increased sizes as well as adherent cells growing in clusters on the feeder layer. The 
differentiated MK were harvested by collecting the culture supernatant as well as by 
detaching them from the culture plate. 
To verify the expression and induction of each transgene, GFP expression was analyzed in 
the differentiated MK. A representative example of the GFP expression in MK at d21 of 
differentiation is shown in Figure 13. 
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Figure 13 Detection of GFP reporter gene expression of the candidate factors at day 21 of differentiation 
in the MK. Representative histogram blot of GFP expression of transduced iPSC differentiated into MK analyzed 
by flow cytometry. Gates for GFP expression were set according to the untransduced negative control. The 
number in the gate indicates the respective percentage of GFP+ cells. 
 
The GFP reporter signal was detectable after differentiation; however, expression was 
highest (43.8%) in MK derived from Gata1.iGFP-transduced cells followed by Cdc42hc.iGFP 
transduced cells (30.1%). GFP expression from Nfe2.iGFP, RhoAhc.iGFP and Pbx1.iGFP 
transduced cells was less distinct and the percentages of GFP+ cells reached only 18.1% of 
GFP expression (Pbx1.iGFP). Nfe2.iGFP-transduced and differentiated MK reached only 
8.6% GFP expression after differentiation. Also, the spread of the GFP signal in all the 
samples was high as indicated by the high peak width. MK differentiated from R26M2K2 
iPSC transduced with iGFP.control, Gata1.iGFP, and Cdc42hc.iGFP showed a clear shift in 
GFP expression. This could not be achieved when differentiating R26M2K2 iPSC transduced 
with Nfe2.iGFP, RhoAhc.iGFP, and Pbx1.iGFP transduced cells.  
 
To evaluate whether the differentiated cells were MK or their respective progenitors or 
whether cells of other lineages were also generated during the differentiation process, a 
May-Grünwald-Giemsa staining on cytospins was applied. After collecting the differentiated 
cells and depleting them from their feeders, cells were spun onto glass microscope slides 
and subsequently stained (see Chapter 3.2.3). In this analysis, different cell types could be 
distinguished according to their color, size and morphological features. Representative 
images of differentiated MK after 3 weeks of differentiation are depicted in Figure 14. 
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Figure 14 Differentiation of transduced R26M2K2 iPSC produced progenitors from the MK/erythrocyte 
lineage. May-Grünwald-Giemsa staining was performed to determine the morphology of cells at day 21-28 of 
differentiation. Nuclei appear in pink color. Staining of the cytoplasm in dark purple color is characteristic for cells 
from the MK/erythrocyte lineage. Scale bars indicate a size of 250µm, red arrows indicate mature MK, green 
arrows indicate blast cells. 
 
The majority of the differentiated cells were of the MK/erythrocyte lineage according to their 
dark stained cytoplasm and to the appearance of a multilobulated nucleus. No other lineages 
like granulocyte/macrophage or granulocytes were detected. In the example of Gata1.iGFP 
overexpressing MK, enlarged cells with multilobulated nuclei as well as smaller 
megakaryoblast-like progenitors could be detected.   
 
During the course of differentiation, MK undergo cytoplasmic reorganization accompanied by 
the formation of cellular protrusions and the development of a widely branched network of 
those cellular elongations. Cellular organelles are transported along the microtubule network 
of the protrusions to the tips. Hereby, the subcellular components of a platelet are provided 
at the tips and the platelets are ready to be released. MK differentiated from Gata1.iGFP 
transduced and induced R26M2K2 iPSC cellular elongations were detected. In Figure 15, 
two examples for cellular elongations from MK on day 21 of differentiation are depicted. 
Taking a closer look on the elongations the typical shapes with branching shafts, 
intermediate swellings and swellings at the tips of the protrusions were detected by 
microscopy (grey arrows). This indicated the generation of mature MK from iPSC 
overexpressing Gata1.iGFP. 
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Figure 15 Gata1.iGFP overexpressing MK extending cellular protrusions.  Representative images of MK 
from Gata1.iGFP-overexpressing cultures, at day 21 of differentiation are shown. The right panel shows the 
highlighted area of the left panel in higher magnification. Scale bars indicate 250µm. 
 
4.1.5.2 Comparison of different candidate factors for their supportive 
effect to differentiate MK 
 
To evaluate the effect of the overexpressed factors on MK differentiation from R26M2K2 
iPSC, GFP+ versus GFP- populations were analyzed and compared for each of the tested 
factors. CD41, the most abundant integrin on the surface of MK and platelets, was used as 
MK marker. Differences in MK differentiation, due to the overexpression of the different 
factors, was analyzed and compared according to the CD41 expression. For this purpose, 
CD41 expression was analyzed for the GFP+ and GFP- populations separately. Figure 16 
shows an example for the iGFP.control and Gata1.iGFP (GFP) transduced cells as 
histogram blots to demonstrate the gating strategy. In a first step, GFP+ (green line) and 
GFP- (black line) populations were defined based on the untransduced negative control 
(Mock) (Figure 16A). The cut-off in CD41 expression in the GFP+ and GFP- population was 
set based on FMO (fluorescence minus one) samples. FMO controls contain all of the 
fluorochromes (or GFP) except one. Overexpression of Gata1 in MK progenitors 
differentiated from R26M2K2 iPSC resulted in a shift towards higher CD41 expression on the 
surface of the cells and in a higher percentage of CD41-expressing cells (Gata1.iGFP, 
82.2%) compared to MK progenitors differentiated from iGFP.control-transduced cells 
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(iGFP.control, 7.0%) in the GFP+ population, indicating an up to 75-fold increase by the 
overexpression of Gata1 (Figure 16B). This shift towards higher mean fluorescent intensities 
(MFI) and increased percentages in CD41 expression on the surface of differentiated 
progenitors was also detected within the GFP- population, but not as pronounced as within 
the GFP+ population. Gata1.iGFP overexpression resulted in an about 20-fold increase in 
CD41 expression on the surface of GFP- differentiated MK progenitors (Figure 16C). 
 
Figure 16 Expression of CD41 on the surface of MK differentiated from iGFP.control and Gata1.iGFP 
overexpressing cells in the GFP+ versus GFP- populations. Representative histogram blot: Cells were 
differentiated as depicted in Figure 11. After seeding on OP9 feeder cells, differentiated MK were harvested at 
day 21 of differentiation. (A) GFP- (black gate) and GFP+ populations (green gate) were determined according to 
the untransduced control (Mock). (B) GFP+ CD41+ population is shown. Gates were set according to the 
appropriate fluorescence-minus-one (FMO) control. (C) GFP-CD41+ population. Gates were set according to the 
appropriate FMO control and the numbers in the gates represent the percentages of positive cells.   
 
The CD41 expression on the surface of MK differentiated from R26M2K2 iPSC is 
summarized in Figure 17. CD41 expression for each of the factors tested was compared 
between the GFP+ and GFP- populations. In general, CD41 expression within the GFP+ 
population was increased compared to the GFP- population for all factors tested. The 
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overexpression of Gata1 resulted in significantly elevated percentages of CD41 expressing 
MK (69%) compared to the iGFP.control (9.7%, ****p<0.0001). Furthermore, the percentage 
of CD41+ cells was also enhanced to almost 39% by overexpression of Pbx1. Also, Nfe2 as 
well as RhoAhc and Cdc42hc overexpression increased the percentage of CD41+ cells after 
3 weeks of differentiation, however not to a significant level. 
 
Figure 17 Summary of CD41 expression on differentiated MK at day 21 of differentiation. The integrin αIIb 
(CD41) on the surface MK differentiated from R26M2 iPSC transduced with the different candidates to support 
megakaryopoiesis was measured by flow cytometry. CD41 served as MK marker. To evaluate differences in 
CD41 expression between transduced and untransduced MK populations, expression was evaluated for GFP+ 
and GFP- populations separately (n=3-9, mean +/- SD,****p<0.0001, *p=0.05, 1-way ANOVA with Dunnett’s 
multiple comparison of different factors (green) and student’s t-test for comparison of GFP+ vs. GFP- population 
(orange) #p=0.124, ###p=0.0007, ##p=0.0025, ####p<0.0001). 
 
The second receptor detected on the surface of MK progenitors differentiated from R26M2K2 
iPSC was the MK-specific marker CD42d (GPV). In in vitro differentiation of human CD34+ 
cord blood cells into MK, this marker only appears at later stages of differentiation and is 
associated with higher ploidy (Lepage et al., 2000). In our study, CD42d was therefore 
utilized to detect MK at later maturation stages. CD42d expression within the CD41+ 
population of the MK differentiated from the transduced R26M2K2 iPSC was analyzed. 
Representative histogram blots of flow cytometry experiments of differentiated MK from 
R26M2K2 iPSC transduced with iGFP.control and Gata1.iGFP at day 21 of differentiation are 
shown in Figure 18. After dividing the GFP+ (green line) and GFP- (black line), equally to 
what is shown in Figure 16A (Figure 18A), and gating on CD41+, the CD42d expression 
within the CD41+ population was evaluated. The cut-off for CD42d positive cells was set 
according to the respective FMO control. In Figure 18B, the CD42d expression of the 
GFP+CD41+ (GFP+CD41+CD42d+ MK) of iGFP.control and Gata1.iGFP transduced and 
differentiated MK is plotted. The cell counts for GFP+CD41+CD42d+ were in general very low, 
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but according to the control, GFP+CD41+CD42d+ population of the differentiated MK from 
iGFP.control and Gata1.iGFP transduced cells were detected. The percentage of 
GFP+CD41+CD42d+ (green line) cells was about 2-fold higher in MK differentiated from 
Gata1.iGFP transduced R26M2K2 iPSC (42.63% GFP+CD41+CD42d+) compared to the 
iGFP.control transduced and differentiated MK on day 21 of differentiation (Figure 18B). In 
contrast, the GFP+CD41+CD42d+ population (black line) in iGFP.control transduced 
differentiated MK (Figure 18B) only reached 13.6%, which was about the half of the GFP-
expressing counterparts, whereas the transduction with the Gata1.iGFP vector showed lower 
levels of CD41+CD42d+ within the GFP- population (Figure 18B). Overall, this indicated a 
beneficial effect of Gata1 on the differentiation of CD41+MK progenitors, whereas the 
terminal maturation and expression of CD42d seemed to be inhibited. 
 
 
Figure 18 Expression of the surface marker CD42d within CD41+ for GFP+ and GFP- populations of 
differentiated MK. CD42d (GPV) is a surface membrane protein specifically expressed in MK and platelets. To 
evaluate differences in the expression of CD42 MK differentiated from transduced R26rtTAM2, iPSC were 
analyzed by flow cytometry. The expression is restricted to later stages of MK differentiation, whereas expression 
of CD41 also appears during early stages of MK differentiation. The CD42d expressing MK within the CD41+ 
population was determined. The figure shows a representative histogram blot of the gating into GFP- (black line) 
and GFP+ (green line) population as described above to verify the effect of transduced candidate factors. (A) 
GFP+CD41+CD42d+ for iGFP.control Gata1.iGFP-transduced and differentiated MK (green line) (B) GFP-
CD41+CD42d+ for iGFP.control and Gata1.iGFP-transduced and differentiated MK (black line). The numbers in 
the gate represent the percentages of positive cells. 
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To summarize the data and further compare between GFP-expressing versus non-
expressing populations as well as to compare the generation of mature MK between all 
factors tested, the results for the expression of CD42d within the CD41+ population of GFP+ 
and GFP- population is plotted as a bar chart in Figure 19. Similar to the CD41 expression on 
the surface of the differentiated MK, the CD42d expression within the CD41 expressing cells 
was generally higher in the GFP+ population compared to the GFP- population for each of the 
factors tested. This increase in the percentage of GFP+CD41+CD42d+ cells was most 
profound in MK differentiated from Nfe2.iGFP-transduced R26M2K2 iPSC (****p<0.0001). 
The CD42d expression on the surface of the differentiated MK did not significantly differ 
between the factors tested. The percentage of CD42d expressing MK within the GFP+CD41+ 
population ranged from 34% (Gata1.iGFP) to 78% (Nfe2.iGFP) within the GFP+ population. 
Interestingly, in contrast to the GFP+CD41+ population, MK differentiated from iPSC 
transduced with Gata1.iGFP showed the lowest percentage of CD42d expression within the 
CD41+ population for GFP- and GFP+ population. In general, MK differentiated after all 
modifications, except for RhoAhc.iGFP overexpression, showed an increase in the 
percentage of GFP+CD41+CD42d+ MK differentiated from R26M2K2 iPSC compared to the 
untransduced control R26M2K2 (Mock), indicating a supportive effect of the factors. 
 
 
Figure 19 Summary of CD42d expression on differentiated MK at day 21 of differentiation. After 
transduction of the R26M2K2, iPSC and subsequent differentiation into MK expression of the CD42d surface 
marker within the CD41+ population was determined (Figure17A). To evaluate the effects of transduced and non-
transduced candidate factors, GFP+ and GFP- populations were analyzed separately. Significant differences in 
CD41+CD42d+ populations between GFP+ and GFP- population were determined by Student’s t-test (n=3-9, 
mean +/- SD, ####p<0.0001, ###p=0.0008, #p=0.017 (Pbx,iGFP), #p=0.206 (Cdc42hc.iGFP), ns: not significant. 
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In addition to the percentages of the surface marker expression, it was of interest how many 
cells were generated in total. To evaluate the beneficial effect of each single factor on the 
amount of differentiated MK from R26M2K2 iPSC on day 21 of differentiation, MK cell 
numbers were determined. The cell numbers of GFP+CD41+ and GFP+CD41+CD42d+ MK 
were calculated from the flow cytometry data and plotted as a bar chart in Figure 20. Since 
1 x 105 CD41+ early hematopoietic progenitors were seeded per well of a 6-well cell culture 
dish after dissociation of the EB, the amount of the MK/105 cells is shown. In Figure 20A, the 
GFP+CD41+ differentiated MK were calculated. However, the yield of GFP+CD41+ in general 
was very low. Numbers of MK differentiated from Gata1.iGFP transduced R26M2K2 iPSC 
were highest (1.5 x 104 MK) and significantly increased compared to the iGFP.control 
(2 x 103 MK), which is a 7.5-fold increase (****p<0.0001). Dox-induced overexpression of 
Cdc42hc.iGFP during the differentiation also resulted in a 6-fold increase in the generation of 
GFP+CD41+ MK at day 21 of differentiation (1.2 x 104 MK, **p=0.0023). Similarly, the amount 
of GFP+CD41+CD42d+MK generated at day 21 of differentiation was highest from 
Gata1.iGFP transduced R26M2K2 iPSC (1.4 x 103) and also significantly increased 
compared to the iGFP.control transduced MK (**p=0.0094) and overexpression of 
Cdc42hc.iGFP during MK differentiation resulted in an increase in MK numbers to 1.3 x 103 
(*p=0.0199) (Figure 20B). 
 
 
Figure 20 Quantification of MK differentiated from R26M2K2 iPSC at day 21 of differentiation. Cells were 
transduced with the respective candidate genes in the pluripotent state and differentiated into MK as explained 
above. MK surface marker expression was analyzed at day 21 of differentiation. (A) Amount of GFP+CD41+ MK is 
plotted. Quantification of surface receptor CD41+ cells in the GFP+ population (B) Amount of GFP+CD41+CD42d+ 
MK is plotted. Quantification occurred according to the expression of the surface receptor CD41 in the GFP+ 
population (n=3-9, mean +/- SD, 1-way ANOVA with Dunnett’s multiple comparison, ****p<0.0001, **p=0.0023 
(GFP+CD41+ MK differentiated from Cdc42hc.iGFP), **p=0.0094 (GFP+CD41+CD42+ MK differentiated from 
Gata1.iGFP), *p=0.0199). 
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4.1.5.3 Effects of the overexpression of different factors on in vitro 
platelet production 
 
Similar to the in vitro differentiated MK, the platelets generated from the same in vitro 
cultures after 21 days of differentiation were characterized via flow cytometry. Platelets were 
harvested and separated from the MK by centrifugation. Subsequently, platelets were 
stained for expression of the surface receptors CD41 and CD42d. Since the expression level 
of GFP in the harvested platelets was not detectable, GFP+ versus GFP- populations were 
not analyzed separately. Representative examples for flow cytometry histogram blots of 
platelets differentiated from R26M2K2 iPSC either from dox-induced overexpression of 
Gata1.iGFP or untransduced control platelets are shown in Figure 21. For the culture-derived 
platelets, the life-cell gate was set according to a murine whole blood control (Figure 21A, left 
panel). Furthermore, the platelets generated from in vitro cultures are expected to be of 
larger size. The reason for this may lay in the lack of shear forces during their release, which 
are important for platelet release in vivo. Additionally, beads of defined sizes were used to 
better define the life-cell gate (Figure 21B middle panel). The resulting life-cell gate is 
indicated in Figure 21A (right panel). The cut-off for CD41 and CD42d expression was set 
according to their respective FMO control. In general, a distinct population of CD41 or CD42d 
expression was not detected. Gata1.iGFP overexpression in platelets lead to an increase in 
the percentage of CD41-expressing platelets compared to the untransduced control, as 
indicated by the shift towards higher CD41 expression in Figure 21B, left panel. In contrast, 
the percentage of CD42d expression was around 30% in both Gata1.iGFP-platelets and 
untransduced control. 
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Figure 21 Expression of CD41 and CD42d on the surface of differentiated platelets. Representative 
histogram blots of the surface receptor expression of the differentiated platelets for their characterization. 
Platelets were harvested on d21 of differentiation together with the respective MK. (A) Left panel: platelet 
population gated from murine whole blood. Middle panel: spherotech accu count blank particles with a nominal 
size of 3.0-3.9µm gated. Right panel: resulting life cell gate from blood platelets and spherotech beads. (B) 
Representative example for differentiated platelets isolated from iGFP.control transduced (upper panels and 
Gata1.iGFP transduced (lower panels) and differentiated R26M2K2 iPSC. CD41 (green histogram) and CD42 
within CD41+ populations (blue histogram) were gated according to the appropriate FMO control (the CD41- 
population is depicted in grey). 
 
 
The output of in vitro generated platelets from R26M2K2 iPSC transduced with the 
transcription factors Gata1, Nfe2, Pbx1 and the GTPases RhoAhc and Cdc42hc and surface 
CD41 and CD42d expression are summarized in Figure 22. 
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Figure 22 Summary of CD41 and CD42d surface marker expression on in vitro differentiated platelets. 
Flow cytometry analysis of platelets differentiated from R26M2K2 iPSC and overexpression of respective 
candidate genes at day 21. Gene expression was initiated by the supplementation of dox at day 7 of 
differentiation when the EB were dissociated (see Chapter 3.2.2.6) (A) Expression of the major integrin CD41 
(αIIb) on the surface of the platelets. Gating occurred as described in Figure 20. (B) Expression of CD42d within 
the CD41+ population. Gating occurred as described in Figure 20 (n=3-9, mean +/- SD, 1-way ANOVA with 
Dunnett’s multiple comparison, **p=0.0029). 
 
Similar to what has already been shown for the MK differentiated from R26M2K2 iPSC, dox-
induced overexpression of Gata1.iGFP lead to an about 10-fold increase in the percentage of 
CD41-expressing cells (31% of Gata1.iGFP platelets express CD41, **p=0.0029) at day 21 
of differentiation. The expression of the MK/platelet-specific marker CD41 on the surface of 
the platelets from iGFP.control differentiated cells was lowest (3.5% iGFP.control 
differentiated platelets express CD41 on the surface) (Figure 22A). In contrast, expression of 
Gata1 increased CD41+ platelets. The overexpression of the other factors generated lower 
percentages of CD41+ platelets which were not significantly different to the iGFP.control. 
There is the trend detectable that the percentage of platelets expressing CD42d within the 
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CD41+ population was slightly increased after dox-induced overexpression of all factors 
compared to the iGFP.control. 
In addition to the expression of MK- and platelet-specific surface markers, platelets also 
show a very specific cellular morphology. First of all, the absence of a nucleus is one of their 
major hallmarks. Furthermore, they also contain different types of granules which can be 
distinguished by their electron density in transmission electron micrographs (TEM). Also, the 
different intramembrane structures like the OCN and dense tubular networks are structures 
unique to platelets. Platelets differentiated from R26M2K2 iPSC in which the Gata1.iGFP 
overexpression was induced were subjected to TEM imaging. Representative examples of 
platelets differentiated from Gata1.iGFP overexpressing R26M2K2 iPSC 3 weeks after 
differentiation are depicted in Figure 23. 
 
Figure 23 Transmission electron microscopy of platelets. Platelets differentiated from R26M2K2 iPSC 
expressing Gata1.iGFP were differentiated as described in Chapter 3.2.2.6 and harvested at d21 of differentiation 
for TEM imaging. Typical platelet morphological features are highlighted in different colored arrows. Yellow 
arrows: mitochondria, red arrows: dense granules, blue arrows: alpha granules, green arrows: OCS. Black bar 
indicates the size of 1µm. 
 
The platelets isolated from the cultures after differentiation of R26M2K2 iPSC and dox-
induced overexpression of Gata1.iGFP were increased in size compared to those isolated 
from murine blood but showed the typical platelet morphology with first of all the absence of 
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the nucleus. They contained mitochondria (light blue arrow) depicted as electron-dense 
structures with internal membranes. Another typical ultrastructure of platelets is the presence 
of the OCN which was also detected in high abundances in the differentiated platelet (green 
arrow). The presence of two different types of granules in which important cytokines and 
coagulation factors are stored was another major hallmark of platelets. Dense granules 
named after the high electron density from electron micrographs were also developed in in 
vitro generated Gata1.iGFP platelets, as indicated by the red arrows. The granules with 
lighter electron-density structures, alpha granules, which are the most abundant type of 
granules in platelets, are shown in yellow. 
Platelets isolated from in vitro differentiated cultures of R26M2K2 iPSC and identified by their 
CD41 expression can be quantified similar to the quantification of the MK. To assess the 
supporting effects of the different factors tested, the output of the amount of platelets 
differentiated in culture was calculated. The gating strategy is depicted in Figure 21 and the 
numbers of CD41-expressing and CD41/CD42d double positive platelets plotted per 105 
CD41+ early progenitors seeded after EB dissociation were determined (Figure 24). 
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Figure 24 Quantification of platelets differentiated from R26M2K2 iPSC. Platelets isolated at d21 of 
differentiation were quantified according to their surface receptor expression pattern by flow cytometry. Different 
candidate factors induced during differentiation were compared. (A) No. of CD41+ platelets harvested per 105 
initial progenitors seeded. (B) Number of CD42d+ platelets within the CD41+ population per 105 cells initially 
seeded. Numbers indicate the mean. (n=3-9, mean +/- SD, 1-way ANOVA with Dunnett’s multiple comparison, 
**p=0.0029 (A), **p=0.0032 (B)). 
 
Overexpression of Gata1.iGFP resulted in about 10-fold increase (4.9 x 105 CD41-
expressing platelets) compared to the iGFP.control (4.4 x 104 CD41+ in vitro platelets 
**p=0.0029). The amount of CD41+ in vitro platelets generated from the other factors was in 
the same range of around 1.0 x 105 CD41 positive in vitro platelets. Calculation of the 
CD41+CD42d+ in vitro platelets differentiated from R26M2K2 iPSC and dox-induced 
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overexpression of candidate factors was again relatively equal and within the range of 
1.5 x 104 (Cdc42hc.iGFP) to 3 x 104 CD41+Cd42d+ (RhoAhc.iGFP) in vitro platelets (Figure 
24B). Only dox-induced overexpression of Gata1 resulted in a significant increase in the 
amount of CD41+CD42d+ in vitro platelets (6.5 x 104, **p=0.0032) at d21 of differentiation. It 
is also important to consider the number of platelets released per MK. In vivo, one MK 
releases about 1000 platelets (Sim et al., 2016). To determine how many platelets were 
released from a CD41+ MK differentiated from R26M2K2 iPSC and transduced with the 
different candidate factors, the numbers of released platelets were set into relation to the 
amount of CD41+ MK differentiated from the same culture at the same day. Interestingly, 
overexpression of Nfe2 resulted in an increase in the amount of CD41+ in vitro platelets 
released per CD41+ MK (102 CD41+ platelets/MK), which is significantly different from the 
iGFP.control transduced and differentiated R26M2K2 iPSC shown in Figure 25A. The 
overexpression of the other candidate factors released similar amounts of CD41+ in vitro 
platelets per CD41+ MK. Similar to these results, also Nfe2 resulted in increased amounts of 
CD41+CD42d+ in vitro platelets per CD41+ MK (Figure 25B), however, this was not 
significantly different from the iGFP.control transduced and differentiated R26M2K2 iPSC. 
 
Figure 25 Quantification of platelets released per MK during in vitro differentiations. The amount of 
platelets released per MK at day 21 of differentiation was quantified by flow cytometry. Different candidate factors 
were transduced in the pluripotent state. Gene expression was initiated by the application of dox at day 7 of 
differentiation. (A) Amount of CD41+ platelets released per CD41+ MK. (B) Amount of CD41+CD42d+ platelets 
released per CD41+ MK (n=3-9, mean +/- SD). 
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4.1.5.4 Functionality of in vitro differentiated platelets 
 
After the occurrence of a vascular trauma, platelets undergo sequential adhesion, activation 
and aggregation, which results in their spreading to increase their contact area, finally 
leading to plug formation which is accompanied with the flattening of the cells and the 
deformation of the plasma membrane (Lee et al., 2012). This can be mimicked in vitro in so-
called platelet spreading assays. In the next step, we wanted to prove whether the in vitro 
differentiated platelets from R26M2K2 iPSC were functional in vitro and performed platelet 
spreading assays on either fibrinogen or CRP-coated cover slips in collaboration with Dr. 
Markus Bender from the University of Würzburg. In vitro generated platelets from R26M2K2 
iPSC transduced with Gata1.iGFP were investigated. Gata1.iGFP overexpression was 
induced at day 7 of differentiation when co-cultivation on OP-9 feeder cells started. The cells 
were cultivated on OP-9 feeder cells for 2 weeks before MK were harvested and re-plated on 
suspension cell culture dishes. In vitro differentiated platelets were harvested by 
centrifugation (see Chapter 3.2.2.6). For comparison, freshly isolated, washed platelets from 
about 1ml of whole blood of a C57BL/6 wildtype (wt) mouse were prepared. Platelets isolated 
from whole blood as well as in vitro differentiated platelets were spread on either fibrinogen 
or CRP-coated cover slips and subsequently stained with antibodies against the CD41/CD61 
integrin and CD42a glycoprotein (GPIX). In addition, especially for visualization of the platelet 
spreading, an antibody against the MK/platelet-specific tubulin (β1-tubulin) was used. To 
compare the resting versus the activated state of the platelets, in some of the samples, the 
cells were applied to poly-L-Lysine-coated cover slips and remained non-activated as a 
control. Platelets isolated from wt murine whole blood showed a typical circular-shaped 
morphology where the CD41/CD61 and CD42a were distributed throughout the surface of 
the resting platelets. The β1-tubulin could be visualized as a distinct ring at the edge of the 
cells. Figure 26 shows the presence of a representative example of a pro-platelet (middle 
panels) and platelets (lower panels) harvested from the in vitro cultures. Similar to platelets 
isolated from whole blood, in vitro differentiated platelets expressed CD41/CD61 throughout 
their surface. Also, the presence of the GPIX could be visualized by confocal microscopy. 
The β1-tubulin distribution showed the same ring-like structure at the edge of the cell of the 
differentiated platelets which was comparable to the wt-isolated platelets. 
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Figure 26 Resting platelets on poly-L-lysine-coated cover slips. Cells were incubated in the resting state on 
poly-L-lysine-coated cover slips and remained non-activated. Washed platelets isolated from murine whole blood 
(upper panels) were compared to in vitro differentiated pro-platelets (middle panels) and platelets (lower panels). 
In the non-activated state, platelets showed the typical circular-shaped morphology. For identification of the 
platelets, the integrin αIIβIII (magenta) and GPIX (yellow) were marked with primary antibodies and then 
incubated with fluorescent labelled antibodies for vizualization via confocal microscopy. Additionally, the 
platelet/MK-specific β1-tubulin was labelled with appropriate primary and secondary antibodies. Merged images 
are shown in the right column. Scale bars indicate a size of 5µm. 
 
In platelets, the β1-tubulin forms monomers together with α-tubulin beneath the cell 
membrane of the cells, maintaining their discoid shape, a feature called marginal bands 
(Patel-Hett et al., 2008; Shin et al., 2017). When platelets get activated by various biological 
stimuli and agonists including ADP, thromboxane receptor agonist U46 and thrombin, this 
leads to cytoskeletal reorganization resulting in the formation of filopodia and lamellipodia. In 
this experiment, we triggered platelet activation in two different approaches. After their 
addition to fibrinogen in the first example, they were stimulated with thrombin to induce 
shape changes leading to the formation of filopodia and lamellipodia, which can be visualized 
by confocal microscopy using the same primary and secondary antibodies as mentioned 
above. Results of wt-isolated platelets and in vitro differentiated platelets differentiated from 
Gata1-overexpressing R26M2 iPSC spread on fibrinogen and activated with thrombin are 
included in Figure 27. During platelet activation of wt-platelets with thrombin, the ring 
structure of the β-tubulin became less distinct whereas the CD41/CD61 was still distributed 
over the entire surface. Filopodia and lamellipodia formation was detected (upper panel 
Figure 27). Similar to platelets isolated from blood, the in vitro differentiated platelets 
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attached to the surface by interaction between the GPIIbIIIa and the fibrinogen (Figure 27 
middle panel, lower panel), however, distinct ring structures of β1-tubulin were reduced. In 
the lower panels, filopodia formation was detected as indicated by the β1-tubulin signal and 
the expression of the CD41/CD61 distribution (Figure 27, lower panel). In contrast to the 
blood-derived platelets, lamellipodia formation was not detected. 
 
 
Figure 27 Platelets spread on fibrinogen-coated cover slips. Platelets isolated from blood of wt mice (as 
control) and in vitro differentiated platelets were incubated on fibrinogen-coated cover slips and activated with 
0.01U/ml thrombin for 60min. For identification of the platelets, the integrin αIIβIII (magenta) and GPIX (yellow) 
were marked with primary antibodies and then incubated with fluorescent labelled antibodies for visualization via 
confocal microscopy. Additionally, the platelet/MK-specific β1-tubulin was labelled with appropriate primary and 
secondary antibody. Merged images are shown in the right column. Scale bars indicate a size of 5µm. In 
comparison to the platelets isolated from whole blood, spreading of culture-derived platelets resulted in the 
formation of filopodia. Lamellipodia formation was absent in culture-derived platelets. 
 
In addition to the spreading on fibrinogen, a second spreading assay on collagen-related 
peptide (CRP) was performed. The major receptors for adhesion to collagen are the 
glycoprotein GPVI and α2β1 (Varga-Szabo et al., 2008; Lee et al., 2012). Platelets isolated 
from wt murine whole blood adhered to collagen and were stimulated in this case with ADP 
and the thromboxane receptor agonist U46. The results are included in Figure 28. Similar to 
fibrinogen-coated cover slips, platelet spreading occurred by the formation of filopodia and 
lamellipodia, however, this occurred only to a lower extent compared to the spreading on 
fibrinogen with thrombin stimulation (Figure 28, upper panels). Filopodia formation was also 
detected in case of platelets differentiated from Gata1-overexpressing R26M2K2 iPSC as 
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indicated by the cellular protrusions detected by the immunostaining of CD41/CD61 and β1-
tubulin. Similar to what has been observed on fibrinogen-coated cover slips, lamellipodia 
formation was also absent in culture-derived platelets (Figure 28, middle panels, lower 
panels). 
 
 
Figure 28 Platelets spread on CRP-coated cover slips. For the performance of platelet spreading assays 
platelets isolated from wt-mice and in vitro differentiated platelets were incubated on collagen-related-peptide 
(CRP)-coated cover slips and activated with 10µM ADP and 3µM U46 thrombin for 60min. For identification of the 
platelets, the integrin αIIβIII (magenta) and GPIX (yellow) were marked with primary antibodies and then 
incubated with fluorescent labelled antibodies for visualization via confocal microscopy. Additionally, the 
platelet/MK-specific β1-tubulin was labelled with appropriate primary and secondary antibody. Merged images are 
shown in the right column. Scale bars indicate a size of 5µm. In comparison to the platelets isolated from whole 
blood, spreading of culture-derived platelets resulted in the formation of filopodia. Lamellipodia formation was 
absent in culture-derived platelets. 
  
RESULTS 
 
83 
 
4.2 Generation of Tet all-in-one gammaretroviral vectors with low 
silencing potential 
 
We have shown that tetracycline-inducible retroviral vectors represent powerful tools for 
time-controlled transgene expression during differentiation of iPSC, however, silencing of 
expression from the vectors is a drawback. In the well-studied gammaretroviral Tet-all-in-one 
vectors initially used in this study and published by Heinz et al., the PGK promoter initiates 
constitutive expression of the reverse transactivator (rt)TA-M2 (Heinz et al., 2011). This 
promoter fragment is highly enriched in CpG sites (63 in total) which are often responsible for 
gene silencing because they can be methylated. We investigated in the second part of the 
project whether the insertion of different UCOE derived from the HNRPA2B1-CBX3 locus 
(A2UCOE) can sustain transgene expression in Tet-all-in-one retroviral vectors especially for 
their use in iPSC. The A2UCOE is well-studied and widely used in constitutive lentiviral 
vectors as indicated in Chapter 1.7. The A2UCOE elements U1.5, U1.0, U670 and U630 are 
derived from different regions of the HNRPA2B1-CBX3 locus and were inserted in sense (s) 
or antisense (as) orientation in respect to the transcriptional orientation of the expression 
cassette in the vector upstream of the PGK promoter as shown in Figure 29. The different 
orientations of the respective elements and the corresponding nomenclature are listed in 
Figure 30. Additionally, the CBX3 element developed by Mueller-Kuller and colleagues 
containing mutations in a canonical splice donor and cryptic splice site was inserted. The 
control (PGK.Tet-control) does not have an A2UCOE incorporated. 
 
Figure 29 Tet-inducible all in one gammaretroviral vectors containing A2UCOE of different sizes.  Different 
A2UCOE spanning the first exons of the HNRPA2B1 and the CBX3. Exons are indicated by the filled squares. 
Annotation of the exons is based on NM_007276.3 (transcript variant 1, CBX3), NM_016587.3 (transcript variant 
2, CBX3), NM_002137.3 (transcript variant A2, HNRPA2B1). Mutations of the splice sites in the CBX1 element 
are indicated by vertical bars. The different A2UCOEs were inserted into a Tet-regulated, all-in-one 
gammaretroviral vector upstream of the PGK promoter. 
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Figure 30 Different A2UCOES are inserted into the Tet-all-in-one gammaretroviral vector in different 
orientations. Orientation is named sense (s) or antisense (as) according to the transcriptional orientation of the 
CBX3 promoter. 
 
Tet-all-in-one vectors are tightly regulated systems and insertion of additional components, 
especially if they potentially have promoter activity like some of the A2UCOE, may interfere 
with regulation and titers. After production of gammaretroviral vector particles in HEK 293T, 
packaging cell lines titers were evaluated in SC1 fibroblast cell lines and are shown in Figure 
31. 
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Figure 31 Titers of non-concentrated viral vector preparations. Determination occurred on mouse SC1 
fibroblasts (mean ± SD, n=4, * p<0.05, ** p<0.01, *** p<0.001 compared to the PGK.Tet-control vector, Student’s 
t-test). 
orientation with respect to 
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The incorporation of A2UCOE elements with sizes larger than 1kb decreased the titers 
sevenfold (U1.0as, U1.0s, U1.5as). The drop in viral titer was most profound after 
incorporation of the U1.5s A2UCOE. Also, the incorporation of the U630as element 
decreased the titer for about two decades to 9800 +/- 3700IP/ml. Incorporation of the 
elements U630s, U670as, U670s and CBX3 did not alter the viral vector titers and reached 
the same level like the PGK.Tet-control (7.3 +/- 2.8 x 105IP/ml) in un-concentrated 
supernatants. In the following, the vectors were further characterized in terms of regulation of 
gene expression and anti-silencing capacity. 
4.2.1 Influence of the insertion of the A2UCOE on the dynamic range of 
transcriptional activation 
 
Tet-on vectors have to be tightly regulated. After induction with dox they should express GFP 
at high levels and the expression should be completely turned off after dox withdrawal, a 
feature called dynamic range. The dynamic range measures the ratio of the transgene 
expression at the induced and non-induced state. To assess the influence of the different 
incorporated elements on the dynamic range, SC1 mouse fibroblast cells were transduced 
with an efficiency of 30% to 50% GFP expression with the different vectors. Histogram plots 
of representative examples of the flow cytometric analysis are shown in Figure 32. 
 
Figure 32 Regulation of A2UCOE-containing Tet-vectors by dox in SC1 fibroblasts. Representative flow 
cytometry plots of GFP expression after transduction of SC1 with different A2UCOE vectors. Induced: dashed 
line; non-induced: black line, grey filled area. Percentages of GFP+ cells are indicated by the respective number in 
the plot. 
 
Transduction with the Tet-vectors containing the elements U630as, U670as, U670s and 
CBX3 showed distinct GFP+ populations which were very similar to the PGK-Tet.control. In 
contrast, GFP+ peaks, especially after incorporation of the elements U1.0as and U1.5, were 
less prominent and the spread of the GFP expression from the vectors U1.0s and U1.5s 
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showed a wider range of GFP expression, indicating a high variegation of the expression 
after transduction. 
 
Figure 33 Regulation of A2UCOE-containing Tet-vectors by dox in SC1 fibroblasts. (A) Percentage of GFP 
expression was monitored by flow cytometry in transduced SC1 cells cultured in the presence of dox (days 3-11 
and days 25-32) and without dox (days 14-21). (B) Intensity of GFP expression (MFI) in induced (black bars) and 
non-induced cells (white bars). (C) Fold induction of expression (MFI) from non-induced to induced state. (D) 
Relative intensity of expression (MFI) normalized to the Tet-control vector (set to 1). (E) Coefficient of variegation 
(CV) of expression of the GFP positive population (n=3, mean +/- SD, 1-way ANOVA with Dunnett’s multiple 
comparison test, *p<0.05. 
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For a better comparison between the tested elements, GFP expression in the induced and 
non-induced states are shown in Figure 33. The difference in GFP expression between 
induced and non-induced state is depicted in Figure 33A. After dox withdrawal, GFP 
expression declined to background levels after 7 days. Expression reached the same levels 
after re-induction in all of the vectors tested. The expression in the non-induced state of the 
PGK-Tet.control declined to below 7%. After incorporation of the U630as, U630s and 
U670as into the vector, the expression showed the same low level compared to the 
PGK.Tet-contol. However, incorporation of the U670s, U1.0s, U1.0as, U1.5s, U1.5as and 
CBX3 elements resulted in higher residual GFP expression (Figure 33A). This was also 
verified by the MFI as shown in Figure 33B. The MFI was highest with the vectors U670s and 
reached a MFI of 2.3 x 106 but also showed the highest background expression with a mean 
MFI of 2.8 x 105. For better evaluation, the fold increase was determined and Figure 33C 
shows that the highest fold induction was observed in the cultures transduced with the Tet-
vector U670s (270–fold, PGK.Tet-control vector 125-fold). This vector also showed the 
highest intensity of expression (MFI) which is increased 3.25-fold compared to PGK.Tet-
control (Figure 33D). The coefficient of variegation (CV) determines the spread of the GFP 
signal within the positive population and is determined by the width of the fluorescent signal 
measured by flow cytometry. Here, the CV was highest in U1.0as transduced SC1 fibroblasts 
followed by U1.5as, indicating the influence of the elements on the variegation. The 
incorporation of U630as, U670as, U670s and CBX3 had no effects on the variegation and 
was within the range of the PGK.Tet-control (Figure 33E). 
4.2.2 Anti-silencing potential of different A2UCOE-Tet vectors in P19 
carcinoma cells 
 
The different A2UCOE-Tet vectors were further characterized in terms of their anti-silencing 
potential. The murine embryonal carcinoma cell line P19 was used for the studies. P19 cells 
are embryonic carcinoma cells derived from teratomas in mice (He et al., 2005). P19 cells 
were transduced with the different A2UCOE-Tet-vectors to an efficiency of 25-55% and the 
vector copy number (VCN) ranged between 1 and 2. The GFP expression was followed up 
for 46 day and was analyzed every 3-4 days by flow cytometry. The results are plotted in 
Figure 34 where each bar represents one measurement at one time point. GFP expression 
was set to 100% at day 3 after transduction to compensate different transduction efficiencies. 
RESULTS 
 
88 
 
 
Figure 34 Stability of transgene expression on the embryonic carcinoma cell line P19 over a period of 46 
days. P19 cells were transduced with viral vectors containing the different A2UCOE or with the PGK.Tet-control 
vector. The GFP expression was determined every 3-4 days by flow cytometry up to 46 days after transduction. 
Each column represents one measurement at the days 3, 7, 11, 14, 18, 21, 25, 28, 32, 35, 39, 42 and 46. The 
percent of GFP expression was normalized to 100% at day 3 after transduction. The horizontal dashed line 
indicates the endpoint value of the PGK.Tet-control (n=3, mean +/- SD, *p<0.05, 2-way ANOVA with Dunnett’s 
multiple comparisons test). 
 
Insertion of the A2UCOEs U670s, U670as, U1.0s and U1.5s upstream of the PGK promoter 
could maintain the GFP expression in more than 50% of the transduced cells after 14 days of 
cultivation, which persisted until the termination of the experiment at day 46. At this day, GFP 
expression from the A2UCOEs-Tet vectors U670s, U670as, U1.0s and U1.5s was still above 
25%. In comparison, the PGK.Tet control was below 25% after 2 weeks. The anti-silencing 
effect after incorporation of U630as, U630s, U1.5as and U1.0as was less profound (in the 
range of 12%) compared to the other A2UCOE counterparts. Incorporation of the U630s 
resulted in the lowest residual percentage of GFP-expressing P19 cells (6%) (Figure 34, 
Figure 35A). 
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Figure 35 Evaluation of the anti-silencing capacity of different A2UCOE-vectors in P19 embryonic 
carcinoma cells. P19 cells were transduced with the respective vector and GFP expression was followed for 46 
days. Differences in transduction efficiency were compensated by normalizing the percent GFP to 100% at day 3 
after transduction. Bars show the residual GFP expression at termination of the experiment 46 days after 
transduction. (A) Percentage of expression at day 46 after transduction. (B) Intensity of GFP expression at day 46 
correlated to the mean vector copy number (MFI/VCN, mean +/- SD, n=3, 1-way ANOVA with Dunnett’s multiple 
comparisons test, ****p<0.0001). 
 
The intensity of expression (MFI/VCN) was also strongest in U670s transduced P19 (5.7-fold 
higher than PGF, p<0.001) at day 46 when the experiment was terminated, indicating the 
best beneficial effect of U670s on the prevention of transgene silencing in Tet-inducible all-in-
one gammaretroviral vectors. To investigate if the drop in the GFP expression was caused 
by silencing of the PGK promoter, another transduction experiment was performed using P19 
cells that only expressed a residual GFP fluorescence after prolonged cultivation time. If 
silencing of the promoter was the reason for the drop in GFP expression, it should become 
reconstituted when a second external (rt)TA-M2 was introduced. To investigate this, the 
U670s-transduced P19 cells were transduced with a second gammaretroviral vector 
expressing the transactivator (rt)TA-M2. This vector was co-expressing M2 and a mCherry 
reporter signal. Percentages of GFP expression as well as fluorescent intensities within the 
M2.mCherry positive (M2 pos) and negative populations (M2 neg) were analyzed 7 days 
after the second transduction as shown in Figure 36A. 
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Figure 36 Re-expression of the transactivator rtTA-M2 in P19 cells by a second retroviral vector. U670s-
transduced P19 cells were again transduced with a second gammaretroviral vector expressing the rtTA-M2 
leading to a co-expression of the residual GFP and mCherry reporter signal at the same time. 7 days after the 
second transduction, GFP expression in the M2 positive population (mCherry positive) of U670s transduced P19 
cells were analyzed by flow cytometry. GFP low and high populations are indicated. (A) Histogram plots of the 
flow cytometry results. (B) Percentage of GFP expression of M2neg and M2 pos cells (n=3, mean +/- SD, 
Student’s t-test two tailed, **p=0.0023). (C) MFI of GFP expression in GFPlow versus GFPhigh expressing P19 cells 
after restoring the GFP reporter expression after transduction of a second transactivator M2 (n=3, mean +/- SD, 
1-way ANOVA with Dunnett’s multiple comparisons test, ****p<0.0001). 
 
Figure 36B summarizes the GFP expression within the M2.mCherry positive population 
which is restored to 67% GFP-expressing cells compared to the M2.mCherry-negative 
counterpart where only 34% express the GFP signal. This is especially prominent when 
analyzing the MFI. Due to the occurrence of the double-peak in Figure 36C, we therefore 
divided the population in GFPhigh and GFPlow expressing populations. MFI of GFP-high 
population rises to more than 1.5 x 104. 
4.2.3 A2UCOE in Tet-inducible all-in-one vectors in murine iPSC 
 
Since the incorporation of A2UCOE elements into Tet-inducible all-in-one vectors was 
designed to be used in pluripotent stem cells and their differentiated progeny, we next 
assessed their performance in the murine iPS cell line CD45.1 published by A. Mucci et al 
(Mucci et al., 2018). We selected the most promising candidates U670s, U1.0s, U1.5s, and 
CBX3 from the data in SC1 and P19 cells (see Chapter 4.2.1 and 4.2.2) and transduced 
CD45.1 iPSC with an initial efficiency of 20-65% and cultivated for 2 weeks after transduction 
before the dox was withdrawn for the first time. GFP expression was analyzed. The results 
are plotted in Figure 37. 
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Figure 37 Regulation of expression from the A2UCOE Tet-inducible vectors in murine induced pluripotent 
stem cells.  Murine iPSC were transduced with the respective A2UCOE Tet-vectors and GFP expression was 
analyzed during a course of repeated induction and withdrawal of dox over 46 days. Highest values of GFP 
positive cells were normalized to 100% GFP expression for each vector at day four after transduction. Dox was 
supplemented (+) and withdrawn (-) repetitively (n=3, mean +/-SD). 
 
After withdrawal of dox, GFP expression was turned off efficiently to 1.2% of the initial 
expression when transducing with the U1.0s and U1.5s vectors. The GFP signal also 
declined to about 10% of the initial expression using the vectors U670s and CBX3. The GFP 
expression was continuously analyzed up to day 46 after transduction and the GFP 
expression was re-induced and turned off multiple times. The U1.0s, U670s and CBX3 
vectors reached the percentage of their initial GFP expression after re-induction 7 days later 
and during 2 following repetitive cycles of dox withdrawal and re-application. 
Despite the percentage of GFP expression, the MFI was of importance for evaluation of the 
performance. To compensate for different transduction efficiencies, the MFI was normalized 
to the corresponding VCN. Transduction of CD45.1 iPSC with the U670s resulted in the 
highest intensity of expression on day 14 after transduction compared to the PGK.Tet-control 
(p<0.02) (Figure 38B). The significantly higher MFI of the U670s Tet-all-in-one vector 
compared to the PGK-Tet.control persisted until termination of the experiment in the induced 
state (*p<0.05). Also, incorporation of the CBX3 element into the Tet-all-in-one vector 
resulted in an increase of the MFI at day 14 and 25 after transduction, but a significant 
difference could not be detected at later time points (Figure 38B, Figure 38C). At termination 
of the experiment at day 46, only the Tet-all-in-one vector U670s resulted in a significant 
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increase in MFI of GFP expression (1.8 x 105, ****p<0.0001). However, also background 
expression was higher when transduced with U670s and CBX3. In contrast, the MFI of the 
GFP expression dropped below the one of the PGK.Tet-control after incorporation of the 
U1.0s and U1.5s elements (Figure 38B+C). In addition, the U670s Tet-all-in-one vector also 
revealed the highest fold induction of the MFI (2.8-fold higher than from the PGK.Tet-control 
vector). The fold induction of the CBX3 vector was in the same range (100-fold) as the 
PGK.Tet-control and the fold induction of U1.0s (fold induction 31) and 1.5s (fold induction 
25) was even below the PGK.Tet-control. 
 
Figure 38 Summary of the regulation of expression from different A2UCOE Tet-inducible vectors in 
murine iPSC.  (A) Coefficient of variegation (CoV) of the percentage GFP expression in murine iPSC. Mean and 
standard deviation were calculated from 3 individual transductions (n=3) at days 14, 25, 38 and 46. Coefficient of 
variation was calculated by the division of the standard deviation by the mean (CoV=SD/mean). Each bar 
represents the CoV at the respective days. (B) Intensity of GFP expression (MFI) normalized to the VCN. The 
analysis was performed at days 14, 25, 38, 46 (induced, grey bars) or after withdrawal of dox (days 21, 35, 42, 
white bars). Comparison of each data point with the corresponding data measured in the PGK.Tet-control group, 
2-way ANOVA with Dunnett’s multiple comparisons test, *p<0.05). (C) Intensity of expression (MFI/VCN) at day 
46 after transduction (n=3, mean +/- SD, 1-way ANOVA with Dunnett’s multiple comparisons test, ****p=0.0001). 
(D) Mean fold induction MFI. Fold induction was calculated on the basis of 3 different induced and un-induced 
cultures at three time points, respectively (n=9, mean +/- SD, 1-way ANOVA with Dunnett’s multiple comparisons 
test, ****p<0.0001, **p<0.01). 
 
With an overall culture period of 46 days in total, cultures were followed up for a relatively 
long culture period. We were interested whether the variance was also different between the 
beginning and termination of the experiment. To show this, the coefficient of variation (CoV, 
SD/mean) was determined of the induced states at days 14, 25, 38 and 46 after transduction 
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(Figure 38A). While the CoV stayed stable for the Tet-all-in-one vectors U670s and CBX3, 
the CoV increased after prolonged cultivation period for the U1.0s up to almost 56% (day 46) 
and U1.5s (up to 53% at day 46) and also slightly for the PGK.Tet-control (30.7%). 
4.2.4 Vector performance after replacement of the PGK promoter by a 
U670s/CBX3 element 
 
The PGK promoter is highly enriched in CpG islands (63 CpG) and was therefore speculated 
to be the sequence within the gammaretroviral vector which is most vulnerable to methylation 
and causes shutdown of the expression. The U670 element is located in close proximity to a 
transcriptional start site of the CBX3 gene and has been reported to have promoter activity 
itself (Müller-Kuller et al., 2015). It is therefore of interest if the PGK promoter can be excised 
from the vector and replaced by U670s or CBX3. Furthermore, the EFS promoter, which is 
already widely used in the field of genetic modification of iPSC with retroviral vectors, was 
also incorporated in our studies. In addition, lentiviral counterparts of the PGK.Tet-control 
and the 670s.M2 vectors were generated to compare the capability to sustain GFP 
expression of gammaretroviral and lentiviral vectors directly. The vector architecture of 
gamma-/lentiviral vectors with exchanged PGK promoters is shown in Figure 39A. After 
production of the viral vectors and subsequent titration on SC1 cells, it was shown that viral 
titers from lentiviral vectors were 30-fold lower compared to their gammaretroviral 
counterparts (titer gamma U670.M2:3.7 x 106IP/ml, titer lenti U670.M2: 1 x 106IP/ml) (Figure 
39B). 
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Figure 39 Gammaretroviral and lentiviral Tet-all-in-one vectors with replaced PGK promoter. (A) Vector 
architecture of the Tet-regulated, all-in-one vectors. The (rt)TAM2 was expressed from either the A2UCOE 
U670s/CBX3, EFS or PGK promoters (PGK.Tet-control vector). The U670s was also introduced in the lentiviral 
backbone and compared to the PGK.Tet-control lentiviral vector. (B) Titration of gammaretroviral and lentiviral 
vectors on SC1 cells. Murine fibroblasts (SC1) cell line was transduced with different volumes of viral vector. 
Transducing particles per ml were calculated based on the amount of GFP reporter positive cells (n=3, mean +/-
 SD). The titers of the two lentiviral vectors was significantly reduced (*p=0.02), Student’s t-test. 
 
Similar to the experiments performed in Chapter 4.2.1, the regulatory and anti-silencing 
potential of the different vectors was assessed by the transduction of the SC1 fibroblast cell 
line as well as P19 carcinoma cells and the results are included in Figure 40. In these 
experiments with P19 cells, the transduced and GFP expressing cells were enriched to 100% 
via FACS to exclude the possibility of competition and selective advantage between GFP+ 
and GFP- cells. The GFP expression was followed over the next 45 days. In SC1 cells, the 
gammaretroviral vectors U670.M2 and CBX3.M2 expressed distinct GFP+ populations similar 
to the PGK.Tet-control and showed the highest relative intensity in GFP expression (Figure 
40A+B). Furthermore, the dynamic range was significantly higher in case of gammaretroviral 
U670.M2 and CBX3.M2 vectors (~400-fold induction in intensity) compared to the expression 
in non-induced cells (Figure 40C). The EFS.M2 vector expressed lower intensities and lower-
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fold induction compared to the PGK.Tet-control vector and the silencing of the GFP signal in 
P19 cells was most profound after transduction of the cells with the gammaretroviral EFS.M2 
vector (Figure 40E). In contrast, transduction of the P19 cells with the gammaretroviral 
vectors U670.M2 and CBX3.M2 sustained GFP reporter gene expression to 41% and 37% 
respectively while the GFP reporter signal of the PGK.Tet-control decreased to 20% (Figure 
40E). Exchange of the PGK promoter by the U670s element increased the coefficient of 
variegation (CV) in gamma-/and lentiviral vectors (Figure 40D). 
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Figure 40 Tet-inducible vectors driving the transactivator by the A2UCOE. (A) Representative flow cytometry 
analysis of murine SC1 fibroblast cells transduced with the U670s.M2, CBX3.M2. EFS.M2 and PGK.Tet-control 
vector (PGK.M2) (gammaretroviral vectors) and U670s.M2 and PGK.M2 (lentiviral vectors). Induced: dashed line; 
non-induced: black line, grey filled area. (B) Relative intensity of GFP+ cells (MFI), expression of the PGK.M2 
(PGK.Tet-control) is set to 1 (n=3, mean +/- SD, 1-way ANOVA with Dunnett’s multiple comparisons test, 
****p<0.0001, ***p=0.0005). (C) Fold induction of expression (MFI) from non-induced to induced state (1-way 
ANOVA with Dunnett’s multiple comparisons test, ****p<0.0001, ***p=0.0004). (D) Mean coefficient of variation of 
SC1 cells transduced with the respective gammaretroviral and lentiviral vectors in the induced state. (1-way 
ANOVA with Dunnett’s multiple comparisons test, ****p<0.0001). (E) GFP expression in P19 cells transduced with 
the U670s.M2, CBX3.M2, EFS.M2 and PGK.Tet-control vector (PGK.M2). Cells were sorted for GFP expression 
on day 4 after transduction, GFP expression was analyzed by flow cytometry every 3-4 days until day 49. 
Horizontal dashed line indicates the endpoint value of the PGK.Tet-control (n=3, mean +/- SD, comparison to 
PGK.Tet-control for both vectors *p<0.5, 2-way ANOVA with Dunnett's multiple comparisons test). 
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4.2.5 A2UCOE in Tet-all-in-one vectors in human induced pluripotent stem 
cells during differentiation 
 
Silencing often occurs during differentiation of iPSC into the cell type of choice when they 
undergo massive chromatin remodeling. We also tested the above-mentioned candidates in 
differentiation experiments of human iPSC. The hiPSC line KOLF2 (Sanger Institute, 
Hinxton, UK) was transduced to an efficiency of 65-100% GFP expression and the 
functionality of the vectors was assessed using two different experimental designs. In the first 
approach, the GFP expression of the Tet-all-in-one gammaretroviral vectors U670s, U1.0s, 
U1.5s and CBX3 as well as the promoter-replaced versions 670s.M2 and CBX3.M2 was 
assessed during formation of EB by fluorescence microscopy and compared to the PGK.Tet-
control. Fluorescent images of the EB are shown in Figure 41. As indicated by the 
fluorescent microscopy images, the GFP intensities of the U670s element and the promotor-
replaced versions U670s.M2 and CBX3.M2 showed the strongest signal. This was verified by 
the determination of the fluorescent intensities of the fluorescence imaging using ImageJ and 
is summarized in Figure 41B. The intensities were normalized to the VCN to compensate for 
the difference in initial GFP expression. The GFP expression could be sustained from the 
U670s Tet-all-in-one vector (intensity/VCN U670s 3) which was increased 2-fold compared to 
the PGK.Tet-control (intensity/VCN U670s:1) after 5 days of EB formation. The intensity of 
GFP expression of U670s.M2 and CBX3.M2 was in a similar range (intensity/VCN 2.9 and 
2.6, p<0.0001). The intensity/VCN of the U1.5s and CBX3 Tet-all-in-one vectors in contrast 
was only slightly increased compared to the PGK.Tet-control (intensity/VCN 1.5, 
*p=0.0042/0.05). Incorporation of the U1.0s upstream the PGK even decreased the 
intensity/VCN to 0.6, which is lower than the PGK-Tet.control. 
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Figure 41 GFP reporter signal analyzed by fluorescent microscopy in EB. (A) Representative pictures of EB 
differentiated from human iPSC at day 5 of EB formation transduced with different A2UCOE vectors or the 
PGK.Tet-control. Left bottom: bright field image of EB. (B) Summary of the intensity of GFP expression in EB at 
day 4 of differentiation (n=3-8 independent transductions and differentiations in four independent fields each, 
mean +/- SD (1-way ANOVA with Dunnett’s multiple comparisons test, ****p<0.00001, *p=0.0042/0.05). The scale 
bars indicate 200µm.  
 
In the second approach, transduced hiPSC were subjected to monolayer differentation into 
ectodermal, endodermal and mesodermal germ layers under defined conditions using the 
StemdiffTM trilineage differentiation kit (Stemcell Techologies). The hiPSC were transduced to 
66-100% GFP expression analyzed by flow cytometry. After completing differentiation into 
the respective germ layer, GFP expression was again evaluated by flow cytometry (Figure 
42). In parallel to the doxycyclin-induced cultures, the respective un-induced cultures were 
analyzed. Here, the transgene expression has not been induced at any time. Interestingly, in 
contrast to the differentiations to the EB, the capability to sustain transgene expression after 
incorporation of the U670s element as well as the replacement of the PGK promoter by 
either U670s or CBX3 was less profound in all 3 germ layers. This was in part due to the high 
variability between independent experiments. The GFP expression from the PGK.Tet-control 
declined after differentiation to about 51 (mesoderm)-61% (endoderm) in meso-, ecto- and 
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endodermal differentiation. During ectodermal differentiation, GFP expression was most 
sustained from the U670s element (91% GFP expression). Furthermore, background 
expression in the non-induced state was highest from hiPSC transduced with U670s and 
CBX3, an effect that was further increased by the excision of the PGK promoter (U670s.M2 
and CBX3.M2). 
 
Figure 42 Evaluation of the GFP expression of different UCOE-Tet vectors during 3 germ layer 
differentiation of hiPSC.  Human iPSC were transduced with the Tet-vectors containing the respective 
A2UCOE. Cells were differentiated into meso-, ecto, and endoderm using the StemDiffTM trilineage differentiation 
kit (STEMCELL Technologies) Initial GFP expression in human iPS cells four days after induction and their 
differentiated progeny are shown. (A) Dox-induced (+, white columns) and non-induced (-, grey columns) are 
plotted for each vector and germ layer respectively. Different symbols represent independent transductions (n=3-
8, mean +/- SD). (B) Percentage of GFP positive cells after trilineage differentiation. Percentages in the germ 
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layers were combined (n=9, PGK N024 mean +/- SD, 1-way ANOVA with Dunnett’s multiple comparisons test, 
**p=0.009). 
 
4.2.5.1 Methylation state of the PGK promoter after differentiation of 
hiPSC into mesodem 
 
The PGK promoter driving the expression of the reverse transactivator (rt)TA-M2 in the Tet-
all-in-one retroviral vectors is highly enriched in CpG sites (63 CpG in total) and therefore 
prone to be silenced by methylation of the cytosine residues. As it was shown in Chapter 
4.2.2, the GFP expression in P19 cell was restored after introducing a second transactivator 
by a second viral vector transduction expressing the (rt)TA-M2-mCherry. DNA methylation is 
one of the major epigenetic silencing mechanisms. We were therefore interested whether the 
incorporation of the A2UCOE influenced the methylation status of the PGK promoter. 
Silencing of the PGK promoter could be one explanation because this could influence the 
generation of sufficient amounts of (rt)TA-M2. Since the U670s gammaretroviral vector 
showed the greatest potential of sustaining the expression of the GFP reporter signal and 
because MK and platelets derive from mesoderm, the hiPSC transduced with U670s and 
PGK differentiated into the mesodermal germ layer were chosen to be investigated. The 
methylation status was determined by bisulfite conversion of the whole genomic DNA. In this 
approach, methylated CpGs are protected from the conversion into uracil residues during the 
conversion whereas non-methylated CpGs are converted into uracil. After PCR amplification 
of a specific bisulfite-converted sequence, in this case a part of the PGK promoter which is 
spanning the majority of the 63 CpG sites, the PCR amplicons were subcloned into a TOPO 
TA cloning (pGEMTM) vector and transformed into chemically competent E.coli (details see 
3.2.1.6.). Different clones were then analyzed by Sanger sequencing and the methylated 
versus non-metylated CpGs were analyzed with the BiQ Analyzer software. The results of 
the different single clones as well as the percentages of the methylation state are shown in 
the diagram in Figure 43. The methylated CpGs are highlighted as black filled circles. The 
percentage of methylated CpGs increased after transduction with the PGK.Tet-control when 
hiPSC were differentiated into the mesodermal germ layer (from 19.1% to 36.6%). This effect 
could not be detected after incorporation of the A2UCOE U670s upstream the PGK 
promoter. Here, the methylation status was at the similar low level between 4.5% and 3.7% 
of the CpGs being methylated. 
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Figure 43 Methylation status of the PGK promoter after incorporation of the U670s element before and 
after mesodermal differentiation. DNA of human iPS cells at the pluripotent state and after mesodermal 
differentiation was purified from cultures transduced with the U670s vector or the PGK.Tet-control vector and 
analyzed by bisulfite conversion and PCR amplifying the PGK promoter. The amplicons were ligated into the 
pGEM vector and clones sequenced by Sanger sequencing. Methylated CpGs are indicated by the black filled 
circles. 
 
4.2.6 Expression of Mpl from the UCOE-Tet gammaretroviral vectors 
 
In all our previous studies, the UCOE-Tet vectors expressed the reporter protein GFP. It was 
therefore of interest whether the Tet-regulated all-in-one vector would also allow the 
controlled expression of a biologically active protein. To prove this, the Thpo receptor Mpl 
was incorporated into the Tet-all-in-one U670s vector termed Tet.U670s.Mpl. Mpl expression 
can be detected on the surface of the transduced cells via an incorporated hemagglutinin 
(HA) tag using an anti HA antibody by flow cytometry. The vector architecture of the 
Tet.U670s.Mpl gammaretroviral vector is depicted in Figure 44. 
 
 
 
Figure 44 Vector architecture of the Tet.U670s.Mpl gammaretroviral vector. For controlled expression of the 
Thpo receptor Mpl from the UCOE-Tet vector, the coding sequence was incorporated downstream of the Tet-
responsive promoter and upstream of the U670s element into the vector containing the U670s element.. 
 
 
For verification of the functionality of the Thpo receptor Mpl, the cytokine-dependent 
hematopoietic cell line 32D was transduced with the Tet.U670s.Mpl using two different MOIs 
RESULTS 
 
102 
 
(10 and 20). In the untransduced state, survival and proliferation of 32D cells are dependent 
on stimulation with the cytokine mIL-3. However, after transduction with Mpl, this can be 
changed into Thpo-dependent growth of the cells. In this experiment, we used the Thpo/Mpl-
dependent growth advantage of Mpl-transduced 32D cells to prove the biological functionality 
of the transgene delivered by the UCOE-vector. Mpl-transduced cells were selected by the 
supplementation of Thpo to almost 100% of Mpl expression as indicated by the dashed line 
in Figure 45A. Cell viability was analyzed by performing PrestotBlue® assays. In this 
fluorescence-based assay, the resazurin blue non-fluorescent dye is incorporated by the 
cells. Metabolically active cells quickly reduce resazurin to the fluorescent active metabolite 
resofurin which can be detected at an excitation wavelenght of 530-570nm and an emission 
of 600nm with a spectrophotometer. 32D cells  expressing Mpl were expected tohave a 
higher viability and proliferation when incubated with Thpo compared to  cells which do not 
express the Mpl receptor. Mpl negative cells will proliferate less and, therefore, a lower 
number of cells will be viable and can be measured in the viability test.  As a control, 32D 
cells were transduced with the U670s.GFP vector. In our experiment, after enrichment of the 
cells, the cell viability was assessed 40h after Thpo re-stimulation and compared to non-
induced cells. During the time of 40h, 32D cells are expected to divide at least once. By the 
application of PrestoBlue®, the measure of the cell viability will also reflect the increased 
number of viable cells due to increased cell proliferation in 32D.Mpl cells in contrast to 
32D.GFP cells. Cell viability of 32D cells transduced with Tet.U670s.Mpl in the non-induced 
state was set to 1 (dashed line). 32D cells expressing the Mpl receptor on the surface in the 
induced state after application of dox showed a viability which was twice as high compared to 
the non-induced counterparts, indicating that the receptor which was transduced was 
functional after application of dox. In contrast, 32D cells expressing no functional transgene 
did not show differences in cell viability between the induced and uninduced state of the 
vector (Figure 45B). 
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Figure 45 Determination of the functionality of the Tet.U670s.Mpl vector. For functionality tests, the murine 
hematopoietic cell line 32D was transduced and analyzed according to their expression of the transgene as well 
as viability as indicator for cell proliferation. (A) Representative flow cytometry plot of Mpl expression in 32D cells. 
After transduction of the cells with the Tet.U670s.Mpl vector, the Mpl expression was analyzed by detection of the 
incorporate HA tag via flow cytometry. (B) Viability of Mpl-expressing 32D cells. After Thpo-dependent enrichment 
of HA-Mpl-positive 32D cells, the cells were plated with 5ng/ml Thpo in the induced and non-induced state for 40h 
and cell viability was analyzed by the addition of the PrestoBlue®. Emission was detected after incubation for 
another 16h. Relative cell viability was determined by normalization to untransduced control (set to one, indicated 
by the dashed line). Cell viability of U670s.Mpl expressing cells was compared to transduced cells with the 
U670s.GFP (n=3, mean +/-SD, Students t-test ****p<0.0001). 
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5 DISCUSSION 
5.1 Production of platelets and megakaryocytes in vitro from 
R26M2 iPSC 
5.1.1 R26M2K2 iPSC for the generation of megakaryocytes and platelets in 
vitro 
 
The production of functional platelets from pluripotent stem cells would provide an 
unlimited supply for patients of acute need for platelet transfusions. Furthermore, the use 
of murine iPSC would provide a powerful tool for disease modeling studies in vivo. 
Transfusion experiments of culture-derived platelets or MK could be performed in a 
syngeneic context. To date, the production of platelets in culture is still challenging due to 
limitations in platelet numbers and impaired functionality of the differentiated cells. 
Overexpression of supporting factors that either increase the numbers of generated MK or 
the release of platelets per MK and the functionality of the differentiated cells would 
provide a powerful tool towards future therapeutic applications of culture-derived platelets. 
In the first part of the study, we were aiming for the defined overexpression of the single 
supporting factors Gata1, Nfe2, Pbx1, Evi1, RhoAhc, and Cdc42hc via dox-inducible 
gammaretroviral vectors to support in vitro MK and platelet biogenesis from murine iPSC. 
The factors were transduced in the pluripotent state and induced in a dox-inducible 
manner to prevent unwanted effects during the course of differentiation. Another hurdle 
was the silencing of ectopic factors by iPSC especially during differentiation. In many Tet-
all-in-one gammaretroviral vectors, the transactivator (rt)TA-M2 is expressed from the 
PGK promoter, which is highly enriched in CpG sites and therefore prone to be silenced. 
The generation of R26M2 iPSC from B6.Gt(ROSA)26Sor tm1(rtTA*M2)Jae/J mice, expressing 
the transactivator from the Rosa 26 safe harbor locus, allowed overexpression of the 
supporting factors independent of the PGK promoter. The R26M2 iPSC allowed stable 
expression of the tested transgenes. Pluripotency was verified on protein expression (flow 
cytometry experiments for SSEA-1 expression, detection of Oct3, Sox2 and Nanog by 
fluorescence microscopy, alkaline phosphatase acitivity) and mRNA levels (detection of 
Oct3, Sox2 and Nanog by qRT PCR). The study of A. Mucci et al., in which the same 
reprogramming vector was applied, also showed similar results, e.g. mRNA expression 
levels of the pluripotency markers Oct4, Sox2 and Nanog reaching the same expression 
levels as OG2 ESC (Mucci et al., 2018). Since the detection of the copy number identified 
R26M2K2 to be the clone having one integration only, further studies have been 
performed with this clone. To date, there are more sophisticated non-integrating 
reprogramming technologies available to generate footprint-free iPSC, e.g. non-integrating 
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viral vectors (sendai viral vectors, adenoviral vectors, adeno-associated viral vectors) 
based on reprogramming, plasmid transfection (including minicircles) and/or RNA delivery 
(Seo et al., 2017). Sendai virus-based viral vectors for example do not rely on the 
entrance to the nucleus and produce large amounts of protein. The reprogramming 
efficiency varies between 0.1 and 4%. However, it can take up to 25 passages until the 
residual viruses are diluted from the cells (Fusaki et al., 2009; Haridhasapavalan et al., 
2019). Reprogramming efficiencies after plasmid transfection and with minicircle vectors 
are even lower due to their transient expression (Si-Tayeb et al., 2010; Haridhasapavalan 
et al., 2019). In our study, we were aiming for the generation of platelets as a final product 
from the differentiation. We were therefore not dependent on non-integrating 
reprogramming methods. However, incomplete silencing of the transgene cassette might 
also have influenced the differentiation efficiency as it has also been reported in several 
other studies (Haridhasapavalan et al., 2019). For example Kadari et al. have shown that 
Cre-mediated excision of the transgene cassette improved cardiac differentiation (Kadari 
et al., 2014). The reprogramming cassette of the vector used in this study is also flanked 
by FRT sites for potential Flp-mediated excision. It could be tested in future experiments 
whether this would also lead to improved differentiation efficiencies in our studies. After 
successful generation of the Tet-responsive gammaretroviral vectors containing Gata1, 
Nfe2, Pbx1, Evi1, RhoAhc, Cdc42hc, titration and transduction of R26M2K2 showed 
Evi1.iGFP to produce markedly lower titers compared to the other factors tested and 
efficient transduction could also not be achieved (Figure 10+11). Overexpression of Evi1 
in the human BM cell line U2OS led to an arrest in the cell cycle in the G0/G1 phase and 
impaired proliferation (Karakaya et al., 2012). Similar results have been obtained in the 
study performed by Kustikova et al. Here, overexpression of Evi after transduction of Lin- 
BM cells led to an initial growth inhibition and cell cycle arrest (Kustikova et al., 2013). For 
these reasons, Evi1.iGFP-transduced cells in our study might not have been able to 
proliferate and were therefore not followed up.  
 
5.1.2 Comparison of single supportive factors during MK differentiation and 
terminal maturation 
 
After transduction of the R26M2K2 iPSC, the cells were subjected to differentiation into 
EB using the approach published by Pfaff et al. The protocol generated immature CD41+ 
hematopoietic stem and progenitor cells after 7 days of EB formation by the 
supplementation with mScf and mIL-3 (Figure 12) (Pfaff et al., 2012). According to what 
was published by A. Mucci et al., the protocol was modified in terms of generating EB via 
application of mechanic forces by orbital shaking (Mucci et al., 2018). Terminal 
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differentiation of MK and platelets occurred after co-cultivation on mitomycin C-treated 
OP9 feeder cells and supplementation of mScf and mThpo. With this protocol, MK and 
platelets were obtained after 2-3 weeks of starting the co-cultivation, which was delayed in 
comparison to the study by Lu et al. where fully mature MK were observed already 6 days 
after starting the co-culture from human ESC with similar cytokine conditions. In contrast 
to the differentiation protocol we used in the study, cells were differentiated into 
hemangioblast cells prior to co-cultivation (Lu et al., 2011). After harvesting the MK by day 
21 of differentiation, the GFP expression from the transduced factors was detected by flow 
cytometry. The occurrence of a distinct GFP+ population was absent for all of the factors, 
indicating a high position effect variegation of the integrated vectors and thereby causing 
the distinct expression profiles (Figure 13). Differentiation of the R26M2K2 into cells of the 
MK lineage was possible, independent of the transduced factors as indicated by the 
apparent dark stain of the cytoplasm and the occurrence of the multilobulation of the 
nuclei (Figure 14). The morphology of the cells was similar to those of the differentiated 
MK from murine and human PSC cells in other studies (Noh et al., 2015). However, in our 
experiments, the occurrence of fully mature multilobulated nuclei was rare, if not 
completely absent. One explanation for this could be that iPSC-derived MK still resemble 
a fetal phenotype. It was observed that MK differentiated from human cord blood are 
generally smaller in size with lower ploidy compared to CD34+ derived MK isolated from 
adult blood or BM (Miyazaki et al., 2000; Mattia et al., 2002). Studies performed by Potts 
et al. also showed that platelets can be generated from yolk sac-derived, relatively small 
MK with only diploid nuclei (Potts et al., 2014). Since the branching of the MK could be 
detected in our in vitro differentiation (Figure 15), this would point to a more fetal 
phenotype which was differentiated in our cultures. 
Furthermore, experiments performed in our own group have shown that the expression of 
the P-selectin marker in non-activated and activated platelets from the in vitro cultures 
was very low whereas the conformational change of the CD41/CD61, which also indicates 
platelet activation, could be detected by flow cytometry (Jahn, 2019). The low level of the 
expression of the P-selectin marker was also previously shown in fetal platelets and is 
another sign for platelets of a fetal phenotype. 
In the next experiments the expression of the MK-specific surface receptors were 
evaluated by flow cytometry. In general, we observed a higher CD41 expression within the 
GFP+ population which was most distinct for MK harvested from Gata1-transduced 
cultures (Figure 17). Higher percentages of CD41 expression is also a sign that MK 
maturation has started. During the course of differentiation, endomitosis leads to an 
increased DNA content this in turn leads to the accumulation of GFP in cells that are more 
mature (CD41+). This is especially of importance for the expression of CD42d (Figure 18). 
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The analysis of the surface phenotype of differentiated MK showed that overexpression of 
Gata1 resulted in higher percentages of cells expressing the CD41 surface marker (about 
70%) within the GFP+ population compared to the other candidate factors which were in 
the range between 19% (Cdc42.iGFP) and 40% (Pbx1.iGFP) (Figure 17). This indicates 
that Gata1 had a positive effect on the differentiation of the earlier MK progenitors. In 
contrast, an increase of CD42d expression could not be confirmed for the Gata1-
overexpressing differentiations (Figure 19). In these cultures, the percentage of CD42d 
within the GFP+CD41+ population was lowest. Overexpression of Gata1 enhances 
differentiation of early CD41+ progenitors which are impaired in terminal maturation. 
We have seen a spread in numbers of MK differentiated from Gata1-overexpressing 
cultures as indicated by the high error bars (Figure 20). Mutations in the GATA1 gene 
occur in almost all of the cases of transient myeloproliferative disorder of Down syndrome-
associated leukemia in neonates with trisomy 21 and are thought to be the founder 
mutations of the malignancies. The mutations are to date utilized as a diagnostic marker 
(Lee et al., 2018). These somatic mutations mostly occur in exon 2 of the gene leading a 
premature stop codon and forcing the start of the gene from the alternative start codon in 
exon 3 leading to an N-terminal truncation of GATA1 (GATA1s). Almost all of the blast 
cells in turn show the same mutation indicating a clonal dominance. The occurrence of the 
blast cells is also associated with a differentiation arrest (Gruber and Downing, 2015; Lee 
et al., 2018). 
In mice, lineage-specific knockout of Gata1 results in low platelet numbers associated with 
deregulated MK proliferation and impaired cytoplasmic maturation (Shivdasani et al., 
1997). In addition, the knockout of Gata1 influences platelet granule formation as well as 
release (see Chapter 1.4). Since these evidences pointed into the direction of Gata1, 
influencing megakaryopoiesis and platelet generation, we thought that overexpressing this 
factor may be sufficient for enhanced MK and platelet production in vitro. The impairment 
of MK maturation of Gata1-overexpressin MK in our experiments shows that the 
hypothesis of Gata1 overexpression alone leading to increased fully mature MK 
generation was not confirmed since the expression of CD42d as mature marker was 
impaired. Rescue experiments in Gata1 knockout mice have shown that overexpression 
of Gata1 together with its co-factor Fog1 was able to restore MK formation and pro-
platelet formation whereas Gata1 overexpression alone was not sufficient (Shimizu et al., 
2004). Expression of Gata1 in combination with Fog1 could be another combination that 
could be tested in future experiments. 
The size and ploidy of the differentiated MK in our experiments was rather low, pointing 
towards a more fetal phenotype. Fetal and neonatal MK proliferate faster, they are smaller 
and have a lower ploidy (Alarcon and Graeve, 1996; Ma et al., 1996; Mattia et al., 2002; 
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Sola-Visner, 2012). In contrast, fetal MK are more cytoplasmatically mature, as indicated 
by the increased expression of the CD42b receptor. It has been shown that the level of 
GATA1 expression is higher in cord blood- than in peripheral blood-derived MK (Liu et al., 
2011). It could be that by overexpression of Gata1 in our experiments, we have shifted the 
phenotype of the differentiated MK towards a fetal state. Fetal and neonatal MK rapidly 
expand to populate the growing BM space and blood volume. To confirm the positive 
effect of Gata1 overexpression in our study, we could analyze Gata1 target genes such as 
VWF, GPIbα and PF4 as it was shown in the study by Noh et al. In contrast to our study, 
Noh and colleagues regulated the Gata1 expression by dox-inducible knockdown. This 
approach generated fully mature MK (Noh et al., 2015). 
In the study by T. Moreau and colleagues, a combination of the transcription factors 
GATA1, FLI1 and SCL1 were expressed in human pluripotent stem cells and led to the 
production of mature and cryopreservable MK (Moreau et al., 2016). Similar approaches 
by defined overexpression of MYC during differentiation and supplementation of the 
culture medium with the anti-apoptotic protein (drug) BCL-XL have led to increased 
expression of GATA1 and NFE2, indicating those to be key factors for in vitro 
differentiation of platelets leading to the generation of immortalized MK progenitor cells 
(Nakamura et al., 2014). In a similar manner, also in our experiments, only cultures 
overexpressing Gata1 could be expanded and allowed the generation of sufficient 
numbers of platelets to perform platelet activation experiments. In these cultures, Gata1 
overexpression led to the differentiation of about 1.5 x 104 CD41+MK progenitors, which 
was a 15-fold higher number compared to the iGFP.control which only produced around 
2000 CD41+ MK (Figure 20). 
 
Nfe2 is a major regulator of platelet release as indicated by prenatal death in Nfe2 
knockout mice due to hemorrhages or development of postnatal thrombocytopenia 
(Shivdasani 1995). Furthermore, loss of Nfe2 in zebrafish blocks thrombopoiesis and a 
secondary expansion of thrombocytic precursors (Rost et al., 2018), underlining the 
essential role of Nfe2 for platelet release. Based on these observations, we chose to 
overexpress Nfe2 as a single factor in our study. Interestingly, MK differentiated from Nfe2 
overexpression showed the highest percentage of CD42d expression within the 
GFP+CD41+ population (78%), although this observation did not test significant, probably 
due to higher variance (Figure 19). 
In addition to the transcription factors, also GTPases such as RhoA and Cdc42 are of 
importance in MK maturation and platelet release. Knockout of both RhoA and Cdc42 
respectively in mice leads to the formation of severe macrothrombocytopenia. We wanted 
to investigate whether their overexpression during in vitro differentiation would also 
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increase platelet formation in vitro. Since GTPases are cycling between inactive (GDP-
bound) and active (GTP-bound) state, hyperactive, fast cycling variants (hc) were 
overexpressed to guarantee their permanent activation (Dütting et al., 2017). Studies in 
MK differentiated from murine Lin- BM cells in vitro detected Cdc42 expression to be 
upregulated during DMS formation and polyploidization and knockout of Cdc42 reduced 
this. In this study it was observed that DMS formation as well as the formation of pro-
platelets relies on F-actin polymerization and that this was regulated by active Cdc42 
(Antkowiak et al., 2016). An increase in demarcation membrane formation by the 
overexpression of Cdc42 would therefore explain the higher percentages of CD41 
expression and CD42d within the CD41 mature MK, indicating a more mature phenotype 
compared to the iGFP.control (Figure 17+19). The influence of Cdc42 overexpression on 
demarcation membrane formation and F-actin polymerization in in vitro cultures has to be 
further verified with electron microscopic imaging and immunofluorescence of the MK in 
future experiments. In addition, the GTPase RhoA has also been identified to be a major 
regulator of megakaryopoiesis and platelet release. Studies performed by A. Suzuki et al. 
have shown that it regulates cytokinesis during the pro-megakaryoblast stage, 
endomitosis, and migration of the MK within the BM matrix and these were impaired in 
mice with a conditional knockout (Suzuki et al., 2013). In the publication from S. Dütting et 
al., it was shown that there exists a regulatory circuit between Cdc42 and RhoA whereas 
RhoA functions more as a stop signal for pro-platelet production (Dütting et al., 2017). In 
our experiments, overexpression of RhoAhc did not lead to increase in numbers of 
differentiated MK that were harvested from the in vitro cultures and also the expression of 
the surface markers CD41 and CD42d were only slightly increased, indicating its influence 
on the MK only to a minor degree (Figure 17, 19, 20). 
Studies performed in our own group have shown that overexpression of Pbx1 in a Mpl-
deficient murine BM transplantation model generated increased numbers of MK 
(Kohlscheen, 2015). In our study, an increase in MK production by the overexpression of 
Pbx1 during the differentiation of murine MK and platelets could not be detected (Figure 
17, 19, 20). The observations made by S. Kohlscheen were based on the Thpo/Mpl 
deficient model. In these experiments, Pbx1 overexpression might function as an 
alternative pathway since all signaling pathways in the iPSC differentiation are intact and 
therefore the effect of Pbx1 may be too weak to have a detectable influence on the MK 
differentiation in vitro from murine iPSC. 
 
In conclusion, the expression of one transcription factor alone might not suffice for 
generating the greatest output of in vitro generated MK. Gata1 should be included in the 
panel because of its great influence on MK proliferation in early stages. Since the 
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overexpression of Nfe2 in our experiments resulted in the increased percentages of fully 
mature MK that also expressed CD42d, the combined overexpression of Gata1 and Nfe2 
may provide another possibility to increase platelet generation from pluripotent stem cells 
in vitro. This has to be further verified in additional differentiations with overexpression of 
Gata1 and Nfe2, simultaneously. For this purpose, we have generated 2 different clones 
of Gata1-transduced R26M2K2 which could be transduced with Nfe2 in an additional step. 
Furthermore, it would be possible to generate a gammaretroviral vector expressing Gata1 
and Nfe2 from the same vector. 
5.1.3 Comparison of candidate factors on platelet generation from R26R2K2 
iPSC  
 
In addition to the MK, also platelets were analyzed. As indicated in Figure 23, the 
ultrastructure of the platelets was similar to that of freshly isolated platelets as shown in 
several publications (White and Rao, 1982; Chang et al., 2007). Even though they could 
not all be detected within one platelet, all different ultrastructural features were present, 
such as the different types of granules, mostly α-granules and δ-granules as well as OCN 
and mitochondria. The size of the cells (approximately 2-7µm) was, however, increased 
compared to platelets freshly isolated from mouse blood. This has also already been 
detected in other in vitro platelet differentiation studies and is a phenomenon that is also 
known from fetal platelets (Saving et al., 1994; Feng et al., 2014). Most likely, the lack of 
the shear force would explain the increased size of the platelets, but in addition it is 
another hint for the generation of more a fetal-like phenotype of platelets that were 
differentiated from our cultures. 
Discrimination between GFP+ and GFP- populations was not performed in platelets since 
GFP expression could not be detected by flow cytometry. The reason for the GFP 
expression not being propagated to the platelets remains unclear. Studies on transduction 
of HSPC by viral vectors expressing GFP from different lineage-specific promoters by our 
own group have shown that in vivo, the transgenes were detected in platelets descending 
from the modified HSC in transplantation experiments, however, this was highly 
dependent on the internal promoter. In this study, promoter fragments of lineage-specific 
genes were analyzed for their expression in MK and platelets. It was shown that the 
promoter descending from the platelet factor 4 (PF4) gene had the strongest activity in MK 
and platelets (Latorre-Rey et al., 2017). It could be the case that the T11 minimal 
promoter used for the expression of the transgenes in this study did not generate 
sufficient amounts of protein that could be propagated to the platelets. Significant 
differences in either CD41 expression or CD42d within the CD41- population were not 
detected, indicating a similar equipment of surface receptors on the platelets released 
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(Figure 22). The percentage of CD42d+ cells within the CD41+ population of the platelets 
differentiated in vitro was in general very low and varied between 7% (iGFP.control) and 
25% (RhoAhc.iGFP). This may also be due to the expression of the CD42d. The GPIb-IX-
V receptor mostly interacts with the VWF and thereby mediates platelet activation. The 
GPIb-IX (CD42a, CD42b, CD42c) subunit of the complex is highly integrated into the 
membrane whereas the GPV (CD42d) is only loosely associated (Modderman et al., 
1992). The expression of the receptor on the plasma membrane only requires the 
association of the GPIbα, GPIbβ and GPIX subunits of the receptor and the subunits 
interact with and stabilize each other (López et al., 1992; Li and Emsley, 2013). The 
deletion of the GPV in mice has shown that expression and functionality of the residual 
receptor components was still present (Kahn et al., 1999; Ramakrishnan et al., 1999). In 
turn, after deletion of the GPIbα, GPIbβ and GPIX, GPV was not expressed on the surface 
of transfected cells (Strassel et al., 2004). Furthermore, the bleeding disorder Bernard-
Soullier syndrome is only associated with mutations within the GPIbα, GPIbβ and GPIX 
subunits but not GPV (Li and Emsley, 2013). PSC-derived platelets from other studies 
with human iPSC have generated higher percentages of CD41/CD42 double-positive cells 
up to almost 60% (Börger et al., 2016; Moreau et al., 2016). In these studies, antibodies 
against the CD42a (GPIX) were utilized for detection of the GPIb-IX-V multiprotein 
complex. In contrast, we utilized the CD42d (GPV) for detection of the receptor complex. 
Even though GPV is a late marker for MK and platelets, taking into account that the GPV 
is only loosely associated with the receptor and that it is not necessary for the assembly 
and receptor expression on the surface and is also shed faster after activation, we should 
include other markers (eg.CD42a) into our analysis to prove the full expression of the 
receptor on the surface. This should also be adapted for the analysis of MK in future 
experiments. Detecting only CD42d may not have been sufficient. Additionally, we have 
shown that platelets released from the Gata1-overexpressing clone were pre-activated in 
the cultures (Jahn, 2019). During platelet activation, shedding of GPV occurs after 
addition of agonists like thrombin, matrix-metallo-proteinases (ADAM10, ADAM17) and 
stress-induced reactive oxygen species (Au and Josefsson, 2017). Taking this into 
consideration, it could be that in pre-activated culture-derived platelets the detection of 
CD42d expression was reduced. 
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5.1.4 Platelets differentiated from Gata1-overexpressing R26M2K2 iPSC 
were functional 
 
Functional analysis of in vitro differentiated platelets by platelet spreading assays was 
only performed in case of Gata1-overexpressing iPSC since they were expandable, as 
indicated by the higher cell numbers of CD41+ cells (Chapter 4.1.5.3). Platelets were 
identified using confocal microscopy according to their expression of GPVI, CD41/CD61 
and β1-tubulin. As seen in the platelets isolated from whole blood as control, platelets 
undergo a shape change losing their discoid shape (resting state, β1-tubulin ring distinct) 
and become spherical, followed by formation of filopodia and lamellipodia (β1-tubulin ring 
disintegrated) (Figure 27+28) (Bearer et al., 2002). We could verify the expression of the 
CD41/CD61 on the culture-derived platelets by confocal microscopy. Additionally, the 
expression of GPVI and the distinct ring structure of β1-tubulin were detectable in the 
resting state on Poly-L-Lysine-coated cover slips. The spreading on CRP and fibrinogen 
indicates that the platelet receptors, responsible for the attachment to the matrices, were 
functional. This goes in line with the results by Moreau and colleagues showing 
attachment of in vitro generated platelets from human iPSC on fibrinogen (Moreau et al., 
2016), who also could visualize the β1-tubulin ring at the cortex of the in vitro 
differentiated platelets as well as their spreading. During activation platelets lose the 
discoid shape and become spherical and extend filopodia which are long (0.1-0.3µm), 
finger-like membrane protrusions which contain tight bundles of F-actin. Formation of 
filopodia increases the contact between the extracellular matrix or juxtaposed other 
platelets (Goggs et al., 2015). Subsequently, lamellipodia, which are also F-actin 
filaments, fill the gaps between the filopodia, leading to the final platelet spreading and 
thereby persistent cellular protrusions (Mejillano et al., 2004; Paknikar et al., 2019). 
Formation of filopodia and lamellipodia relies on cytoskeletal rearrangements controlled 
by GTPases such as RhoA, Cdc42 and Rac1 (Goggs et al., 2015). In contrast to our 
observations, Moreau et al. observed lamellipodia formation (Moreau et al., 2016). 
Spreading of the in vitro generated platelets in our experiments resulted in the formation 
of filopodia, however, the formation of lamellipodia and thereby the endpoint of platelet 
spreading was absent. The platelet spreading on fibrinogen in our study was, therefore, 
similar to results observed from studies which lack the expression of Rac1, another very 
important GTPase involved in cytoskeleton reorganization (Hall et al., 2003). Rac1 
stimulates actin polymerization via suppressor of cyclic AMP receptor (SCAR)/WASP 
family verprolin-homologous protein (WAVE) (Rac binding proteins). The SCAR/WAVE 
complex in turn activates the Arp2/3 complex which leads to the forming of branching 
actin-filaments and absence in Rac1 also implicates lack of lamellipodia formation in 
platelets (McCarty et al., 2005). The reason for the impairment of lamellipodia formation of 
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our in vitro generated platelets has to be further investigated, but in addition to RhoAhc 
and Cdc42hc, we could include Rac1 in future overexpressing experiments. The inducible 
overexpression MK still might indeed improve the platelet functionality. This absence of 
lamellipodia formation was independent from the matrices and agonists applied. In a very 
recently published article by Y. Schurr et al., it was shown that lamellipodia formation was 
not required for thrombus formation and stability, indicating that culture-derived platelets, 
even though their spreading is impaired, still can be utilized for clinical application (Schurr 
et al., 2019). This has to be further verified in in vivo studies with the in vitro differentiated 
platelets. 
5.1.5 Overexpression of Nfe2 during differentiation increased the platelet 
production per megakaryocyte 
 
The general number of platelets produced was highest from Gata1-overexpressing 
differentiations with 5 x 105 CD41+ platelets and 6.5 x 104 CD42d+ within the CD41+ 
population (shown in Figure 25). This might also be due to the overall higher numbers of 
CD41 positive progenitors that were also differentiated from Gata1-overexpressing cells. 
However, the highest numbers of platelets per MK were generated from Nfe2-
overexpressing cells (Figure 25). Here, 101 CD41+ platelets and 22 CD42d+ (within the 
CD41 positive population) were generated per MK (Figure 25B). In case of the CD41+ 
platelets, this is about 5 times higher than the number of CD41+ platelets that were 
generated from the iGFP.control-overexpressing cells. This is also markedly higher than 
the numbers of platelets per MK that were generated in other studies which are in the 
range between 3 and 10 platelets per MK (Moreau et al., 2016; Sugimoto and Eto, 2017). 
The results for platelet counts received from these studies were based on the expression 
of the two surface antigens CD41 (GPIIb) and CD42d (GPV). Again, the detection of the 
CD42d (GPV) on the surface of differentiated platelets could be misleading since it can be 
shed during platelet activation. Taken into consideration that the receptor is shed, the 
actual amount of platelets generated by MK with the overexpression of Nfe2 might be 
even higher, making it an ideal candidate for combined-regulated overexpression in future 
experiments. However, in vivo MK are capable of releasing up to 1000-2000 platelets per 
MK (Sugimoto and Eto, 2017). To date, these amounts are still not achieved with any of 
the differentiation studies in vitro. It might be possible that due to the embryonic/iPSC 
background of the cells, also the differentiated MK may resemble more a fetal phenotype. 
Fetal MK differentiated from human cord-blood-derived CD34+ cells form fewer pro-
platelets compared to those isolated from adult blood (Mattia et al., 2002; Elagib et al., 
2018). Since the platelets isolated from our in vitro differentiations were also larger in size 
(up to 6µm) compared to murine platelets in vivo (0.5µm), another explanation for the low 
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cell numbers could be the lack of the shear force which in vivo leads to the shedding of 
the platelets into the circulation. Several groups have been working on the development of 
bioreactors to mimic these shear forces and could escalate the platelet yield (Thon et al., 
2014; Blin et al., 2016). Based on the observation that turbulence is a critical factor for 
platelet release in vivo, Y. Ito et al. generated a bioreactor mimicking the turbulence in 
vitro and resulting in a yield of 70-80 platelets per MK (Ito et al., 2018). Although this 
approach still is nowhere close to the 1000-2000 platelets per MK produced in vivo, a 
combined approach of Nfe2 overexpression and application of a platelet bioreactor would 
lead to a faster generation of in vitro platelets to generate the tremendous amount of 4-
5 x 1011 platelets needed for one transfusion unit. 
5.2 Incorporation of A2UCOE to prevent silencing of Tet-all-in-
one gammaretroviral vectors 
 
5.2.1 Incorporation of some of the A2UCOE lowers titers and interferes with 
regulation of Tet-all-in-one gammaretroviral vectors 
 
After incorporation of the different elements upstream of the PGK promoter in either sense 
or antisense orientation, it turned out that elements of larger sizes lowered viral vector 
titers of about 7-fold. This was most profound after incorporation of the U1.5s element 
which only reached a titer of about 1 x 104IP/ml and is about 70-fold lower compared to 
the PGK.Tet-control (Figure 31). Most likely, bi-directionality of the promoter interfered 
with efficient transcription during packaging and after integration, thereby impairing the 
function of the vector. Not only the titers, but also the regulation of the Tet-all-in-one 
vectors was altered after incorporation of some of the elements. Transduction of the 
fibroblast cell line SC1 with U630s, U1.0s, U1.0as and U1.5as resulted in less distinct 
GFP+ populations in the dox-induced state (Figure 32) accompanied by low dynamic 
ranges and fold inductions (MFI) in GFP expression (Figure 33B+C). In contrast, 
regulation of dox induction was similar to that of the PGK.Tet-control after incorporation of 
the elements U630as, U670as, U670s and U1.5s and CBX3 (Figure 32). The dynamic 
range and fold induction of vectors with the U670s incorporated was highest, but at the 
cost of an elevated background expression and coefficient of variegation (Figure 33E). 
Promoter activity of the A2UCOE was also verified in other studies and it was decided to 
replace the promoter by the CBX3 and U670s element (Müller-Kuller et al., 2015; Kunkiel 
et al., 2017). Replacement of the PGK promoter by the U670s and CBX3 elements 
resulted in similar regulation in SC1 cells without impairment of the viral vector titers 
(Figure 39+40). The relative intensity of GFP expression and fold induction were even 
doubled from these vectors, which was a very interesting observation indicating that the 
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(rt)TA-M2 expression levels from the CBX3 promoter were sufficient. In studies performed 
with constitutively expressing retroviral vectors in pluripotent stem cells, the EFS promoter 
in combination with the U1.5s element is a popular strategy for sustained vector 
expression (Ackermann et al., 2014; Hoffmann et al., 2017). We therefore decided to 
replace the PGK promoter also by the EFS in Tet-all-in-one gammaretroviral vectors. 
Titers in the range of the PGK.Tet-control were also obtained from gammaretroviral 
vectors containing the EFS promoter to drive the expression of the (rt)TA-M2 
(1 x 106IP/ml) and regulation was also similar as indicated by the distinct GFP positive 
population in SC1 cells (Figure 39+40A), but relative intensity of GFP expression in the 
same cell line as well as fold induction were impaired (Figure 40B+C). Comparison of the 
lentiviral Tet-all-in-one with U670s.M2 and PGK.Tet-control showed that titers of were 
about 30-fold lower than those of their gammaretroviral counterparts (Figure 39). For this 
reason and because of high percentage of mean CV indicating higher variegation, the 
lentiviral vectors were not followed up in further experiments.   
 
5.2.2 Anti-silencing efficiency in P19 cells 
 
Incorporation of the elements U670s, U670as, U1.0s, and U1.5s was shown to protect 
expression of GFP in the P19 cell line. At the termination of the experiment on day 46, the 
U670s element performed best as indicated by the overall GFP expression which was 
more than twice as high (34% residual GFP expression at day 46) compared to the 
PGK.Tet-control (10% residual GFP expression at day 46) (see Figure 34). But the GFP 
expression could also be sustained from the U1.0s (21% residual GFP expression at day 
46) and U1.5s elements (21% residual GFP expression at day 46). This is consistent with 
other studies in which the incorporation of the U1.5s element into lentiviral vectors 
sustained GFP expression in human and murine iPSC including their differentiated 
progeny (Ackermann et al., 2014). Interestingly, after incorporation of the CBX3, silencing 
of the GFP expression was not sustained, which is surprising since results from U. Müller-
Kuller et al. showed that incorporation of the element into constitutive lentiviral vectors 
could prevent the silencing in P19 cells very efficiently (Müller-Kuller et al., 2015). It could 
be possible that the absence of the splice sites and the presence of the downstream 
transcription start site might reduce efficient transcription of the (rt)TA-M2. When replacing 
the PGK promoter in the gammaretroviral Tet-all-in-one vectors by CBX3, GFP expression 
in P19 cells was sustained probably because in this configuration potential promoter 
interference could not impair expression. The major effect on chromatin opening by 
A2UCOEs seems to be dependent on the CBX3 part of the region (Müller-Kuller et al., 
2015). Efforts made in tracking down the minimal required region in the A2UCOE have 
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shown that the 455pb 3’ to exon1 or U670s/CBX3 element mediated most of the 
protective effects (Zhang et al., 2017). An additional study by Kunkiel et al. showed that 
most of the promoter activity of the CBX3 region resides in a core region of 500bp 
upstream and exon1 of the CBX3 sequence (Kunkiel et al., 2017). The drop in GFP 
expression from the U670s.M2 and CBX3.M2 vectors was less pronounced (42% and 
37% residual GFP expression) than from the PGK.Tet-control which declined below 20% 
after 42 days. In case of these experiments, cells were sorted by fluorescent activated cell 
sorting to 100% of GFP expression to compensate for different expression levels. 
Interestingly, in contrast to the results observed in PGK-containing candidates, GFP 
expression was sustained from U670s and CBX3 to a similar level. In addition to the lower 
intensity of GFP expression obtained in SC1 cells, the EFS.M2 also did not prevent 
silencing of GFP expression in P19 cells and was therefore also not followed up in further 
experiments (Figure 40 B, C, E). The incorporation of the U630 element per se did not 
contribute to anti-silencing, independent of the orientation. A2UCOEs devoid the CBX3 
part also has been shown to have lower anti-silencing activity (Antoniou et al., 2003). 
5.2.3 Expression of Mpl from the Tet-all-in-one vectors confers growth 
advantage to cytokine dependent cells 
 
To detect an effect of a functional protein expressed from Tet-all-in-one gammaretroviral 
vectors, we incorporated the Mpl coding sequence (containing an HA Tag for easier flow 
cytometric analysis), the receptor for the cytokine Thpo, into our U670s containing 
gammaretroviral vectors. The survival and proliferation of 32D cells is dependent on IL-3. 
Proliferation of the cells can be shifted towards Thpo-dependent growth after transduction 
of the cells with the respective receptor. In our experiments, the HA-Mpl expressing cells 
were selected by the supplementation of Thpo and thereby enriched to almost 100%, 
demonstrating the functionality of the transgene (Figure 45). Further characterization of 
the functionality was demonstrated by determining whether the expression of Mpl confers 
growth advantage to 32D cells under Thpo stimulation. For these experiments, the 
PrestoBlue® viability assay was utilized (see Chapter 4.2.6). The viability assays were 
performed 40h after Thpo re-stimulation and compared to the non-induced state. During 
this time, 32D cells can be expected to divide and therefore, the determination of viable 
cells was also an indirect measure of proliferation. The fold increase in cell viability was 
2.5-fold higher in HA-expressing cells compared to their non-expressing, non-induced 
counterparts. With this experiment, we have been able to demonstrate that Mpl was 
efficiently expressed and that the Tet.inducible vector was effectively shut off in the 
absence of dox. 
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Similar to our observations, lentiviral vectors containing the U1.5 element upstream the 
PGK promoter allowed sustained expression of the drug resistance gene MGMT. After 
transduction and transplantation of Lin- BM cells with the lentiviral vector containing the 
UCOE to protect MGMT expression, treatment with chemotherapeutics (O6-
benzylguanine, 3-bis(2-chloroethyl)-1-nitrosourea) in the mice was better tolerated 
(Phaltane et al., 2014). Also functional tests of differentiated iPSC with gene correction for 
Chronic Granulomatous Disease have shown that ROS levels and functionality of the 
neutrophils differentiated from patient-derived iPSC could only be satisfactorily restored 
after incorporation of a 1600bp element in the vector (similar to the U1.5 in our study) 
(Haenseler et al., 2018). 
 
 
5.2.4 Anti-silencing effects of A2UCOE in pluripotent stem cells 
 
The phenomenon of silencing of Tet-regulated vectors in pluripotent stem cells has been 
observed also in earlier studies. This does not only hold true for Tet-inducible vectors but 
also for constitutively vectors and is independent from the species that needs to be 
transduced (Hong et al., 2007; Xia et al., 2007; Stewart et al., 2008). In our case, the 
gammaretroviral vectors which were most promising in terms of anti-silencing in P19 cells 
and maintained the regulatory potential were analyzed in murine and human iPSC. Due to 
the fact of the lower viral vector titer achieved, lentiviral Tet-all-in-one vectors were not 
followed up further. Murine CD45.1 iPSC were transduced and subjected to several 
rounds of dox-induction and withdrawal (Figure 37). In these cells, the regulation of the 
gene expression by application and withdrawal of dox was confirmed (Figure 37, 38B). 
The incorporation of the U670s element again showed the highest fold induction (fold 
induction MFI: ~300) in the pluripotent state (two-fold induction compared to PGK.Tet-
control). In contrast, the incorporation of the elements U1.0s and U1.5s showed even 
lower-fold inductions in GFP expression than the PGK.Tet-control (Figure 33C). This is 
consistent with the findings of the latest studies focusing on different A2UCOE elements. 
Incorporation of a U1.5 into vectors expressing cytidine deaminase restored gene 
expression after differentiation of murine iPSC (Pfaff et al., 2013). Similar results were 
obtained in human iPSC using the same approach (Ackermann et al., 2014). Furthermore, 
GFP expression from the vectors with the U670s incorporated showed the highest 
intensity of expression (MFI/VCN 1.8 x 106) at day 46 when the experiment was 
terminated compared to the PGK.Tet-control (MFI/VCN 2.7 x 104), making this a potent 
candidate for the usage in pluripotent stem cells. Results obtained in the study by Müller-
Kuller et al. that compared different A2UCOE elements incorporated in constitutive 
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lentiviral vectors were similar to what we have shown with the A2UCOE-Tet-vectors in 
hiPSC. In the study by Müller-Kuller, hiPSC were transduced with lentiviral vectors 
containing the CBX3 element and the U1.5 element and differentiated into myeloid cells. 
They could demonstrate that the anti-silencing potential after incorporation of CBX3 was 
increased compared to the U1.5 part (Müller-Kuller et al., 2015). However, in addition, the 
background expression from all of the vectors tested in our study was also relatively high 
(up to an MFI/copy number of 1150 for the U670s element) and all within a similar range. 
Even though in our study we analyzed polyclonal cultures where a position effect should 
be no major bias, the variegation of the expression was increased during prolonged 
cultivation periods. This could be problematic in future applications when a tight regulation 
of the expression is indispensable. The increase on CoV was highest for the U1.0s and 
U1.5s vectors. The CoV of the U670s in contrast was stable (Figure 38A). A strategy to 
overcome position effects in pluripotent stem cell is the integration of the Tet-regulated all-
in-one expression cassette into the AAVS1 locus in human iPSC by gene editing. Results 
by Ordovas et al. have shown that also the AAVS1 site did not in all cases protect the 
accessibility of the Tet-regulated cassette during differentiation (Ordovás et al., 2015). 
Another reported strategy to prevent transgene silencing in Tet-all-in-one vectors is the 
incorporation of insulators in the LTRs allowing a tight regulation of the Tet-vectors 
achieved with only one integration. Insulators are derived from naturally occurring DNA 
sequences known to shield gene expression of one gene from other adjacent located 
genes to form functional boundaries and thereby prevent uncontrolled gene expression 
(Benabdellah et al., 2016). Incorporation of insulators into the LTR might also prevent 
expression of genes in close proximity and thereby contribute to the vector safety for the 
usage in gene therapy approaches. On the other hand, as shown by Benabdellah et al., 
incorporation of the insulator did also lead to lower viral vector titers (Benabdellah et al., 
2016). To compensate for variations in copy number, the intensities were normalized to 
the VCN in our study.   
The promoter-replaced candidates U670s.M2 expressed GFP with higher fluorescent 
intensities (Intensity/MFI: 2.9) and CBX3.M2 (Intensity/MFI 2.6) like the PGK.control in 
SC1 cells, making them potent candidates for the usage in iPSC. In a second approach, 
the transduced iPSC were subjected to ecto-, endo- and mesodermal differentiation, 
respectively. These experiments showed that the silencing of the vectors was most 
distinct during mesodermal differentiation in general (Figure 42A). In this case, the anti-
silencing effect from all elements tested was in a similar range (between 61% and 51% 
residual GFP expression) and therefore only slightly sustained (residual expression 
PGK.Tet-control: 41%). Interestingly, the differentiation into mesoderm resulted in the 
highest percentage of GFP expression of the U670s.M2 vector which showed almost 80% 
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residual expression and the lowest spread in the individual experiments. Unfortunately, 
the results could not be confirmed in the endo- and ectodermal differentiation 
experiments. The overall spread between single measurements was in general very high 
in all vectors tested. One problem might be the high (almost 100%) transduction efficiency 
which was achieved during initial transduction. Percentages of GFP expression of more 
than 30% are associated with multiple vector integrations in different integration sites. Due 
to the different locations of the integrated vector in the genome and the fact that there was 
more than one integration present, silencing might not be as strong as it would be after 
single vector integration only. Furthermore, as it is known from other differentiation studies 
with human iPSC, some lines have a preference in differentiation to a specific cell type, 
which can be related to an epigenetic memory of the cells (Kim et al., 2010; Vaskova et 
al., 2013). The iPSC line utilized in our study was originally generated to identify host 
factors of Chlamydia trachomatis pathogenesis after infection of iPSC-derived 
macrophages, also originating from the mesodermal germ layer (Yeung et al., 2017). It 
could be the case that the KOLF2 iPSC line used in this study is more efficient in 
differentiation into mesodermal origin and since the differentiation into the ectodermal and 
endodermal layer is reduced, also the silencing is less pronounced due to the lack of 
chromatin modifications. We could test the differentiated germ layers from the iPSC for 
the differentiation efficiency for example by the expression of germ-layer specific mRNAs 
in gene expression analysis by real time PCR in the next experiments. Nonetheless, the 
combination of the data from each of the germ layers again resulted in a significantly 
higher residual GFP expression after incorporation of the U670s element (Figure 42B).   
 
The methylation status of the PGK promoter after incorporation of the U670s element was 
therefore examined before and after mesodermal differentiation and compared to the 
methylation of the promoter of the PGK.Tet-control. As indicated in Figure 43, 
incorporation of the U670s resulted in lower PGK promoter methylation in the pluripotent 
state of the cells which could be maintained also during mesodermal differentiation. 
Another element vulnerable to silencing could be the Tet-responsive promoter T11. It has 
been reported from experiments in murine ES cell that promoter methylation was 
observed even though incorporation into the Rosa26 locus occurred (Gödecke et al., 
2017). The minimal promoter utilized in this study was derived from the CMV promoter 
making it per se more susceptible for silencing. In contrast the promoter used in our study 
is a chimera of the promoter-sequences of LTRs of mouse mammory tumor virus 
sequence (MMTV) and Human Immunodeficiency Virus 1 (HIV1) in combination with 
sequences from the transcription factor IIb (TFIIb) and therefore mostly synthetic and less 
prone to be silenced (Loew et al., 2010; Heinz et al., 2011; Heinz et al., 2013).  
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This again highlights the beneficial effect of the U670s after incorporation into Tet-
inducible-all-in one gammaretroviral vectors and makes them a promising tool to apply the 
beneficial effects of Gata1 overexpression on the proliferation of MK progenitors from in 
vitro cultures which was obtained from the approach in murine iPSC also to the human 
system. 
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6 CONCLUSION 
 
Taken together, we have successfully developed an approach for the increased 
production of platelets in vitro by the expansion of progenitor cells. This approach can be 
used for disease modeling studies of MK and platelets. Especially the murine systems are 
beneficial to better understand rare hematological platelet disorders and improve their 
treatment opportunities. The final goal of all the in vitro platelet differentiation strategies is 
to transfuse the culture-derived platelets into a living organism to actually mimic a patient 
situation. The huge benefit of the murine differentiation approach is that in the end we 
could investigate the actual patient situation in syngeneic preclinical transplantation 
studies. In contrast, human iPSC-derived platelets rely on humanized mouse models to 
test for actual functionality, which does not fully resemble a patient situation. The 
generation of Tet-inducible-all-in one gammaretroviral vectors with the incorporated 
U670s was most efficient in terms of anti-silencing and regulation with the lowest 
background. This vector therefore is a very promising tool to apply the strategy also to 
human iPSC to increase platelet numbers. After successful demonstration of functionality 
of the in vitro generated platelets and completion of clinical trials with safe and efficient in 
vitro differentiated platelets, this would be a powerful strategy for donor-independent 
platelet transfusion into patients of acute need. To date, there are three major concerns 
about platelet transfusion. First of all, the risk of bacterial contamination within the 
transfusion units could be minimized utilizing in vitro derived platelets for cellular 
therapies. Due to the manufacturing under sterile conditions, the potential contamination 
hazard is minimized and the storage at room temperature would no longer be a problem. 
This would in turn lead to extended dates of expiry of the transfusion units and thereby to 
a reduction of waste and minimization of the costs to the healthcare system. In the long 
run, it provides a cost minimization due to increased manufacturing of batches. Another 
obstacle of today’s platelet transfusion is the development of platelet autoimmune 
reactions refractoriness as a result of repetitive transfusions. To date, the most promising 
approaches of T. Mureau et al and Y. Ito et al. rely on the huge expansion of MK 
progenitors to achieve a sufficient amount of platelets while still the amount of platelets 
released per MK is very low. Our strategy of Tet-inducible overexpression of GATA1 and 
NFE2 as a second factor in the human context would provide a strategy to also increase 
production of culture-derived HLA-compatible platelets from a master bank. This would 
help to overcome the difficulties of finding HLA-compatible or crossmatch-negative 
donors. A knockdown of the HLA in iPSC has already been performed, however, the 
generated numbers of MK and platelets also were not very efficient (Börger et al., 2016). 
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The donor dependence is another issue which is widely discussed in the field because of 
the increasing demands of platelet transfusion but static donor pool. Pluripotent stem cells 
as basis of in vitro differentiated platelets provide an infinite source which ensures the 
generation of high numbers of transfusion units and could help to contribute to therapies 
being also available to more patients worldwide. 
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